Optimisation de stents actifs by Bozsak, Franz
Optimization of Drug-Eluting Stents
Franz Bozsak
To cite this version:
Franz Bozsak. Optimization of Drug-Eluting Stents. Cardiology and cardiovascular system.
Ecole Polytechnique X, 2013. English. <pastel-00858100>
HAL Id: pastel-00858100
https://pastel.archives-ouvertes.fr/pastel-00858100
Submitted on 4 Sep 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
École Polytechnique
Laboratoire d’Hydrodynamique
Thèse présentée pour obtenir le grade de
DOCTEUR DE L’ÉCOLE POLYTECHNIQUE
Spécialité : Mécanique
par
Franz BOZSAK
Optimization of Drug-Eluting Stents∗
∗Optimisation de stents actifs
Thèse soutenue le 03 juin 2013 devant le jury composé de
Gabriele Dubini rapporteur Politecnico di Milano
James E. Moore, Jr. rapporteur Imperial College London
Alexander I. J. Forrester examinateur University of Southampton
Antoine Lafont examinateur INSERM, HEGP
Abdul I. Barakat directeur de thèse CNRS, École Polytechnique
Jean-Marc Chomaz directeur de thèse CNRS, École Polytechnique

Optimization of Drug-Eluting Stents

Franz Bozsak
Optimization of Drug-Eluting Stents
Laboratoire d'Hydrodynamique (LadHyX)
École Polytechnique, France
Advisors:
Abdul I. Barakat
Jean-Marc Chomaz
©2013 Franz Bozsak
For my Princess

Contents
Contents v
Abstract ix
Résumé ix
Acknowledgments xi
List of Figures xiii
List of Tables xv
Nomenclature xvii
1 Introduction 1
1.1 Atherosclerosis: a human condition? . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Treatment of atherosclerosis: a brief history . . . . . . . . . . . . . . . . . . . . . . . 3
1.3 Anti-proliferative drugs: bliss and curse of drug-eluting stent design . . . . . . . 4
1.4 Modeling drug transport in the arterial wall . . . . . . . . . . . . . . . . . . . . . . . 5
1.5 Stent design optimization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.6 Scope and outline of the present dissertation . . . . . . . . . . . . . . . . . . . . . . 6
2 Modeling the Transport of Drugs Eluted from Stents 9
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.2 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.2.1 Model geometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.2.2 Physical model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.2.3 Governing equations and boundary conditions . . . . . . . . . . . . . . . . 11
2.2.4 Determination of physiological parameters . . . . . . . . . . . . . . . . . . . 15
2.2.5 Numerical methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.3.1 Baseline model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.3.2 Sensitivity analysis of the model . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.3.3 Effect of one-layer modeling . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.3.4 Effect of reaction modeling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.3.5 Effect of the choice of drug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
v
vi CONTENTS
2.4.1 Drug release is coupled to the drug and its transport properties in the
arterial wall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.4.2 Multi-layer model offers improved accuracy for pathological situations . 31
2.4.3 Reduction of the reaction model fails to capture important features of the
transport dynamics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
3 Optimized Drug Delivery for Drug-Eluting Stents 33
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.2 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
3.2.1 Computational model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
3.2.2 Cost function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
3.2.3 Optimization framework . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.2.4 Optimization cases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.3.1 Paclitaxel delivery optimization . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.3.2 Sirolimus delivery optimization . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.4.1 Paclitaxel-eluting stents require quasi-bolus or zero-order drug release
kinetics to avoid adverse concentration levels at the endothelium . . . . . 51
3.4.2 Sirolimus-eluting stents require zero-order release kinetics due to sirolimus’
weak retention capabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.4.3 Low-dose P-DES and S-DES with zero-order release kinetics lead to a
similar shape of the cost function . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.4.4 The cost function responds to drug kinetics in the arterial wall . . . . . . 53
3.4.5 Paclitaxel vs. sirolimus: a settled debate? . . . . . . . . . . . . . . . . . . . . 53
4 Optimizing the Strut Design of Paclitaxel- and Sirolimus-Eluting Stents 55
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
4.2 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
4.2.1 Computational model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
4.2.2 Cost function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
4.2.3 Optimization method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
4.2.4 Sensitivity estimation of the cost function to design variables and model
parameters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.3.1 Sensitivity estimation of the cost function . . . . . . . . . . . . . . . . . . . . 71
4.3.2 Optimization results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
4.4.1 Optimal DES strut designs are tailored to optimized transport dynamics
in the arterial wall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
4.4.2 Optimal two-layered DES polymer coatings are tailored to the eluted drug 87
4.4.3 Challenges of the FDI weight factor . . . . . . . . . . . . . . . . . . . . . . . . 88
5 Conclusions 91
5.1 Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
5.1.1 Additional physiological considerations . . . . . . . . . . . . . . . . . . . . . 93
5.1.2 Expanding the cost function . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
CONTENTS vii
5.1.3 Improved representation of the arterial wall . . . . . . . . . . . . . . . . . . 96
A Appendix 97
A.1 From the Brinkman equation to Darcy’s Law . . . . . . . . . . . . . . . . . . . . . . . 97
A.2 Derivation of the weighted concentration . . . . . . . . . . . . . . . . . . . . . . . . . 97
A.3 Including reaction at the endothelial surface . . . . . . . . . . . . . . . . . . . . . . . 98
A.4 Governing equation for the equilibrium case . . . . . . . . . . . . . . . . . . . . . . . 98
A.5 Remaining drug-dependent parameters of the model . . . . . . . . . . . . . . . . . 98
A.6 Diffusivity of sirolimus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Bibliography 101

Abstract
Drug-eluting stents (DES), which release anti-proliferative drugs into the arterial wall
in a controlled manner, have drastically reduced the rate of in-stent restenosis and revolu-
tionized the treatment of atherosclerosis. However, late stent thrombosis remains a safety
concern of DES, mainly due to delayed healing of the wound inflicted during DES implan-
tation. We present a framework to optimize DES design such that restenosis is inhibited
without affecting the healing process. To this end, we have developed a computational
model of blood flow and drug transport in stented arteries which provides a metric for
quantifying DES performance. The model takes into account the multi-layered structure of
the arterial wall and incorporates a reversible binding model to describe drug interaction
with the cells of the arterial wall. The model is coupled to a novel optimization algorithm
that minimizes the DES performance metric to identify optimal DES designs. We show that
optimizing the period of drug release from DES and the initial drug concentration within the
coating has a drastic effect on DES performance. Optimal paclitaxel-eluting stents release
the drug either within a few hours or slowly within a year at concentrations considerably
lower than current DES. Optimal sirolimus-eluting stents require a slow drug release. Op-
timal strut shapes for DES are elongated and can be streamlined only if the drug release
occurs quickly. The results offer explanations for the performance of recent DES designs,
demonstrate the potential for large improvements in DES design relative to the current
state of commercial devices, and define guidelines for implementing these improvements.
Résumé
L’utilisation de stents actifs (DES) a révolutionné le traitement de l’athérosclérose. Le
relargage contrôlé de médicaments anti-prolifératifs dans la paroi artérielle (PA) a permis
de réduire fortement le taux de resténose intra-stent. Mais le risque de thromboses intra-
stents tardives demeure un enjeu majeur des DES en partie lié au retard de cicatrisation de
la PA endommagée lors de l’implantation. Cette thèse présente une méthode d’optimisation
du design des DES afin d’inhiber la resténose sans affecter la cicatrisation. Pour quantifier
la performance des différents designs, un modèle numérique décrivant l’écoulement san-
guin et le transport de médicaments dans les artères stentées a été développé. Il prend en
compte la structure multi-couches de la PA et les interactions du médicament avec les cel-
lules. Un algorithme d’optimisation est couplé au modèle afin d’identifier les DES optimaux.
L’optimisation du temps de relargage ainsi que de la concentration initiale du médicament
dans le revêtement du DES ont un effet significatif sur la performance. Lorsque le médica-
ment utilisé est le paclitaxel, les solutions optimales consistent à relarguer le produit à des
concentrations nettement inférieures à celles des DES actuels soit pendant quelques heures,
soit pendant une durée d’un an. Pour le sirolimus, un relargage lent est nécessaire. Les
formes optimales des spires du DES sont toujours allongées mais profilées seulement lorsque
le relargage est rapide. Ces résultats permettent d’expliquer en partie les performances des
différents DES récents et révèlent un fort potentiel d’amélioration dans la conception des
DES par rapport aux dispositifs commerciaux actuels.
ix
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CHAPTER 1
Introduction
1.1 Atherosclerosis: a human condition?
Ischemic heart disease, stroke, and other cerebrovascular disease are the leading cause of
mortality in the world accounting for one in four deaths [195]. In most cases, the development
of these pathologies is attributed to the slow but steady process of narrowing and calcification
of arteries, known as atherosclerosis.
Though sometimes referred to as a “disease of affluence” [46] or “lifestyle disease”, the
factors contributing to the development of atherosclerosis go beyond a high cholesterol diet, a
sedentary lifestyle, and smoking. Diabetes, reduced levels of high density lipoprotein (HDL)
to low density lipoprotein (LDL) ratio in the bloodstream, male gender, family history of
cardiovascular disease, and hypertension all point to an important involvement of genetics in
the development of atherosclerosis. A recent investigation performed on 137 mummies from
four different ancient cultures (including pre-agricultural hunter-gatherers) [176] shows that
atherosclerosis has afflicted humans for at least four millennia and suggests the possibility that
atherosclerosis may be a condition inherent to human aging.
The development of atherosclerosis is a complex process initiated, according to current
understanding, by an inflammation of the endothelium [109]. The endothelium, the cellular
monolayer lining the inner surfaces of blood vessels, usually acts as a selective permeability
barrier that protects a healthy arterial wall from antagonistic substances in the bloodstream.
Inflammation increases endothelial permeability, enabling the deposition and accumulation of
plasma proteins, most prominently LDL, in the subendothelial space (SES) of the arterial wall
[47, 117, 160]. Trapped in the SES, LDL is oxidized, which positively reinforces the inflamma-
tory response of the endothelium. Simultaneously, monocytes are recruited to the site of inflam-
mation and transmigrate through the endothelium, where they differentiate into macrophages
and take up oxidized LDL. The rapid uptake of oxidized LDL transforms macrophages into
foam cells. The debris created by apoptosis and necrosis of foam cells initiates the formation of
plaque in the SES. Subsequent smooth muscle cell (SMC) proliferation into and migration from
the medial layer of the arterial wall [110, 161] further advances the lesion and its protrusion
into the lumen (Fig. 1.1).
This cascade of events results in the formation of a complex plaque in the arterial wall
which, if sufficiently advanced, can result in restriction of blood supply to the surrounding
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Figure 1.1: Development of atherosclerosis. Left: Healthy artery comprising the three arterial layers:
intima (covered by endothelial cells), media (with smooth muscle cells), and adventitia. Right: Artery
diseased by atherosclerosis – lipids, marcophages, and smooth muscle cells have penetrated the intima
at a site of dysfunctional endothelium; foam cells and cellular debris form the atheroslcerotic plaque.
Adapted from Encyclopædia Britannica Online.
tissue. If the obstructed artery is a coronary artery, the reduced oxygenation, referred to as
myocardial ischemia, leads to pathological consequences that range from chest pain under
stress conditions (stable angina) to constant pain even at resting conditions (unstable angina).
In the most severe cases, the blood supply to parts of the heart muscle is cut off entirely (acute
coronary syndrome) resulting in a heart attack.
A central question in the study of atherosclerosis is to identify the mechanism that initiates
the inflammation and subsequent dysfunction of the endothelium. Although this question has
attracted tremendous scientific attention, it has yet to be conclusively answered. A critical
observation in this regard, however, is that atherosclerosis is a focal disease with early lesions
developing preferentially in regions of arterial branching and curvature [159, 169]. Within
these regions of abrupt changes in arterial geometry, arterial blood flow is “disturbed”, strongly
suggesting fluid mechanical implication in the initiation of atherosclerosis [8, 14, 28–30, 33,
58, 98, 133].
Understanding the role of arterial flow disturbance in the development of atherosclerosis
requires elucidating the effect of flow on endothelial cell (EC) function and dysfunction. Over
the past two decades, numerous studies have demonstrated that flow elicits humoral, metabolic,
and structural responses in ECs [13, 32, 41]. The mechanisms by which ECs sense fluid me-
chanical forces and subsequently transduce these forces into biochemical signals that regulate
cellular function remain incompletely understood and are under intense investigation. One of
the most well documented flow responses in the literature is the effect of flow on EC morphol-
ogy. ECs exposed to steady flow or to non-reversing pulsatile flow become highly elongated and
aligned in the direction of flow [15, 43, 45, 75, 115, 134]. On the other hand, ECs subjected
to “disturbed” flow in the form of very low or directionally oscillating flow maintain a cuboidal
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morphology similar to that of cells in static culture [72, 75]. Interestingly, cuboidal ECs appear
to exhibit significantly higher permeability to macromolecules than elongated ECs. Elucidating
possible relationships between EC morphology and cell function and dysfunction promises to
provide critical information regarding the role of flow in the development of atherosclerosis.
1.2 Treatment of atherosclerosis: a brief history
While treatment of stable angina typically involves administration of medication and specific
recommendations for lifestyle changes [22], lesions leading to unstable angina or even acute
coronary syndrome require surgical intervention. In 1977 Andreas Grüntzig opened an entirely
new chapter in the treatment of obstructed coronary arteries by inflating a catheter-mounted
balloon at the site of the stenosis to re-open the artery [130]; percutaneous coronary inter-
vention (PCI) was thus born. The great benefit of catheter-based balloon angioplasty (today
referred to as "plain old balloon angioplasty" or POBA) for the patient was that the treatment
was minimally invasive and did not require open heart surgery leading to significantly reduced
recovery times.
Despite representing a major advance in cardiovascular intervention, POBA was not without
its problems. In more than 50% of the cases this treatment failed due either to immediate
vessel recoil or arterial restenosis (re-occlusion of the blood vessel due to uncontrolled growth
of smooth muscle cells (SMCs) in reaction to the injury inflicted by the balloon). Another
major advance was made in 1986 when Jacques Puel performed the first PCI on a human with
a Palmaz-Schatz stent mounted on the balloon. The stent1, a tubular wire-mesh, remained in
the artery after the intervention to serve as a permanent scaffold (Fig. 1.2). Although the use
of a stent in PCI cut the rate of restenosis in half compared to POBA, restenosis remained a
major complication in an unacceptably large fraction of the procedures. Restenosis occurs due
to the uncontrolled proliferation of SMCs and their migration from the media into the intima
(neointimal hyperplasia) and ultimately into the lumen where they form a new obstruction to
blood flow.
The breakthrough that would eventually lead to almost complete elimination of restenosis
[157] was the development of drug-eluting stents (DES) which involve the addition of an anti-
proliferative drug to the metallic bare-metal stent (BMS). The drug, most commonly sirolimus
(or one of its derivatives) or paclitaxel, is released into the arterial wall where it inhibits
SMC proliferation and hence prevents neointimal hyperplasia. With more than 7 million stent
implantations per year worldwide (most of which are DES), the stent has become the most
successful medical device for the treatment of advanced coronary atherosclerosis today.
The drawback of using anti-proliferative drugs on stents is that these drugs also retard the
healing process following the implantation process, mostly (but not exclusively) by delaying the
recovery of the endothelium [54, 84, 85, 190]. Delayed endothelial recovery is associated with
an elevated risk of late and very late stent thrombosis [53, 69, 84, 116, 131]. Stent thrombosis
is the sudden formation of blood clots at the site of stent implantation. Depending on the time
of occurrence relative to the intervention, stent thrombosis is classified in four types [170]:
acute, within the first 24 hours; sub-acute, within the first 30 days; late, within the first year;
and very late, after the first year.
Whereas acute and sub-acute stent thrombosis are inherent to the foreign body response
following implantation of stents (BMS or DES) [150], late and very late stent thrombosis
1named after English dentist Charles Thomas Stent (1807–1885) [21, 104, 154]
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Figure 1.2: Stenting procedure. A: A balloon-mounted stent is introduced to the site of the occlusive
atherosclerotic lesion via a catheter. B: The balloon is inflated at high pressure so that the ballon and
stent compress the atherosclerotic plaque thereby re-opening the artery and restoring blood flow. C: The
balloon is retracted and the stent remains as a permanent scaffold. Source: Encyclopædia Britannica
Online.
are far more likely to occur with DES than BMS. The unpredictability and high mortality of
stent thrombosis make this complication, though rare, particularly serious. Addressing this
complication requires extending the duration of an anti-thrombotic treatment in the aftermath
of the surgery. The optimal duration of anti-thrombotic treatment remains, however, unknown.
In light of these complications, questions have recently arisen on whether the scaffolding
and drug elution characteristics of a stent are needed for longer than 6 months after the surgery.
Proliferation of SMCs is significant for only the first few weeks [150], and complete remodeling
of the arterial all is achieved within approximately 3 months [137]. In recent years, the above
considerations have resulted in the development of biodegradable stents [61, 137] and in
the revival of balloon angioplasty but now using balloons coated with an anti-proliferative
drug, usually paclitaxel [66]. While both treatment options show very promising results, their
long-term efficacy are yet to be established.
1.3 Anti-proliferative drugs: bliss and curse of drug-eluting stent
design
A DES is comprised of three components: a stent body which provides the structural support,
the drug to be eluted, and the drug carrier in which the drug is loaded and through which
it is delivered. Each of these components has its own requirements [27, 101, 142]. The
stent body needs to supply sufficient radial and axial strength, it needs to be very flexible to
be easily deliverable even to the most complicated lesion, and the struts need to have a low
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profile to limit arterial damage at implantation and to minimize disturbance of the flow field
in order to reduce the risk of thrombosis and facilitate re-endothelialization [33, 44, 96]. The
geometry of the stent body also determines the release pattern for the drug into the arterial
wall [11, 24, 51, 125, 127, 128, 162, 183, 201].
The drug carrier (typically a polymer) should be bio-compatible to prevent an inflammatory
or rejection reaction. It should also enable controlled and sufficient release of drug, such that
drug concentration in the arterial wall remains within the therapeutic window, i.e. sufficiently
high to be effective and yet sufficiently low to avoid toxicity. The drug itself should effectively
inhibit SMC proliferation within the first few weeks after the implantation [150] without
causing secondary or long-term effects that compromise the integrity of the arterial wall. Finally,
all of the stent’s components need to be finely tuned for the treatment to be successful both in
the short and long terms.
How crucial stent design is to the success of a stenting procedure was emphasized by the
results of the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) study [157]
which demonstrated the superiority of second generation DES over both first generation DES
and BMS. Second generation DES have undergone major design changes in their geometry, drug
composition, and the composition of the drug carrier relative to the first generation devices [60].
Even among different second generation DES, significant differences in re-endothelialization
outcomes have been observed with different stent designs [85, 132, 172].
The release kinetics of the drug from the drug carrier also play a crucial role for determining
the therapeutic efficacy of a DES [7, 68, 102, 152, 165]. Moreover, the drug itself can be a
design variable; interestingly, all drug-coated balloons currently under development use paclita-
xel as the therapeutic agent of choice which is in contrast to developments in second generation
DES, where manufacturers have for the most part opted for sirolimus (or its analogues) as the
drug of choice.
1.4 Modeling drug transport in the arterial wall
The transport of an eluted drug within the arterial wall is governed by convection and diffusion
through the tortuous pore space and to interactions with the cells of the arterial wall, most
notably ECs and SMCs. If we want to understand and evaluate the therapeutic performance
of DES, we need to first understand the processes occurring in the arterial wall, for which
computational models would be particularly helpful. Consequently, significant scientific effort
has been dedicated to study and model the transport of drugs [38, 81, 82, 105, 114, 179–
181] in the arterial wall, resulting in a variety of different modeling approaches ranging from
relatively simple models that assume either a low drug diffusivity in the arterial wall [128]
or a constant partition of bound and free drug [200] to more sophisticated models where
drug interactions with the arterial wall are described by a second-order reversible reaction
[24, 179]. With very few exceptions [51], these models approximate the arterial wall as a
single homogeneous layer and often neglect convective drug transport within the wall.
1.5 Stent design optimization
The broad variability in therapeutic success of DES in clinical use suggests that today’s DES
designs are not necessarily optimal. Recognizing the shortcomings of today’s stents, pioneering
studies of stent design optimization have been conducted over the past few years [9, 70, 71,
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140, 141, 171]. These studies have so far been limited to optimizing geometrical features of
stents.
Modeling the physiologically relevant phenomena associated with stenting leads to complex
computational models (see Chapter 2, [24, 51, 139]) that are computationally expensive to
evaluate. A very versatile optimization framework used in the case of expensive computational
simulations is the surrogate management framework (SMF) [23], since the use of classical
optimization methods is often rendered infeasible. The SMF algorithm is a derivative-free
optimization method which explores the space of possible designs by repeatedly evaluating the
computational model for different sets of design variables. The algorithm uses a succession of
search and poll steps to identify a set of design variables that yields the most optimal design.
This method has previously been applied to the optimization of various aerospace [118, 119]
and bioengineering [120, 198] systems.
1.6 Scope and outline of the present dissertation: optimization of
drug-eluting stents
The present dissertation applies computational modeling to derive guidelines for novel stent
designs that optimize DES performance. Recovery of the endothelium is particularly important
for the success of a DES. Thus, we will focus our attention on the phenomena that appear to
have a crucial impact on the endothelium: transport of the anti-proliferative drug eluted from
the stent drug carrier and disturbance of the flow field due to the geometric design of the stent.
In this work we will try to answer the following questions: What is an optimal stent? What
design elements are crucial for obtaining an optimal stent? What should these design elements
look like for an optimal stent? What is the role of the choice of drug in the optimization?
We propose the following strategy to answer these questions: 1) We develop a computa-
tional model of fluid flow and drug transport in stented arteries which serves to evaluate the
performance of DES design. 2) We formulate a metric that quantifies DES performance. 3) We
use a derivative-free optimization algorithm to minimize the cost function derived from the
metric and hence identify optimal DES designs.
In Chapter 2 we develop a computational model of drug transport that takes into account
the multi-layered structure of the arterial wall, includes both convective and diffusive transport
in the arterial wall, and incorporates a reversible binding model to describe drug interactions
with the cells of the arterial wall [179]. The computational model is applied to study the
transport dynamics of the two hydrophobic drugs paclitaxel and sirolimus. The sensitivity of
the model predictions to several modeling parameters is also presented. The results of the
simulations indicate a strong coupling between the drug dynamics in the arterial wall and the
release kinetics of the drug from the stent drug carrier. This finding motivates the optimization
of the drug delivery strategy, which we perform in Chapter 3.
In Chapter 3 we introduce a cost function that serves as a quantitative measure of DES
performance that assesses how well the applied drug delivery strategy maintains efficacious but
sub-toxic drug concentration in the media while simultaneously minimizing drug concentration
at the endothelial surface to facilitate re-endothelialization. We then minimize this cost func-
tion by coupling a novel SMF optimization algorithm [16, 17] with our physiologically-based
computational model derived in the previous chapter. Applying this approach, we identify the
different drug delivery strategies that are needed for paclitaxel and sirolimus to yield optimal
DES performance.
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Once drug delivery is optimized, Chapter 4 moves on to optimize DES strut shape. To this
end, we extend our cost function to include a measure of the flow disturbance caused by the
stent geometry. The particular SMF algorithm used here, which to our knowledge has never
before been applied to engineering optimization, is particularly well suited to perform these
more complex optimizations due to its regular and dense discretization of the design space
and its novel poll step procedure. An analysis of the sensitivity of our cost function motivates
the refinement of the optimization of the DES drug delivery strategies. The results of our
investigation demonstrate that, to achieve optimal DES performance, strut shape and drug
delivery need to be tailored to the drug dynamics in the arterial wall.
The concluding remarks at the end of the dissertation contain a comprehensive summary of
the results of all three chapters and make specific recommendations for future investigations.

CHAPTER 2
Modeling the Transport of Drugs
Eluted from Stents
2.1 Introduction
Despite the recent data of the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
study [157] that suggest that the overall performance of drug-eluting stents (DES) is superior
to that of bare-metal stents (BMS), the long-term safety and efficacy of DES remain controver-
sial. The primary concern stems from the risk of late and very late stent thrombosis, thought
to be principally attributable to delayed endothelial healing at the site of stent implantation.
In an attempt to avoid the complications associated with DES, an emerging technology is the
use of drug-coated balloons (DCB), either with or without subsequent stent implantation [66].
Interestingly, all DCB devices currently under development use paclitaxel as the therapeutic
agent of choice. This is in contrast to developments in the latest generation DES, where manu-
facturers have for the most part opted for sirolimus or its derivatives as the drug of choice. DCB
and DES have fundamentally different strategies for delivering drugs to the arterial wall: DCB
deliver a very high drug dose (200− 300 µg/cm2) in a very short time whereas DES deliver a
considerably lower dose (100 µg/cm2) over a period of several weeks.
Another important finding of the SCAAR study is that second-generation DES (such as
Medtronic’s Endeavor Resolute stent or Abbott’s Xience V stent), which have undergone major
design changes in their geometry, drug composition, and the composition of the polymeric coat-
ing within which the drug is embedded relative to first-generation DES, exhibit clearly superior
performance. Most investigations to date of the effect of stent design on stent performance
have focused on the role of detailed geometric features [11, 99, 163] or of DES polymeric
coating [73]. The role of the drug elution process itself [12] and its coupling to the specific
drug used [181] have received less attention and have thus far been limited to sirolimus.
Computational models of the transport of drugs eluted from DES or DCB within the arterial
wall promise to significantly enhance our understanding of the performance of these devices. A
number of different modeling approaches have been proposed ranging from relatively simple
models that assume either a low drug diffusivity in the arterial wall [128] or a constant partition
of bound and free drug [200] to more sophisticated models where drug interactions with the
arterial wall are described by a second-order reversible reaction [179]. Multi-dimensional
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models ([24, 128]), with the exception of the 3D model by Feenstra et al. ([51]), approximate
the arterial wall as a single homogeneous layer and often neglect convective drug transport
within the wall. Only 1D studies ([124, 146]) have thus far included the layered structure of
the arterial wall into their models for describing the elution of drugs from stents. The diversity
of modeling approaches, the different assumptions on which the models are based, and the
limited experimental validation of the models render it difficult to compare the predictions of
the different models and to make general conclusions. In some cases, different models can even
lead to contradictory predictions: for example, the calculations by Vairo et al. [183] indicated
insensitivity of the drug concentration profile in the arterial wall to lumenal blood flow, while
the work by Balakrishnan et al. [11] reached the opposite conclusion.
In an effort to better understand the validity and applicability of different model assump-
tions, the present work develops a computational model of the transport of the two drugs
paclitaxel and sirolimus eluted from DES in the arterial wall. The model takes into account
the multi-layered structure of the arterial wall and incorporates a reversible binding model to
describe drug interactions with the constituents of the arterial wall. The effects of assuming a
one-layer model for the arterial wall or equilibrium reaction conditions are explored. Finally,
the model is used to study the coupling between the drug release kinetics from the stent and
the drug dynamics in the arterial wall.
2.2 Materials and methods
2.2.1 Model geometry
A 2D axisymmetric geometry is used in all simulations. We consider a straight arterial segment
within which a model DES represented by 10 circular struts is deployed (Fig. 2.1). Stent strut
size, polymer thickness, and stent inter-strut spacing are adapted from the geometry introduced
by Mongrain et al. [127] and recently also used by Vairo et al. [183]. Due to the reduction in the
number of struts relative to those studies (10 struts instead of 15), our geometry is considered
to represent a smaller lesion (7 mm). We have verified that this has no significant impact on
the parameters of interest. Embedment of the stent struts in the arterial wall is assumed to
be 50%. A sensitivity study investigating the effect of strut embedment in the 20% to 80%
range revealed that while the magnitude of drug concentration in the arterial wall changes,
the overall behavior and the conclusions drawn are not altered. We also define a therapeutic
domain that extends three inter-strut spacings both upstream and downstream of the stent (Fig.
2.1) and that we consider to be the target zone for drug delivery. All computed variables are
for this therapeutic domain.
2.2.2 Physical model
The mathematical framework for the description of the arterial wall is based on the two-layer
model presented by Formaggia et al. [55]. We apply this model to the elution of the two
small hydrophobic drugs paclitaxel and sirolimus from DES and complement it with a recently
developed reaction model in the arterial wall [179]. Wherever possible, the model input
parameters are derived from experimental data available in the literature.
The arterial wall is assumed to be rigid and is modeled as a two-layered structure with the
subendothelial space (SES) and the media defined as distinct domains while the endothelium
and internal elastic lamina (IEL) are treated as interfacial matching conditions. The adventitia
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Figure 2.1: A: Model geometry with stent strut diameter ds = metallic strut diameter + 2 ·
polymer thickness = 0.15 mm + 2 · 0.05 mm = 0.25 mm. All scales are given in mm. Geometry not
drawn to scale. B: Computational mesh: Left: Close-up on struts 4 through 6. Right: Detail of the
intersection of polymer, lumen, SES and media with indication of boundary layer elements.
is not modeled as a distint layer but rather as a boundary condition at the outer surface of
the media. Because stent deployment is thought to lead to near complete denudation of the
endothelium at the deployment site, we assume in the modeling a baseline configuration where
the endothelium is absent within the stented portion of the vessel but is intact otherwise.
Drug transport is assumed to occur in the following four different domains: the arterial
lumen, the stent polymer coating, the SES, and the media. Different physical phenomena
dominate transport in each of these domains. In the polymer coating, we assume drug transport
to be purely diffusive. In the lumen, drug is transported via both convection and diffusion.
Each of the two layers of the arterial wall, i.e. the SES and the media, is modeled as a porous
medium with its distinct homogenized (but in some cases anisotropic) properties. The SES is
assumed to be devoid of all cells, so that drug transport within this layer occurs by convection
and diffusion. In the media, three different processes govern drug concentration: convective
and diffusive transport within the pore space, specific binding of the drug to smooth muscle
cells (SMCs), and non-specific binding of the drug to the extracellular matrix accounted for
through hindered diffusion.
2.2.3 Governing equations and boundary conditions
Unless stated otherwise, variables and equations are presented in non-dimensional form. Di-
mensional quantities are denoted by a tilde, and the reference values used in the non-dimensionalization
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are provided in Table 2.1.
2.2.3.1 Momentum transport
In the arterial lumen, blood flow is assumed to be steady and is thus governed by the time-
independent Navier-Stokes equations: 
u l∇u l =−∇pl+ 1Re0∆u l , (2.1)
∇u l = 0 , (2.2)
where u l and pl respectively denote the velocity and pressure in the lumen. Blood is assumed
to be a Newtonian fluid, and a lumenal Reynolds number of Rel = ˜¯ud˜lρ˜/µ˜b = 400 is considered
based on blood velocity magnitudes typically encountered in coronary arteries.
The SES and the media are considered as porous layers, and flow within these layers is
assumed to be governed by Darcy’s Law:
∇p j =− µp, jPD, jRe0 u j , (2.3)
where the subscript j denotes either the SES or the media, u j is the average fluid velocity in the
total volume (matrix plus pores), and µp, j and PD, j are the non-dimensional dynamic viscosity
Table 2.1: Reference values for the non-dimensional equations and reference non-dimensional quantities
Quantity Reference expression
(free and total) concentration c, cT initial drug concentration c˜0
(bound) concentration b maximum binding site density b˜max
hydraulic conductivity Lp ρ
−1
0 u
−1
0
second Damköhler number Da2 Da
0
2 =
k˜f b˜maxL
2
0
(1−" j)D0
fluid density ρ blood density ρ0 = ρ˜
diffusion D diffusivity in blood D0 = D˜b
length r, z strut diameter L0 = d˜s
Peclet number Pe Pe0 =
u0L0
D0
Darcy permeability PD L
2
0
permeability P diffusive velocity scale u˜D =
D0
L0
pressure p dynamic pressure p0 = ρ0u20
Reynolds number Re Re0 =
u0L0ρ0
µ0
time t diffusive time scale t0 =
L20
D0
fluid dynamic viscosity µ blood dynamic viscosity µ0 = µ˜b
velocity ~u= (u v w)T mean inlet velocity u0 = ˜¯uin =
u˜max,in
2
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and Darcy permeability, respectively. In the polymeric coating of the stent, the flow is assumed
absent and thus drug transport occurs solely by diffusion.
The following boundary conditions apply: at the inlet of the lumen region a laminar
Poiseuille velocity profile is prescribed:
wl,in = 2u¯

1−

2r
dl
2
, (2.4)
while at the outlet the pressure is fixed at the physiological excess pressure value of p˜out =
100 mmHg. The top boundary of the lumenal domain is the symmetry axis of the problem. The
endothelium and IEL are approximated as semi-permeable membranes with the endothelium
coupling flow in the lumen to that in the SES and the IEL serving as an interfacial matching
condition between the SES and the media. To describe these membranes, we use the Kedem-
Katchalsky equation [91] governing the fluid flux Jv across these membranes. Due to the
very small size of the drug molecules (≈ 1 nm ([76])) compared to the junction size of the
endothelium (leaky junction size ≈ 20 nm) or the pore size of the IEL (≈ 150 nm), the osmotic
reflection coefficient is very small (∝  rmol/rpore2), and the flux simplifies to ([55]):
Jv, j = n ju j = Lp, j∆p j , (2.5)
where Lp, j is the hydraulic conductivity of the respective membrane. In the central region
where endothelial cells do not hinder the fluid flow across the arterial wall, the matching
condition simplifies to continuity of radial velocity (ul = uses). In all cases, the axial velocity
at the lumen/arterial wall interface is set to zero (wl = 0). A zero axial pressure gradient
is assumed normal to the upstream and downstream boundaries of the arterial wall layers
resulting in no fluid flux across these boundaries and imposing a strictly radial flow field at
these boundaries. This assumption is strictly valid in an axially homogeneous arterial wall; the
upstream and downstream boundaries are sufficiently far from the therapeutic domain so that
these boundary conditions have no effect on the results. On the adventitial boundary (outer
boundary of the arterial wall), an excess pressure of p˜eel = 30 mmHg is assumed.
2.2.3.2 Drug transport
Drug transport in the lumen is governed by the unsteady convection-diffusion equation:
∂ cα, j
∂ t
+ Pe0uα, j∇cα, j =∇

Dα, j∇cα, j

. (2.6)
Equation (2.6) describes the concentration cα, j of a drug transported in the liquid phase
(intrinsic drug concentration) with a non-dimensional diffusion coefficient Dα, j at a refer-
ence Peclet number Pe0 (see Table 2.1). To describe mass transport in the porous arterial
wall, averaging is required. Neglecting dispersion, superficial averaging (averaging over both
phases of the porous medium containing the pore space and the solid tissue space) as described
by Whitaker [193] yields the following macroscopic transport equation in the arterial wall
(henceforth simply referred to as transport equation):
∂ c j
∂ t
+Λ jPe0u j∇c j =∇

D j∇c j

+ R j , (2.7)
where the reaction term R j accounts for drug flux to and from the tissue corresponding to
the binding and unbinding of drug molecules to their binding sites in the arterial wall. The
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two parameters that arise in the averaging process, the non-dimensional lag coefficient Λ j and
the effective non-dimensional diffusivity D j, will be discussed later. For a pure fluid (porosity
" = 1), Λ j = 1 and the effective diffusivity equals the diffusion coefficient Dα, j in the fluid (in
our case, Dα,l = 1 and uα,l is the velocity calculated from the Navier-Stokes equations in the
lumen.) In this case the liquid concentration cα, j equals the superficial average concentration
c j.
A general way of expressing the reaction term R j is by:
R j =− 1fcb
∂ b
∂ t
, (2.8)
which describes reaction as the negative of the rate of creation of bound drug concentration b
as the drug binds to the porous material. The factor fcb is defined as c˜0/b˜m, the ratio of the initial
concentration c˜0 in the stent polymer to the maximum binding site density b˜max. In recent
literature two common ways of modeling drug uptake by arterial tissue can be found:
1. Equilibrium model: A simplified approach to model drug uptake assuming that the bound
and free states are in a constant equilibrium [183, 200]. This assumption is valid when
the binding and unbinding processes are fast compared to convection and diffusion and
leads to:
R j = (κ− 1) ∂ c j∂ t , (2.9)
where κ is the total binding coefficient.
2. Dynamic model: A second order model (discussed in detail in Section 2.2.4.1) that
describes a saturating reversible binding process [179] treating bound drug as a dynamic
variable:
1
fcb
∂ b
∂ t
= Da02

c j (1− b)− 1fcbBp b

(2.10)
with the reference Damköhler number Da0 and the binding potential Bp. The baseline model in
the present work uses this dynamic model to describe drug interaction with cells of the arterial
wall; however, we also explore the ramifications of an equilibrium model assumption for the
predictions of drug transport from DES.
The transport equations are subject to the following boundary conditions: zero drug con-
centration at the inlet boundary in the lumen. Because convection is dominant in the lumen,
we set the outlet boundary condition to: ∆c = 0. At the upstream and downstream boundaries
of the arterial wall layers, a zero normal concentration gradient is prescribed. At the adventitial
boundary, we investigated the following three different boundary conditions:
1. cm = 0: considering the adventitia as a perfect sink.
2. −∇ Dm∇cm= 0: assuming drug transport across the adventitia to be purely convective.
3. Js,eel = Peelcα,m + c¯α,eelJv,eel: modeling the external elastic lamina (EEL) as a Kedem-
Katchalsky membrane assuming the drug concentration in the adventitia to be negligible.
We have verified that the choice of boundary condition has no significant effect on the param-
eters of interest. The baseline model uses the third option since it is considered the closest to
the physiological situation.
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At both the lumen-arterial wall interface and the SES-media interface, the Kedem-Katchalsky
formulation is used to describe the concentration discontinuity across the thin endothelium
and IEL:
Js, j =−n j

Λ jPe0u jc j − D j∇c j

= Pj∆cα, j + s j c¯α, jJv, j , (2.11)
where Pj is the permeability of the respective interface and the local average liquid concentra-
tion c¯α, j is calculated as the weighted average concentration of the layer (for more details see
Appendix A).
At the outer boundary of the stent polymer, drug flux continuity is prescribed:
Js,c =−nc  Dc∇cc= n j Λ jPe0u jc j − D j∇c j . (2.12)
Drug flux across the stent strut surface is zero, and the polymer is the only initial drug reservoir
yielding the following initial condition:
• c˜
 
t˜ = 0

= c˜0 = 100 molm−3 in the polymer.
• c = 0 elsewhere.
This intital concentration is representative for a high dose stent [152].
2.2.4 Determination of physiological parameters
Special attention was paid to the choice of the physiological parameters of the model. We use
experimental data wherever available, complemented with values from fiber matrix and pore
theory ([55] and references therein) when necessary. The solely tissue-dependent parameters,
namely the hydraulic conductivity L˜p, the porosity ", the Darcy permeability P˜D, and the proper-
ties of blood and plasma are well documented in the literature. All values with their respective
sources are summarized in Table 2.2. Fluid density is assumed to be the same for plasma and
whole blood with ρ˜ = 1060 kgm−3. The hydraulic conductivities of the endothelium and IEL
were calculated from Lp, j = PD, j/(µpL j) following the approach in [4] and [148]. In agreement
with [55], the fiber matrix porosity and total porosity of the media were respectively set to
Table 2.2: Fluid model parameters
Symbol Unit Lumen ET SES IEL Media
µ˜ Pas 3.5·10−3 (a,b)7.2·10−4 (a,b) 7.2·10−4 (a,b)7.2·10−4 (a,b) 7.2·10−4 (a,b)
P˜D m
2 N/A 3.22·10−21 (a)2.2·10−16 (a) 3.22 · 10−19 (a) 2.0 · 10−18 (a)
L˜p m
2 s kg−1 N/A 2.2·10−12 N/A 2.2·10−9 N/A
" – 1 5·10−4 (a) 0.983 (d) 4·10−3 (a) 0.25 (c)
L˜ µm d˜l = 3 mm 2 (a) 10 (a) 2 (a) 500 (a)
a [4]
b [148]
c [55]
d [79], [197], [92]
values without a reference are computed as presented in this section
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"f,m = 0.45 and "m = 0.25, yielding a SMC fraction in the media of "SMC = 1− "m/"f,m = 0.44,
which agrees well with previous data [89].
The effective diffusivities for the different layers D j, the lag coefficients Λ j, the membrane
permeabilities Pj and the sieving coefficients s j depend on the interplay of the drug with the
surrounding tissue. Here we will mainly focus on the diffusivities used in the model. The
calculation of the remaining parameters can be found in Appendix A.
In the present study, we will consider the two DES drugs paclitaxel and sirolimus. Paclitaxel
is a small hydrophobic agent with a molecular weight of M˜PAX = 853.9 Da [105] and an average
radius of r˜PAXmol = 1.2 nm [76]. Diffusion of paclitaxel in blood is reduced due to non-specific
binding to blood proteins; therefore, the free diffusivity in plasma for paclitaxel is taken as the
measured value in calf serum as determined in [114] D˜free,p,PAX = 20.3 · 10−12 m2 s−1. Using this
value, the free diffusivity in whole blood is determined using the Stokes-Einstein equation as:
D˜free,b,PAX =
µ˜p
µ˜b
D˜free,p,PAX = 4.176 · 10−12 m2 s−1 . (2.13)
The effective diffusivity D j in Eq. (2.7) is a lumped parameter that arises from the averaging
process of the diffusive term which accounts for the reduced transport of the solute on its
tortuous path through the fibrous structure of the extracellular matrix. Apart from this passive
effect, it can also account for an active reduction due to non-specific binding to the tissue of
the arterial wall. No experimental work on the effective diffusivity in the SES is known to the
authors. Given the assumptions of our model, we will consider the effective diffusion coefficient
to be a simple scaling of the free diffusivity D˜free by a factor that depends solely on material
properties [192]. We will thus approximate the effective diffusivity as
D˜eff,f, j = D˜free exp

−1− "f,i 12 1+ r˜molr˜f

, (2.14)
where r˜mol is the average radius of the drug molecule and r˜f is the average radius of the fibers
of the extracellular matrix. Levin et al. [105] determined experimentally anisotropic effective
bulk diffusion coefficients for paclitaxel, corresponding to the diffusivities in the media of the
arterial wall. These measurements suggest a very high anisotropy between radial and axial
diffusivities with Dz/Dr ≈ 1000. The work conducted in [81] suggests an anisotropy between
radial and circumferential diffusivities in the media of Dϕ/Dr ≈ 10. The structure of the media as
investigated in [136] suggests that the circumferential and axial diffusion coefficients are of the
same order of magnitude, whereas the diffusion coefficient in the radial direction is significantly
smaller. Therefore, in our baseline model, we assume the axial and circumferential effective
diffusivities to be of a comparable order of magnitude [188] and Dz/Dr = 10. Because the
importance of anisotropic diffusion has been highlighted in [80], we will explicitly investigate
the effect of different anisotropies. A summary of all coefficients for the transport of paclitaxel
can be found in Table 2.3.
Similar to paclitaxel, sirolimus is a small hydrophobic drug that binds to the FKBP12 receptor
of SMCs and endothelial cells. To calculate the transport properties of sirolimus, we applied
the same procedure as described for paclitaxel. Due to the slightly larger molecular weight
of M˜SIR = 914.2 Da [105], the Stokes-Einstein radius and blood plasma diffusivity need to be
adjusted (details in Appendix A). All transport coefficients for sirolimus are summarized in
Table 2.3.
It can be readily seen that the diffusivities of paclitaxel and sirolimus are not very different.
Rather, the primary difference between the two drugs stems from differences in their reaction
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Table 2.3: Transport model parameters for paclitaxel (upper part) and sirolimus (lower part)
Drug Symbol Unit Lumen ET SES IEL Media
Pa
cl
it
ax
el
Λ – 1 N/A 1.02 N/A 3.4
s – N/A 0.86 N/A 1.0 N/A
P˜ ms−1 N/A 3·10−6 N/A 9.8·10−6 N/A
D˜r m2 s−1 4.2·10−12 N/A 1.7·10−11 N/A 2.0 · 10−(11+n) (a,b)
D˜z m2 s−1 4.2·10−12 N/A 1.7·10−11 N/A 5.0·10−11 (a)
Si
ro
lim
us
Λ – 1 N/A 1.02 N/A 3.4
s – N/A 0.855 N/A 1.0 N/A
P˜ ms−1 N/A 3.6·10−6 N/A 9.6·10−6 N/A
D˜r m2 s−1 4.1·10−12 N/A 1.67·10−11 N/A 7.0 · 10−(11+n) (a,b)
D˜z m2 s−1 4.1·10−12 N/A 1.67·10−11 N/A 4.0·10−11 (a)
a [105]
b n= 1,2,3
values without a reference are computed as presented in this section
kinetics. More specifically, sirolimus binds and unbinds significantly more rapidly than pacli-
taxel as seen in Table 2.4 (discussed in more detail in Section 2.2.4.1). The diffusion coefficient
in the stent polymer coating is the result of an interplay of several factors including the polymer
matrix, the drug, and the stent platform release kinetics. Balakrishnan et al. [12] showed that
simple diffusion is appropriate to model this complex process. Reported values for diffusion co-
efficients range from D˜c = 1 · 10−13 m2 s−1 [183] down to D˜c = 1.5 · 10−17 m2 s−1, representing
the range from fast to slow release kinetics. The baseline configuration in this study assumes a
drug diffusivity in the polymer at the fast release end of this range (D˜c = 1 · 10−13 m2 s−1).
2.2.4.1 Time scales and dimensionless quantities for drug transport
In order to better interpret the results, it is useful to analyze the time scales introduced by the
full reaction model (Eq. (2.10)) and compare them to the other time scales in the transport
equation (Eq. (2.7)). Considering the dimensional form of Equation (2.10):
∂ b˜
∂ t˜
=

1− " j
−1
k˜f c˜ j

b˜max− b˜
− k˜r b˜ , (2.15)
Table 2.4: Non-equilibrium reaction model parameters for paclitaxel and sirolimus [179]
Drug Da2 Bp =
b˜max
(1−" j)K˜d K˜d =
k˜r
k˜f
(molm−3) b˜max (molm−3)
Paclitaxel 2700 41 3.1 · 10−3 0.127
Sirolimus 5 · 104 139 2.6 · 10−3 0.366
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the first term on the right hand side (RHS) represents drug binding to sites in the arterial
wall which requires the presence of both free drug and free binding sites. The binding rate is
additionally controlled by the forward reaction coefficient k˜f and the porosity " j of the tissue.
Thus, the characteristic time scale for drug binding is:
t˜f =

1− " j

k˜f b˜max
. (2.16)
The second term on the RHS of Equation (2.15) describes the drug unbinding due to the
assumed reversible nature of the reaction. The typical time scale characterizing this process is
determined by the reverse reaction rate k˜r:
t˜r =
1
k˜r
. (2.17)
The ratio of the forward to reverse reaction coefficients K˜d = k˜r/k˜f is the equilibrium dissociation
constant [179] and characterizes the overall affinity of the drug to its binding sites with low
values corresponding to high affinity.
We would now like to compare the time scales of drug binding and unbinding to those of
drug convection and diffusion. The typical flow velocity in the arterial wall is very different
from that in the lumen. The characteristic (radial) convective flow velocity in the arterial wall
can be written as:
u˜w =
p˜out− p˜eel
µ˜pH˜w
= 1.5 · 10−8 ms−1 (2.18)
with
H˜w =
∑
j
L˜ j
P˜D, j
, (2.19)
with j summed over the endothelium, SES, and media. With this we can now calculate the
typical time scale for convection in the media as
t˜C =
L˜m
Λmu˜w
(2.20)
and for diffusion
t˜D =
L˜2m
D˜rm
. (2.21)
To weigh the relative importance of these various processes, we form the following three
dimensionless quantities:
• Peclet number Pe: ratio of diffusion time scale to convection time scale,
• First Damköhler number Da1: ratio of convection time scale to forward reaction time
scale,
• Second Damköhler number Da2: ratio of diffusion time scale to forward reaction time
scale.
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The resulting computed time scales and dimensionless quantities, summarized in Table 2.5
(the different magnitude of the second Damköhler number compared to [179] stems from the
adapted length scale ( L˜m) and diffusivity (D˜
r
m) used), indicate that due to differences in their
reaction properties, paclitaxel and sirolimus concentration profiles in the arterial wall may be
very different despite the fact that both drugs have largely similar transport properties. For
both drugs, convection and binding clearly dominate diffusion. The major difference in the two
drugs lies in the relative importance of convection compared to reaction: sirolimus’ binding
rate is so high that it even dominates the convective transport (Da1 1), whereas paclitaxel is
more sensitive to convection (Da1 < 1). This table reveals an additional important time scale
for the transport problem, namely the release time from the stent, which approximates the time
over which the stent effectively releases its drug load from the polymer coating. Thus, for the
baseline stent, fresh drug supply only lasts for several hours.
The two Damköhler numbers defined above compare the initial maximum reaction rate
to the rates of convection and diffusion. This is adequate when considering a first-order
reaction process but is limited in its informative value when the reaction is second-order and is
reversible. To get a more comprehensive view of the binding and unbinding process, we define
an integral time-dependent first Damköhler number which compares the averaged magnitude
of the reaction term to that of the convection term in the media at each time point:
Daint (t) = Da1
∫
Vm

cm (1− b) + bfcbBp

dV∫
Vm
cmdV
. (2.22)
Daint (t) thus estimates the relative importance of reaction to convection in the media over
time.
2.2.4.2 One-layer approximation
Due to the small thickness of the intima compared to the media, it is tempting to simplify the
problem and represent the intima as a single Kedem-Katchalsky matching condition. Conse-
quently, the arterial wall would consist of a single porous layer representing the media. We
wanted to probe the validity of this assumption and to compare the results of the one-layer
Table 2.5: Time scales and dimensionless quantities for the stented part of the media for paclitaxel and
sirolimus
Drug Convection Diffusion Binding Unbinding Stent emptying Peclet 1st Damköhler 2nd Damköhler
time (h) time (h) time (h) time (h) time(a) (h) number number number
t˜C =
L˜m
Λm u˜w
t˜D =
L˜2m
D˜rm
t˜f =
(1−" j)
k˜f b˜max
t˜r =
1
k˜r
t˜E =
pi L˜2c
4D˜c
Per = t˜D
t˜C
Da1 =
t˜C
t˜f
Da2 =
t˜D
t˜f
Paclitaxel 2.8 34.7 5.1 210.7 5.5 13.0 0.5 6.75
Sirolimus 2.8 9.9 0.08 11.2 5.5 3.7 34 125.0
a [186]: assuming the stent elutes into a perfect sink surrounding
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model to those of our baseline two-layer model. To generate the equivalent effective hydraulic
conductivities for the matching boundary condition with and without endothelial coverage, we
reinterpreted the different layers involved (endothelium, SES, and IEL) as flow resistances in
series [148] and used the total resistance to obtain an effective hydraulic conductivity as:
Lp,eff =
µp∑
j
L j
PD, j
−1 . (2.23)
For the effective parameters for solute transport, we choose the same values as for the endothe-
lium in the non-denuded case and those of the IEL in the denuded case, since these correspond
to the largest resistance to transport.
2.2.5 Numerical methods
The governing equations are discretized by means of the finite element method (FEM) using
the commercial software package COMSOL Multiphysics 4.3 (COMSOL AB, Burlington, MA,
USA). The following types of elements are used:
• Momentum transport: third-order Lagrangian elements for the velocity and second-order
Lagrangian for the pressure (P3-P2)
• Drug transport: second-order Lagrangian elements
• Reaction equation: second-order discontinuous Lagrangian elements
The tolerance threshold for the relative error of the solution (relative tolerance) of the mo-
mentum equations was set to 10−9. An analysis of the transport problem showed no change
of the solution below a combination of relative tolerance 10−3 and absolute tolerance 10−4.
The computational domain of the momentum equations was extended beyond that of the drug
transport to ensure insensitivity of the results to the inflow and outflow boundary conditions.
The time advancing scheme is a backward differentiation formula (BDF) with variable order
and time step size [77]. The maximum time step size is restricted to 1 hour (h). Reducing the
maximum time step to 1/8 h did not change the solution, validating our choice for the maximum
step size.
The minimum mesh element size is set to two times the concentration boundary layer
thickness δ˜c as estimated by δ˜c ≈ 2p3d˜hRe−1/2d Sc−1/3b using the Reynolds number Red based on
the hydrodynamic stent diameter d˜h and the Schmidt number in blood Scb [183]. We note
that Red = Re0 in this particular case, since the reference length and velocity scales used to
non-dimensionalize the governing equations are the same as the length and velocity scales
used to compute Red. The mixed triangular and quadrilateral mesh (Fig. 2.1) is enhanced
with boundary layer elements (BLE) at the interface between lumenal flow and arterial wall
and at the interface of the stent polymer coating with the arterial wall. To smoothen the sharp
initial condition from the stent polymer to the surrounding domain, the inner boundary of
the triangular polymer mesh is enhanced with BLEs and the initial condition itself transitions
from c (t = 0) = 1 to c (t = 0) = 0 using an infinitely differentiable step function. The classical
approach of a mesh independence study [5] determined the number of elements in the lumen,
the SES and in the polymer. We consecutively increased the number of mesh elements in each
of these layers by a factor of 1.5 to 2 until the time evolution of the average concentration
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in the SES and the polymer showed a relative difference of less than 1% from one mesh
iteration to another. Similarly, we used the average wall shear stress along the lumen-wall
interface and the flow profile downstream of the stent as the test quantities to verify grid
independence in the lumen. In the media, however, the maximum cell size was limited by the
occurrence of spurious oscillations in the solution. This resulted in an overall very fine mesh
with approximately 290000 elements. Computation time for the baseline simulation performed
on 4 cores of an Intel® Xeon® CPU X5680 @ 3.33GHz processor is about 1 h.
2.3 Results
2.3.1 Baseline model
To capture the global predictions of the baseline model, we compute the spatially averaged
normalized mean concentration (NMC) of the eluted drug in each of the layers ( j) of the
arterial wall. The NMC at any instant in time is defined as follows:
NMC j (t) =
1
Vj
∫
Vj

c j (x , t) +
b j (x , t)
fcb

dV . (2.24)
In the case of the one-layer model (OLM), the theoretical subendothelial space (SES) NMC can
be calculated from:
NMCses (t) =
1
Γses
∫
Γses
"ses c¯α,ses (s, t)dΓ . (2.25)
Figure 2.2 shows simulation results for the baseline model eluting paclitaxel from the stent
coating at the fastest rate of the presented range. Representative for the entire stent, Fig. 2.2
A compares the total drug concentration (i.e. bound drug b plus free drug c) distribution
in the upstream region of the therapeutic domain up to the first two stent struts. The three
time points after stent implantation shown are: t˜ = 50 min, which corresponds to the time of
maximum NMC in the media; t˜ = 1 day (d); and t˜ = 7 d post implantation. At t˜ = 50 min,
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Figure 2.2: Baseline simulation (paclitaxel). A: Normalized concentration (NC) distribution in the
media and the SES at three different time points: t˜ = 50 min, t˜ = 1 d, and t˜ = 7 d post stenting. B:
Temporal evolution of the normalized mean concentration (NMC) in the SES and the media.
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the drug has already completely invaded the arterial wall. From the second strut onwards, a
symmetric drug distribution pattern surrounds the struts. The concentration is highest close to
the struts and is relatively low close to the lumen between the stent struts. The concentration
field around the first strut is asymmetric and skewed upstream. This is due to the fact that the
endothelium is denuded between the stent struts but intact upstream of the stent. Crossing the
intact endothelium the pressure drops by more than 50% from the lumen to the arterial wall
while in between struts, the pressure drop is virtually negligible. Thus, convection is higher in
between struts than at the upstream and downstream end of the stent, creating a recirculation
zone around the strut that distorts the symmetry in the concentration distribution.
Over the course of the next few days, the concentration distribution pattern homogenizes in
the media while the SES rapidly empties of drug. After one day, the concentration level in the
media has already dropped by an order of magnitude compared to the maximum concentration.
This is due to the fact that the fast-release kinetics of the baseline stent has already emptied the
entire drug supply at this point. After a week, the maximum concentration in the therapeutic
domain has dropped by two orders of magnitude. The radial concentration distribution is now
skewed towards the adventitia (rather than the intima) while a small concentration reservoir
has formed upstream of the stent where convective transport forces are not as strong because
the endothelium is not denuded.
Figure 2.2 B depicts the temporal evolution of the spatially averaged NMC in the SES and
media. Peak concentration in the SES occurs minutes after stent implantation and attains only
a quarter of the peak concentration in the media. Within the first day, the drug vanishes from
the SES. The high concentration in the media (≈ 8 · 10−3) is followed by a rapid drop within
the following 12 h to an NMC of 1 · 10−3, which corresponds well to the value of the maximum
binding site density of paclitaxel (bmax = 0.127). The decrease then slows down considerably
for the remainder of the week.
2.3.2 Sensitivity analysis of the model
In light of the uncertainty in some of the transport model parameters, we studied the sensitivity
of the baseline results to the drug diffusivity coefficients in the SES and the media while
maintaining the first Damköhler number constant. Given that all equations are non-dimensional,
the analysis is presented in terms of the sensitivity of the NMC to the Peclet number in the
different layers:
Peij =
u˜wL0
D˜ij
. (2.26)
Figure 2.3 illustrates the sensitivity of the model results to the Peclet number in the SES as
well as to the radial and axial Peclet number in the media. We have selected two different
parameters to measure the sensitivity of the model: 1) the magnitude of the peak NMC in the
SES and in the media (Fig. 2.3 A, C, E) and 2) the ratio of the NMC after one day, 5 days and
7 days compared to the maximum value (Fig. 2.3 B, D, F); this retention coefficient quantifies
the drop following maximum concentration in the media.
Varying the Peclet number in the SES over several orders of magnitude has a fairly small
effect on the concentration levels in the SES and media (Fig. 2.3 A). More specifically, varying
the SES Peclet number over 4 orders of magnitude leads to an increase in the maximum NMC
of ≈ 55% in the SES and only ≈ 10% in the media. The retention coefficient at one day changes
only by 6% (Fig. 2.3 B). The NMC in the wall is more sensitive to a variation of the radial
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Figure 2.3: Sensitivity analysis (paclitaxel). Dependence of maximum NMC in the SES and media on
A: SES Peclet number, C: radial medial Peclet number, and E: axial medial Peclet number. Dependence
of retention coefficient at three different time points ( t˜ = 1 d, t˜ = 5 d, and t˜ = 7 d post stenting) on B:
SES Peclet number, D: radial medial Peclet number, and F: axial medial Peclet number.
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Peclet number in the media (Fig. 2.3 C and D). While the peak NMC in the SES changes by
only a moderate 32%, the peak concentration in the media changes by ≈ 300%. The highest
sensitivity is observed as one goes from Perm = 0.02 to Pe
r
m = 0.2. With the peak concentration
increasing, the retention coefficient at one day decreases by 75% over the entire Perm range.
Here, too, the majority of the variation occurs in the Perm < 1 domain. The retention coefficients
at 5 and 7 days decrease by more moderate values of ≈ 45% and ≈ 34%, respectively.
The NMC in the SES appears to be largely insensitive to the axial Peclet number in the
media (Fig. 2.3 E), whereas the medial NMC is weakly affected, with a ≈ 14% total decrease
over a two order-of-magnitude change in Pezm. The retention coefficients for all three time
points decrease by ≈ 30%. Interestingly, in all cases the retention coefficients at 5 and 7 days
(Fig. 2.3 B, D, F) are less sensitive to Peclet number variations than the day one retention
values, implying that the long term evolution is affected differently than the short term.
A value commonly used in computational models for the medial porosity is "m = 0.25.
However, the porosity of the media largely depends on its state of health. With the fiber matrix
porosity of the media fixed at "f,m = 0.45, we varied the "m in the range of 0.1− 0.4 so that the
model remains consistent with its definition of the fraction of SMCs ("SMC). Fig. 2.4 depicts the
sensitivity of the peak concentrations in the SES and the media (Fig. 2.4 A) and the retention
coefficient in the media (Fig. 2.4 B) to "m. The SES concentration is unaffected by the medial
porosity; however, the maximum NMC in the media more than doubles in the considered "m
interval. Accordingly the magnitude of the drop at one day increases by 38%. Drug retention
at 5 and 7 days is largely unaffected by the porosity variations.
Changing the lumenal Reynolds number in the physiological range (Rel ∈ [100,800]) re-
veals a significant dependence of the concentration evolution in the SES on blood flow in the
lumen (Fig. 2.5). The maximum NMC in the SES decreases significantly (more than 85%) with
increasing Reynolds number; however, consistent with previous results [128], the maximum
total NMC in the media is only weakly affected.
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Figure 2.4: Sensitivity analysis (paclitaxel). A: Dependence of maximum normalized mean concentra-
tion (NMC) in the subendothelial space (SES) and media on medial porosity. B: Dependence of the
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Figure 2.5: Sensitivity analysis (paclitaxel). Dependence of the maximum NMC in the SES and media
on Reynolds number in the lumen.
2.3.3 Effect of one-layer modeling
It is currently common in DES modeling to treat the arterial wall as as a single layer with
homogenized transport properties mostly representing the media. However, it was shown in
[80] that the layered structure of the arterial wall can affect the deposition and distribution of
drugs. Figure 2.6 illustrates the differences in the concentration distribution occurring when a
one-layer model (OLM) is used instead of the two-layer model (TLM). To amplify the effects,
we have reduced the total strut size of the baseline with a diameter of ds = 250 µm to a diameter
of ds = 150 µm (representing a second generation DES strut) and considered a case where the
SES is thickened by a factor of three compared to the baseline situation due to the development
of atherosclerosis. Figure 2.6 shows the superimposed flow and drug concentration field around
the first strut of the stent. Both the TLM and OLM predict a back flow pattern around the first
strut; however, the TLM predicts a more pronounced back flow whereby the back flowing fluid
0 0.5 max
max NC = 0.02
arterial wall
lumen
two-layer one-layer
max NV = 
Figure 2.6: One-layer vs. two-layer modeling (paclitaxel). Normalized velocity (NV) and normalized
concentration (NC) field around the first stent strut for a situation where the SES has been thickened
by a factor of 3 and the total stent strut size has been decreased to 150 µm. Time shown is the point of
maximum concentration in the media.
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enters the SES, while the OLM is incapable of capturing this characteristic flow feature. We
can also see that the local changes in the flow field affect the concentration distribution and
magnitude close to the stent strut.
Fig. 2.7 compares the OLM and TLM predictions for the NMC in the SES and in the media
for the baseline model. Using equation (2.25) recovers the qualitative temporal evolution
of the NMC in the SES. However, the peak concentration is underestimated by about 30%,
and this offset continues to grow to ≈ 100% at 2 hours post implantation. For a “diseased”
configuration with a three-fold thickened SES, the differences between the TLM and OLM
become yet more pronounced, and the peak concentration is underestimated by 100%. In the
media, the agreement is very good qualitatively and quantitatively. Here also the discrepancies
grow when the SES thickness is increased.
2.3.4 Effect of reaction modeling
We wished to establish if an equilibrium reaction model adequately represents drug transport
in the arterial wall. Fig. 2.8 compares the temporal evolution of the total concentration
(NMC) in the media for the reversible binding reaction model to the case where free and
bound drug are assumed to be in a constant equilibrium. Using an equilibrium assumption,
the very early behavior predicted by the non-equilibrium model can be qualitatively recovered.
However, the peak concentration predicted by the equilibrium model occurs considerably later
and is significantly higher compared to the reversible binding model. For the commonly used
value of κ = 20 [183], the peak concentration is ≈ 3 times higher than that predicted by the
dynamic reversible reaction model and occurs ≈ 9 h later. With increasing κ, the peak becomes
progressively higher and is predicted to occur later. In all cases including the dynamic reaction
model, the arterial wall becomes completely void of drug within a week of stent implantation.
The emptying time is quicker for smaller values of κ.
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Figure 2.7: One-layer vs. two-layer modeling (paclitaxel). NMC for two different SES thicknesses
(Lses = Lses,0 and Lses = 3Lses,0) A: in the SES (both predictions of the OLM collapse onto one curve) B:
in the media.
2.3. RESULTS 27
0 1 2 3 4 5 6 7
0
0.5
1
1.5
2
2.5
Time (d)
N
M
Cm
e
di
a
 
 
dynamic reaction model
κ = 10
κ = 20
κ = 40
⋅ 10−2
Figure 2.8: Temporal evolution of the total NMC in the media as predicted by a reversible binding
reaction model (baseline model) compared to an equilibrium model for different values of the total
binding coefficient κ.
2.3.5 Effect of the choice of drug
All results presented thus far focused on paclitaxel. Another common drug used in DES is
sirolimus. Although different in their mode of action in preventing smooth muscle cell (SMC)
proliferation and migration [60], sirolimus and paclitaxel have similar transport properties (see
Table 2.3). With a binding potential Bp > 40, both drugs fall in the category of strongly retained
drugs [179].
Figure 2.9 compares the distribution of the bound drug fraction (b) in the upstream region
of the therapeutic domain for paclitaxel and sirolimus at the time of maximum total NMC in
the media ( t˜ = 50 min) and one day after stent implantation. Within the first hour binding has
occurred over the entire width of the arterial wall for both drugs. Binding is maximal close to
the stent struts and drops gradually with distance away from the polymer. The concentration
flow
paclitaxel sirolimus
0 0.5 1
t = 50 min
t = 1 d
Figure 2.9: Paclitaxel vs. sirolimus. Bound drug fraction b at two different time points: t˜ = 50 min (first
row) and t˜ = 1 d (second row).
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gradient is sharper in the case of sirolimus. For paclitaxel, there is a region near the lumenal
surface in between the struts where little drug binding occurs; such a region exists but is
considerably smaller in the case of sirolimus. At one day, the binding pattern has spread further
upstream. Interestingly, paclitaxel has invaded a larger portion of the upstream therapeutic
domain than sirolimus, although the axial diffusion coefficient of sirolimus is larger. These
observations underscore the more convection-dominated transport of paclitaxel compared to
sirolimus. Following the emptying of the stent, the unbinding process becomes the dominant
effect: the binding fraction in the case of paclitaxel drops to ≈ 70% on average while the
equivalent value for sirolimus is ≈ 60%.
Fig. 2.10 compares drug transport characteristics for stents loaded with either paclitaxel
or sirolimus for the baseline fast-release case (panels A, C and E) and for the case of a slow-
release stent (panels B, D and F). Figures 2.10 A and C demonstrate that for the fast-release
stent, the differences between paclitaxel and sirolimus are rather minor. Peak concentration
magnitude and timing in the SES and media are comparable. The one difference is the slower
drop following peak concentration in the media in the case of sirolimus compared to paclitaxel:
for paclitaxel the drop to 25% of the peak average concentration takes ≈ 6 h while for sirolimus
the same drop almost requires one day.
The slow-release stent is geometrically identical to the fast-release stent; only the diffusion
coefficient in the polymer coating has been reduced by three orders of magnitude to D˜c =
1 · 10−16 m2/s. When comparing the concentration profiles for the two drugs in the SES (Fig.
2.10 B) and media (Fig. 2.10 D) for the slow-release stent, a very different picture emerges:
while the qualitative behavior for both drugs remains similar, the concentration levels of siro-
limus are continuously above those of paclitaxel. At peak concentration in the SES, the NMC
of sirolimus is ≈ 50% higher than that of paclitaxel. This discrepancy grows to more than
100% at 8 weeks. The peak concentration of sirolimus in the media is three times the peak
concentration of paclitaxel, and after 8 weeks the NMC remains more than twice as high.
Figures 2.10 E and F compare the time-evolution of the integral Damköhler number for both
drugs for the fast-release and slow-release stent platforms. In the fast-release case, paclitaxel
begins in the convection-dominated regime (Daint < 1) and after the first half day transitions
into a slightly more binding-dominated regime. The transition is faster for sirolimus since
with the exception of the first few hours after the beginning of drug elution, the transport of
sirolimus is dominated by the binding and unbinding process. For the slow-release stent, the
balance of convective and reactive terms is less variable: paclitaxel remains in a regime where
convection and binding/unbinding are of comparable importance, whereas sirolimus is clearly
dominated by the binding/unbinding process over the entire time.
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Figure 2.10: Paclitaxel vs. sirolimus. Temporal evolution of the NMC in the SES for a A: fast-release
and B: slow-release stent. NMC in the media for a C: fast-release and D: slow-release stent. Integral
Damköhler number for a E: fast-release and F: slow-release stent (the horizontal line indicates the
Daint = 1 threshold).
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2.4 Discussion
2.4.1 Drug release is coupled to the drug and its transport properties in the
arterial wall
Considering the differences in the binding and unbinding time scales of paclitaxel and sirolimus
(see Table 2.5), it might appear surprising that both drugs behave so similarly in the case of a
fast-release stent platform. The integral Damköhler number sheds light on this: for paclitaxel,
the drug is initially predominantly in the free (and thus mobile) state and invades the media
driven by plasma flow in the arterial wall, since the time scale of convection is faster than that
for binding. This phase determines the initial distribution of the drug within the arterial wall.
With rising concentration levels of free drug in the media, the binding rate increases, leading
to an increased Daint and a transitional passage through a phase of competition between the
binding and convection terms. Once all binding sites are saturated, any excess drug is washed
out. As soon as the stent polymer is empty and the arterial wall has become void of all excess
drug, the transport becomes dominated by unbinding since t˜r t˜C and t˜r t˜D. For sirolimus,
on the other hand, the initial dominant process is binding. When the drug enters the media,
binding sites are very rapidly occupied, since t˜f is several orders of magnitude smaller than t˜C
or t˜D, and only drug exceeding the maximum binding capacity invades new areas of the media.
At the same time, this exhaustion of binding sites reduces the binding rate which initiates a
shorter, transient passage through a more convection-driven phase. Once the stent polymer
coating is empty, the behavior becomes dominated by the unbinding of drug from its binding
sites, since the time scale of the unbinding process is longer than that of either convection or
diffusion.
As a result, we can subdivide the activity of DES releasing hydrophobic drugs into two
phases: an initial release phase where new drug is supplied from the stent and a secondary post-
release phase where the drug effect is predominantly determined by the binding and unbinding
process. The first phase is prone to changes in the convective and diffusive transport of the free
drug. The relevance of this sensitivity is determined by the two Damköhler numbers and not
only depends on the release rate (determined by D˜c) but also on the initial concentration in the
polymer c˜0. As demonstrated by the evolution of the integral Damköhler number for the fast-
release stent, even the highly reactive sirolimus transport can become convection-driven, which
explains the similarity in concentration distributions of both drugs. The sensitivity analysis of
the radial Peclet number in the media Perm and the medial porosity "m illustrate this nicely: in
the first case we do not simply vary the relative importance of diffusion and convection but also
bring the second Damköhler number down from a regime where binding/unbinding dominates
to a diffusion-dominated regime and, thus, we get such a large variability for the low Perm range.
Once Da2 > 1 the results become almost insensitive to further variation. The same is true for
the variation of the medial porosity where effectively the first Damköhler number is varied:
going from a low to a high porosity we approach Da1 ≈ 1, and the peak variability goes down.
At the same time the retention coefficient almost does not vary since, with the free drug gone,
it is solely determined by the unbinding process.
Once we reduce the drug release rate significantly, we obtain a very different picture: the
slow, long-lasting drug supply balances the otherwise rapid unbinding process of sirolimus
ensuring a high, only slowly decaying concentration level. The transport of paclitaxel does
not benefit as significantly from the more permanent release since the very slow time scale of
unbinding determines the retention characteristics independent of the release kinetics.
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The present results demonstrate that paclitaxel and sirolimus have widely different transport
dynamics in the arterial wall. These differences suggest that different drug delivery strategies
should be used for these drugs. Moreover, both drugs have different therapeutic behavior: pacli-
taxel has a broad therapeutic window with a minimum effective concentration of c˜eff = 1 · 10−5
molm−3 and a maximum concentration level of c˜tox = 1 · 10−2 molm−3 above which the drug
becomes toxic [87, 124], while for sirolimus to be effective, saturation of the FKBP12 binding
sites appears to be required [187], raising the minimum effective concentration significantly.
Thus, the choice of a drug delivery strategy for a particular drug becomes a crucial design
parameter in DES development. Based on the present results and for the present geometric and
flow conditions considered, a paclitaxel stent platform should optimally employ fast-release
kinetics with a low initial drug load, whereas a sirolimus stent should target slow-release
kinetics with a higher initial drug load. It was well established in [12] that drug release kinetics
are an important factor in the DES design process. Our results complement those findings and
highlight the close coupling between the drug chosen and the applied drug delivery strategy.
The interplay between stent, flow, and drug parameters provides an opportunity for im-
plementing sophisticated optimization strategies for targeting “desirable” drug concentration
profiles in the arterial wall. Optimal drug profiles would be defined in terms of various criteria
including how uniformly the drug is distributed within the arterial wall and whether or not
drug concentrations fall within the therapeutically efficacious window.
An additonal conclusion from the present results is that the uncertainty in the diffusion
coefficients in the arterial wall are of a relatively minor importance for the concentration
distribution as long as the relevant dimensionless quantities, most notably the Peclet and
Damköhler numbers, remain in the appropriate physiological range.
2.4.2 Multi-layer model offers improved accuracy for pathological situations
Delayed re-endothelialization occurring with DES motivates the need for more detailed drug
concentration information, especially close to the endothelial surface. The SES and media are
characterized by fundamentally different transport properties (Table 2.3). Accounting for these
differences in the TLM revealed that higher concentration levels can be obtained in the SES
than in the media especially early after stent implantation (Fig. 2.7 A). The strong sensitivity
of the SES drug concentration to the lumenal flow field (Fig. 2.5) underscores the differences
between the two layers of the arterial wall. This also indicates that assuming a steady arterial
flow may not be sufficient to make accurate predictions for the concentration levels in the
arterial wall close to the lumen. In the future, time-dependent flow computations should
investigate this issue.
A detailed description of drug concentration within the SES is only available in the TLM.
The concentration in the SES as an averaged quantity can be extracted from the OLM with
the presented approach (eqn. (2.25)). Except for an offset, the qualitative behavior of this
global metric is very well recovered and even the distribution pattern at the endothelial surface
is in good agreement (Fig. 2.6 B) between the TLM and OLM cases. The reason for this
offset is the absence of the drug flux from the stent polymer entering the SES in the model
equation. Accordingly, the offset increases with thickening of the SES where the drug flux from
the polymer into the SES increases due to the larger contact area between the SES and polymer.
This weakness could be overcome by adding an averaged source term to the equation (eqn.
(A.5)). However, averaged concentration levels might not be the only information necessary for
unraveling the processes leading to delayed re-endothelialization (especially when incomplete
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endothelial coverage can be observed even up to five years after DES implantation [151]). As
the diseased configuration in Fig. 2.6 A demonstrated, predictions of the flow field diverge
significantly depending on the model. Convective forces can contribute considerably to the
drug distribution in the arterial wall when free drug levels are elevated (Figs. 2.9 and 2.10 E).
The representation of a diseased arterial wall as presented in this study are drastically
simplified for demonstration purposes. In its early stages, atherosclerosis affects primarily the
intima and as such the TLM offers the potential to account for different diseased states. For
example, the presence of SMCs that have migrated into the SES can be modeled by adding a
reaction term to the transport equation in the SES with customized reaction parameters (like
the maximum binding site concentration) or changes to the transport parameters in the SES.
This could also enable improved evaluation of experimental results that are often performed
on healthy vessels [152] and facilitate conjectures to the diseased case.
2.4.3 Reduction of the reaction model fails to capture important features of the
transport dynamics
As we could see, the drug transport process is highly dynamic and intertwined with the release
process. From a computational point of view, it would certainly be desirable if possible to avoid
the stiff (especially in the case of sirolimus) and computationally expensive reaction equation.
Tzafriri et al. [179] explored several possible concentration-dependent simplifications of the
dynamic reaction model. As considered here, the crudest simplification to account for drug
binding is to assume a constant partitioning of bound and free drug inherent in the equilibrium
model (eqn. (2.9)). Fig. 2.8 illustrates that an equilibrium reaction model fails to capture
essential features of the transport process: the binding coefficient κ reduces the transport term
permanently and thus the predicted accumulation of drug far exceeds that of the dynamic
reaction model. Moreover, the coupling of the convection-diffusion and reaction equations
transfers free (i.e. mobile) drug into a bound (i.e. stored) state. This cannot be reflected with
the equation obtained by the equilibrium model and thus the residence time of the drug in
the arterial wall is underestimated. Matching the prediction of the drug accumulation by the
equilibrium model to that of the dynamic reaction model requires a reduction of the partition
coefficient, while matching the drug residence time demands an increase. Both objectives
cannot be achieved simultaneously.
CHAPTER 3
Optimized Drug Delivery for
Drug-Eluting Stents
3.1 Introduction
A primary concern associated with the use of drug-eluting stents (DES) is late stent thrombosis
(LST). LST, which involves the formation of blood clots at the site of stent implantation, can
occur up to several years after the intervention [20, 26, 151]. Although its development is
incompletely understood, LST is thought to occur as a result of the delayed healing of the
endothelium following its denudation by both the stent and the balloon upon which the stent
is deployed. In support of this notion, a recent study has demonstrated that DES can in some
cases remain unendothelialized five years after stent placement [151]. In contrast, bare metal
stents (BMS) are typically covered with new endothelium within six months of the stenting
procedure [156, 182].
Drugs eluted from DES, typically paclitaxel or sirolimus, act on smooth muscle cells (SMCs)
in the arterial wall to arrest their proliferation and hence inhibit vascular restenosis. A likely
reason for the delayed endothelial healing in the case of DES is that these same drugs also affect
endothelial cell (EC) migration and proliferation [40, 54, 107, 112, 116] and thus greatly limit
endothelial wound healing. A key question that arises in the design of DES is whether or not
it is possible to deliver anti-proliferative drugs at sufficiently high concentrations to SMCs to
prevent restenosis while simultaneously maintaining a sufficiently low drug concentration at
the EC surface to allow sufficiently rapid endothelial wound closure.
In the previous chapter, we developed a computational model for the transport of drugs
eluted from DES within the arterial wall. The model considered the arterial wall to consist
of a two-layered porous structure comprising the subendothelial intima and the media. Drug
release from the stent was assumed to occur by diffusion and drug transport in the arterial wall
was assumed to occur by convection and diffusion with the drug also undergoing a reversible re-
action in the media to represent its binding to SMCs. The baseline model assumed a completely
denuded endothelium in the stented portion of the artery, while the endothelium remained
intact both upstream and downstream of the stent. The model was applied to the transport
of both paclitaxel and sirolimus, and the results revealed important differences between the
two drugs in transport characteristics and dynamics. Importantly, the results suggested that
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drug distribution within the arterial wall depends on a number of parameters including the
drug, its release rate into the arterial wall, and its initial concentration in the stent polymer.
These findings serve as the primary motivation for the present chapter which focuses on the
optimization of drug delivery strategies from DES for both paclitaxel and sirolimus.
The notion of using optimization in stent design and performance assessment has previously
been invoked in other contexts. For instance, previous studies have reported the optimization
of stent strut geometry with the goal of minimizing blood flow disturbance in the arterial lumen
[9, 70, 71, 171], stresses in the stent itself [196], or stresses in the arterial wall [178]. Pant and
collaborators recently reported the first attempt at including multiple cost functions and multi-
ple physical phenomena in the optimization process with the use of a steady (time-independent)
transport model to investigate the effect of DES geometric design on the homogeneity of drug
distribution and its average concentration in the arterial wall [140, 141]. In all previous
studies, stent geometric design served as the design space under consideration. DES drug de-
livery strategies, which are determined by the release kinetics (elution process) in the polymer
coating and the drug concentration initially loaded onto this coating, were not part of these
investigations. Release kinetics have been at the heart of experimental [7, 57, 68, 102, 138]
and computational [12, 181] investigations over the past few years. However, optimal release
kinetics remain an open question in the design process of DES [175, 185]. Optimizing the
delivery process of the eluted drug holds the promise of providing strategies that at least in
part address the problem of delayed endothelial healing.
In the present chapter, we focus on the development of a strategy to identify optimal drug
delivery strategies of DES. To this end, we begin by formulating a cost function that needs
to be minimized. The cost function evaluates how well a particular drug delivery strategy
maintains an efficacious but sub-toxic drug concentration in the arterial media, provides mini-
mal drug concentration at the endothelial surface in order to allow stent re-endothelialization,
and results in a spatially homogeneous drug distribution within the arterial wall. For the
purpose of the optimization, the design space is assumed to consist of two parameters: the
initial drug concentration on the drug coating and the drug release rate from the coating; thus,
these two parameters are assumed to provide an adequate representation of the drug deliv-
ery strategy. Minimization of the cost function is accomplished by coupling a novel surrogate
management framework optimization algorithm [16, 17] with our physiologically-based com-
putational model of drug transport in stented arteries (see Chapter 2). This approach is applied
to determine optimal drug delivery strategies for paclitaxel- and sirolimus-eluting stents.
The results of the optimization suggest that the concentration that needs to be initially
loaded onto a DES is dependent on the therapeutic window of the drug. Thus, paclitaxel-eluting
stents require very low initial concentrations to comply with the aforementioned objectives.
We also observed that optimal drug release times are dependent on the drug kinetics in the
arterial wall; this allows either very rapid (quasi-bolus) or long-term zero-order release kinetics
for paclitaxel-eluting stents but restricts the release of sirolimus-eluting stents to long-term
zero-order kinetics. For both drugs intermediate release kinetics (implying first-order release
kinetics) are inappropriate to achieve optimal stent designs.
3.2. MATERIALS AND METHODS 35
3.2 Materials and methods
3.2.1 Computational model
Chapter 2 described the computational model for drug transport used in the present optimiza-
tion analysis. The optimization is performed on a DES consisting of three circular struts spaced
at intervals of 0.7 mm and deployed within a straight and rigid-wall arterial segment repre-
sented as an axisymmetric cylinder. The stent struts have a diameter of 100 µm to which a
10 µm-thick polymeric coating is applied reflecting approximate dimensions of typical second
generation DES [60]. We apply the transport model of Chapter 2 to the elution of the two small
hydrophobic drugs paclitaxel and sirolimus. The baseline simulations consider an endothe-
lium that is completely denuded within the stented portion of the vessel but intact otherwise
(configuration E1 in Fig. 3.1 A). Some simulations assume a second model configuration
where the endothelium is considered denuded not only in the stented zone but also upstream
and downstream of the stent for a distance half the length of the inter-strut spacing, always
measured from the strut centers (configuration E2 in Fig. 3.1 B). As a consequence of removing
the shielding capacity of the endothelium upstream and downstream of the stent, the flow field
becomes symmetric around all struts, effectively increasing convection in those two domains of
the arterial wall. We define the therapeutic domain as the volume of the arterial wall containing
the stent and extending by 2/3 of the stent length both upstream and downstream of the stent.
3.2.2 Cost function
As already mentioned in the Introduction, we propose a cost function that needs to be mini-
mized for optimal drug delivery from DES. Minimization of the cost function serves to accom-
plish the following three objectives:
1. Therapeutically efficacious but sub-toxic drug concentration in the media: The eluted drug
needs to have its desired therapeutic effect. We assume that as long as the local drug
concentration in the media remains within the drug’s therapeutic window, i.e. above an
endothelium denudedendothelium endothelium
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stent strut
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Figure 3.1: Two configurations of the computational model used in the simulations. A: Configuration E1
considers an endothelium that is completely denuded within the stented portion of the vessel but intact
otherwise. B: Configuration E2 considers an endothelium that is completely denuded in the therapeutic
domain but intact otherwise.
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efficacious minimum threshold and below a toxic maximum concentration, the drug effec-
tively arrests SMC proliferation thereby having the desired effect of preventing neointimal
hyperplasia and vascular restenosis.
2. Minimal drug concentration at the arterial wall lumenal surface: We need to minimize
drug concentration at the lumenal surface in order to allow endothelial wound healing
to occur. We postulate that if the drug concentration at the lumenal surface remains
below the lower limit of the drug’s therapeutic window, then EC proliferation will be
unhindered.
3. Maximal homogeneity of the drug concentration distribution in the media: We assume that
local concentration extrema are detrimental and that a homogeneous drug distribution
in the media is desirable.
How well a particular stent design performs in accomplishing the three above goals can serve
as a metric of the quality of the design. For the purpose of the current investigation, a design
is defined by the two parameters that determine the drug delivery strategy from DES: the
initial drug concentration c0 in the stent polymer coating within which the drug is loaded
and the characteristic drug release time from this polymer coating. Because drug release is
assumed to occur by diffusion only, this characteristic time is given by tE = piL
2
c/(4Dc), where Lc
is the thickness of the polymer coating and Dc is the drug diffusion coefficient in the coating.
The two parameters defining a particular design serve as input for a simulation using our
computational model. The resulting concentration distribution is then used as the basis to
quantify the performance of a particular design by means of the following cost function:
JETH
 
c0, tE

= Im+
1
3

T l+ T ses+ Tm

+Hm . (3.1)
The cost function is formulated as the sum of three scores evaluated within the therapeutic
domain of the numerical model: a score that denotes drug inefficacy in the media ( Im), an
overall toxicity score that consists of the arithmetic average of the three toxicity scores in the
lumen, subendothelial space (SES), and media (T l, T ses and Tm, respectively), and a drug
homogeneity score (Hm). The shapes of the cost function JETH as well as the inefficacy, toxicity,
and homogeneity scores are schematically depicted in Fig. 3.2. We will now describe the three
scores that constitute the cost function in detail.
Inefficacy score
The inefficacy score in the media Im is defined as follows:
Im =
1
Vm,th
∫
Vm,th
ϕ dV where ϕ =
(
1, if cT,m ≤ ceff,
0, otherwise.
(3.2)
Every point in the medial portion of the therapeutic domain with a drug concentration below
the minimum efficacious threshold ceff is assigned a score of 1 and a score of 0 otherwise (Fig
3.2 A). The inefficacy score Im is obtained by integrating the point-by-point scores over the
entire medial therapeutic domain volume (Vm,th) and then dividing by this volume. Therefore,
Im represents the percentage of the media within the therapeutic domain where the total drug
concentration cT,m (i.e. sum of free and bound drug) falls below the minimum efficacy threshold.
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Figure 3.2: Shape of the cost function and its contributing scores. A: inefficacy score Im; B: toxicity
score Tm; C: homogeneity score Hm; D: cost function JETH representing the sum of the individual scores.
Equation (3.2) is evaluated for every time point of the simulation and then averaged over the
entire simulation time tend yielding the time-averaged inefficacy score Im. The simulation time
tend corresponds to the period of time over which the optimization is performed.
Toxicity score
While the minimum efficacious concentration ceff sets the lower limit of the drug therapeutic
window, the toxic concentration ctox defines the upper limit. In the media, the toxicity score Tm
is obtained through the following series of steps. First, similar to the inefficacy parameter, the
expression
ϑm =
1
Vm,th
∫
Vm,th
ϑ dV where ϑ =

cT,m− ctox
γthrctox
, if cT,m ≥ ctox,
0, otherwise.
(3.3)
is evaluated. This integral quantifies the fractional volume of the media in the therapeutic
domain that is exposed to toxic drug concentrations, with the score weighted by the relative
deviation from the toxic threshold so that the higher the concentration above the toxic threshold,
the higher the score (and hence the larger the penalty). The scaling factor γthr provides a
mechanism for adjusting the weighting to establish which deviation from the toxic threshold is
considered equally harmful as a concentration that is not efficacious (i.e. a score of 1). Once
this first step is completed, the second step consists of mapping the result of Equation (3.3)
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onto a hyperbola whose asymptote is at the limit value ϑlim:
Tm =
1+
ϑlim− ϑthr
ϑlim− ϑm
ϑm
ϑthr
, if 0≤ ϑm < ϑlim,
∞, otherwise.
(3.4)
The slope of this hyperbola is adjusted such that it passes through 1 at the threshold value
ϑthr. Furthermore, the hyperbola is lifted by 1 to emphasize that any toxic concentration is
undesirable. The rapid increase in toxicity score as drug concentrations increase above the
toxic threshold emphasize that these concentrations should be avoided by all means and serve
to drive the optimization away from these concentrations. Fig. 3.2 B schematically depicts the
variation of the toxicity score with drug concentration.
The arterial wall lumenal surface is handled virtually identically to the media with the
following two equations:
ϑS,l =
1
Sl,th
∫
Sl,th
ϑS dS where ϑS =

cl− ceff
γthrceff
, if cl ≥ ceff,
0, otherwise.
(3.5)
Tl =
1+
ϑlim− ϑthr
ϑlim− ϑS,l
ϑS,l
ϑthr
, if 0≤ ϑS,l < ϑlim,
∞, otherwise.
(3.6)
There are two differences to point out: 1) Given that we are now considering the lumen-wall
interface, the integral in Equation (3.5) becomes a surface integral rather than a volume inte-
gral. 2) At the lumenal surface we do not want the drug to impair EC proliferation; therefore,
we consider that the “toxic” concentration limit is the minimum efficacious concentration and
formulate the toxicity score in a manner to drive the algorithm towards concentrations lower
than this threshold. We note that because a concentration jump occurs across the lumenal
surface whenever endothelium is present, we evaluate the interfacial toxicity parameter from
both the lumenal side (denoted by ϑS,l and Tl) and the SES side (denoted ϑS,ses and Tses). The
SES evaluations are similar to those shown above for the lumen but with the concentration cl
replaced by cses. The arithmetic mean of the toxicity scores from the lumenal and SES sides
provides the toxicity score of the lumenal surface Te. As in the case of the inefficacy score, the
toxicity scores are evaluated for every time point of the simulation and then averaged over the
entire simulation time tend yielding the desired time-averaged toxicity scores.
Homogeneity score
The final term appearing in the cost function is the homogeneity score Hm which is defined as
follows:
Hm =
1
Vm,t
∫
Vm,t
η dV where η=

cT,m− ctol
ctox− ctol , if ctol ≤ cT,m < ctox,
0, otherwise.
(3.7)
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The portion of the therapeutic domain of the media with a concentration superior to a tolerable
value ctol but inferior to the toxic threshold ctox is weighted on a scale that increases linearly
from 0 to 1 as the drug concentration approaches ctox (see score function in Fig. 3.2 C).
The spatially-averaged Hm is then averaged over the simulation period tend to form the final
homogeneity score Hm.
The primary purpose of Hm is to drive the optimization to designs with a more spatially
homogeneous drug distribution in the arterial wall. Designs which lead to concentrations that
lie within the reduced concentration window bound by ceff and the tolerable concentration
threshold ctol have a smaller concentration variation and are thus more homogeneous. They
are favored over less optimal designs with concentrations that lie in between ctol and ctox. In
addition to this role role, the tolerable concentration ctol as formulated here also serves the
purpose of creating a buffer region in the optimization by penalizing concentrations close to
the toxic limit. This ensures a certain robustness of the optimization, in the sense that optima
that are immediately adjacent to non-optimal regions would be avoided.
Choice of cost function parameters
The cost function described above provides a set of calibration parameters that offer flexibility
in balancing the relative importance of the efficacy against toxicity. While the two concentration
thresholds ceff and ctox need to be determined experimentally, the remaining four parameters
ctol, γthr, ϑthr and ϑlim allow calibration of the stringency of the toxicity constraint. Thus, it
might be deemed acceptable to live with a certain level of wall toxicity in some cases but
not in others, and these adjustable parameters allow this form of fine tuning. In light of the
severe consequences of delayed endothelial healing [53, 69] and in view of currently available
experimental data, we chose the calibration parameters summarized in Table 3.1.
The choice of parameter values for ctol, γthr, ϑthr and ϑlim is rather conservative and is
expected to allow us to avoid arterial wall toxicity. Lacking experimental data on the relative
severity of toxic concentration in the different layers of the arterial wall covered by each
toxicity score we (arbitrarily) assume the three toxicity scores to be of equal importance. As a
consequence we choose the same set of calibration parameters for each of the toxicity scores
and a weight factor of 1/3 multiplying each toxicity score of the cost function. It should be
recognized, however, that new experimental results or clinical studies might lead to future
changes in some or all of these parameters as well as choosing a different set of parameters for
each individual score.
Both paclitaxel and sirolimus inhibit the proliferation of SMCs and ECs by arresting the
cells at a point in their cell cycle. At sufficiently high concentrations, paclitaxel is cytotoxic
and leads to cell death [112]. Values for toxic paclitaxel concentrations are available in the
Table 3.1: Calibration parameters of the cost function
Drug ctol γthr ϑthr ϑlim ceff (molm−3) ctox (molm−3)
Paclitaxel 90% · ctox 1% 1% 5% 1 · 10−5 1 · 10−2
Sirolimus 90% · ctox 1% 1% 5% 0.29 0.73
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literature [87, 102]. The values of minimum efficacious concentration and toxic concentration
for paclitaxel used in the present work, ceff = 1 · 10−5 molm−3 and ctox = 1 · 10−2 molm−3, are
taken from [124].
Unlike paclitaxel, sirolimus is a cytostatic agent, i.e. its arrest of the cell cycle is not
associated with cell death even at relatively elevated concentrations. This behavior allows for
a wider therapeutic window for sirolimus than for paclitaxel. While the minimum sirolimus
efficacious concentration may be as low as 1 · 10−6 molm−3 [94, 123, 147, 191], the toxic
threshold is less clear, even if limited toxic reactions to sirolimus have been reported [83, 191].
In the present work, we investigated two different therapeutic windows. The first is based
on the results of Wang et al. [187] that suggest that for effective inhibition of restenosis, it
is desirable to maintain the cellular binding sites for sirolimus occupied; thus, we use a very
narrow therapeutic window spanning only 80% to 200% of the maximum binding site density.
The second therapeutic window we study aims to isolate the effect of the drug itself on our
results and thus uses the same three order of magnitude-wide therapeutic window used for
paclitaxel.
The effect of total drug dose (integral of drug concentration over time) is not considered
as a separate metric in the present cost function because the experimental evidence in the
literature of the effect of drug dose is too sparse to be translated into a reliable metric. Also,
we did not include any measure of the homogeneity of the drug concentration distribution per
se, as the homogeneity score considered here is completely dependent on the choice of the
therapeutic window and ctol, both of which are specified model parameters.
Practical considerations
To avoid spending valuable calculation time on undesirable parameter configurations, we
implemented additional criteria terminating the evaluation process of the cost function if the
toxicity parameter ϑm surpasses a value of 5% or if beyond five days of simulated time the
maximum total concentration in the media cT,m drops below the efficacious limit. The latter
criterion automatically discards designs that do not lead to efficacious concentration levels
within that five day period. If the simulation is terminated early, we take the score calculated at
the last computation prior to termination as the basis for the remaining time in the averaging
process. The toxicity parameter was capped at a maximum value Tmax = 10, since this already
corresponds to a ten-fold increase over what by design is considered an undesirable situation.
To impose a gradient in the case of non-efficacious designs, we add 1− max(cT,m)/ceff to Im.
Based on typical DES release times and motivated by the pathobiology following stent implan-
tation, we set four weeks as the target simulation time tend [3, 94, 121, 150]. A sensitivity
study of the cost function has shown that our results are fairly insensitive to a variation of the
evaluation period between one and eight weeks.
To keep the simulation time of each function evaluation to a minimum and as has already
been mentioned, we only include three stent struts in our numerical model with the endothe-
lium completely denuded in the stent region and intact upstream and downstream of the stent.
Thus, the overall stent length simulated is considerably smaller than real stents. Our simula-
tions have shown that the concentration distribution around the struts within the arterial wall,
with the exception of the first and last strut, is symmetric (Chapter 2). Since this concentration
distribution serves as the basis for the evaluation of our cost function, we can approximate
a longer stent by appropriately multiplying the score obtained for the symmetric mid-section
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of our strut setup. A sensitivity analysis has revealed that the final results are only minimally
altered by this manner of stent prolongation.
3.2.3 Optimization framework
We use a Surrogate Management Framework- (SMF-) type optimization algorithm [23] to
minimize the cost function JETH. Here we will only outline the basic concepts of this method.
The reader is referred to Chapter 4 for more details.
The SMF method belongs to the class of pattern search algorithms for numerical optimiza-
tion. These algorithms minimize a given cost function by gradually exploring the design space.
Booker et al. [23] introduced the idea of a global search step that efficiently leverages informa-
tion obtained from previously evaluated points of the design space. All previously evaluated
points are used to create an approximation of the cost function hypersurface which serves as an
inexpensive surrogate to identify potential new minimum points in the entire design space. As
long as the potential minimum points revealed by the search step yield improved cost function
values, the information from these points is added to the approximation surface and a new
search is performed.
The most common interpolation method used in this context is the Kriging method [97, 122].
A major advantage of this interpolation method is that on top of an estimation of the function
value, it also provides an uncertainty about the estimated value. This information can then be
used to enhance the search procedure: instead of minimizing the Kriging interpolant directly,
new prospective optimum points are identified by maximizing the probability of improvement
over the current optimum by a predefined margin [86].
The optimization procedure begins with the evaluation of a set of initial sampling points to
create the very first surrogate surface. We use the latin hypercube sampling algorithm presented
in [56] to assure a uniform distribution of these points throughout the design space. We use
20 initial designs for our 2-dimensional design space.
When a search step fails to provide a new minimum a poll step is initiated. Starting from
the current minimum point of the design space, a set of new points is chosen in the design
space. The choice of these points is restricted to a grid which discretizes the design space and
follows a distinct set of rules which defines the search pattern. The cost function values at these
points are then evaluated (a process referred to as polling). If any one of these points yields
a cost function value that is lower than the value associated with the initial point, then this
point becomes the new minimum point from which the next poll step originates. If, however,
none of these points is able to improve the cost function, then the grid spacing is refined and
a new set of points is chosen on this new grid. As long as certain conditions are met in this
process, convergence to a minimum is guaranteed. A new search step succeeds the poll step,
independent of its outcome.
We consider the design space to have been exhaustively explored once the mesh of the
poll step is refined 10-fold and the search step fails to identify new optimum points in five
consecutive search steps. At this point the optimization is terminated.
We employ a novel SMF algorithm which was developed by our collaborators Belitz and
Bewley and is described in detail in [16, 17]. The major novelty of this algorithm lies in the
choice of the underlying lattice used for the optimization: instead of the classical Cartesian
lattice, the search and poll steps are performed on a “laminated” lattice [16], which maximizes
the regularity and density of the grid points for the respective dimension of the design space.
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Also, the poll step of our method uses a new mesh adaptive direct search (MADS) algorithm,
dubbed “λ-MADS” [16].
3.2.4 Optimization cases
In this chapter, we performed six different optimization runs in total: two runs with the baseline
model as described in section (configuration E1 in Fig. 3.1 A) with paclitaxel and sirolimus as
the eluted drugs and two runs with a modified model where the endothelium was considered
denuded upstream and downstream of the stent (configuration E2 in Fig. 3.1 B) (again both
drugs). The fifth run investigated the effect of having paclitaxel loaded only onto the part
of the stent coating that was embedded in the arterial wall. The final run was performed on
the baseline model with sirolimus as the eluted drug but assuming the therapeutic window of
paclitaxel.
3.3 Results
We wish to determine the optimal drug delivery strategy, defined here as the combination
of the drug concentration initially loaded onto the stent c0 and the drug release time tE as
characterized by the diffusion coefficient of the drug Dc within the 10 µm-thick polymeric matrix
in which it is embedded. The optimization is performed for both paclitaxel and sirolimus.
3.3.1 Paclitaxel delivery optimization
Figure 3.3 A depicts the surface of the cost function obtained using the default model setup of
paclitaxel elution. The axes span equivalent release periods of a few minutes to several years
and concentration values from 0.1 to 100 µgcm−2. The plot is the result of a natural neighbor
interpolation [166] of the evaluated designs indicated by the gray dots. Point 1 indicates the
design with the lowest value of the cost function and is thus considered the global minimum.
Borrowing terminology from topographical maps (equating function value magnitude with
elevation), we can describe the resulting shape of the cost function as a mountain range with
two valleys marking two optimal regions. Further exploiting this analogy, we will refer to the
direction pointing towards increasing concentration as north, while we denote the direction of
increasing release times as east. As indicated by the black coloring, no feasible designs can be
found for initial loading concentrations that exceed 10 µgcm−2 (demarcated by a horizontal
white dashed line). Below 10 µgcm−2 the optimization reveals two valleys separated by a
ridge. The separation occurs at the one week mark. We distinguish the following three regions
demarcated approximately by the white dashed lines in the figure: a rapid release (release
time of only hours) region labeled QB representing quasi-bolus administration of the drug; an
intermediate release (weeks) region labeled FO where release is concentration-dependent and
follows first-order kinetics; and a slow release (months) region labeled ZO where drug release
becomes concentration-independent and thus follows zero-order kinetics. The first row in Fig.
3.4 illustrates typical release profiles for these three cases. Points 1 - 3 are typical example
designs for each of these regions. Their scores are decomposed in Table 3.2.
Three colored contours are shown in Figure 3.3: the green contour line traces Im = 1 and
thus defines a border for inefficacious designs; the yellow contour line traces Tm = 1 and thus
marks the threshold of toxicity in the media; the red contour line traces T e = 1 and hence
demarcates the zone of unacceptable endothelial toxicity. At the northern border of the QB
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Figure 3.3: Paclitaxel baseline optimization. A: Filled contour plot of the cost function over the design
space of initial concentration in the stent polymer c0 and release time tE. The scale for the cost function
representation is truncated at a maximum of 1; all values larger than 1 are colored black. The white
dashed vertical lines separate the three regions of quasi-bolus, first-order and zero-order release kinetics.
The dashed magenta line marks the time scale for drug unbinding. The green contour line traces Im = 1,
the yellow contour line Tm = 1, and the red contour line T e = 1. The horizontal axis on top of the plot
marks the time points of 1 (h)our, 1 (d)ay, 1 (w)eek, 1 (m)onth and 1 (y)ear. Detailed scores of the
representative design points 1 - 4 are summarized in Table 3.2. B: Time evolution of the endothelial
toxicity score T e for points 1, 2, and 3 taken respectively from the QB, FO, and ZO regions. C: Time
evolution of the inefficacy score Im for points 1, 2 and 3.
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Table 3.2: Detailed cost function score data of the points 1 - 4 in Fig. 3.3 and 5 - 7 in Fig. 3.5
# c0 (molm−3) Dc (m2 s−1) J Im T l T ses Tm
1 3.4 1.8 · 10−14 0.059 0.012 0.060 0.060 0.020
2 2.0 2.6 · 10−18 0.13 0.13 0 0 0
3 3.1 2.8 · 10−17 5.2 0.0091 5.6 10.0 0
4 0.37 3.5 · 10−17 0.48 0.10 0.32 1.1 0.037
5 9.7 2.4 · 10−18 0.080 0.080 0 0 0
6 2.3 2.6 · 10−14 0.11 0.071 0.060 0.060 0.024
7 3.4 1.9 · 10−14 0.062 0.016 0.060 0.060 0.020
valley, the medial and endothelial toxicity almost coincide. It is important to highlight that
care should be taken when interpreting the results. The interpolated surface is only as good
as the underlying evaluated designs (indicated by gray dots). While the western bound of the
QB valley is a good representation of the actual shape, the shape of the northern bound is less
certain since no designs have been evaluated east of the optimum point 1. While this limits our
ability to come to detailed conclusions in some local regions of the design space, the overall
conclusions are unaffected.
Figure 3.3 broadly reveals two optimal regions. The first lies in a polygonal, relatively flat
valley spanning an initial concentration range of 0.3 to 3 µgcm−2 and covering a release time of
1 to 6 hours. The second optimal region is in a chasm beginning at a release time scale of ≈ 5
months and an initial concentration of ≈ 0.2 µgcm−2 and ending at a release time of ≈ 6 years
and an initial concentration of ≈ 8 µgcm−2. It is interesting to note that designs corresponding
to today’s stents are found in the release range of a few weeks to a few months with initial
concentration loads beyond 10 µgcm−2 [152] and thus lie on top of the central mountain in
the north of our landscape.
Figure 3.3 B compares the time evolution of endothelial toxicity (Te) for the three different
release strategies defined by points 1, 2, and 3 in panel A over the 4-week simulation period. As
already mentioned, point 1 (in the QB region) corresponds to the overall optimum of the cost
function. Point 2 (ZO region) is the local optimum within the chasm described above. Point
3 (FO region) has a release time scale of about one month with a similar initial concentration
as point 1. The endothelial toxicity score of point 1 exhibits a very short but high peak within
the first day after stent implantation. Except for a very small bump on day two (not visible
on the current scale), the endothelial toxicity associated with point 2 has a constant value
of zero. Point 3 shows a maximal toxicity score for more than a week before beginning to
decrease gradually. The transition to a level of Te = 5 in the following weeks reflects the fact
that drug release decreases so that the concentration from the lumenal side drops below the
toxic threshold. The concentration on the SES side, on the other hand, remains above this
threshold for the entire 4-week period.
Figure 3.3 C depicts the time evolution of the inefficacy score in the media Im over the
4-week simulation period for the same three points as in panel B. The behavior is very similar
for points 1 and 3 with Im attaining minimum inefficacy (i.e. maximum efficacy) within a day
of stent deployment and remaining at this level for almost the rest of the time. The inefficacy
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associated with point 1 begins to increase marginally after about 3 weeks leading to a slightly
worse average inefficacy Im score than point 3 (see Table 3.2). The inefficacy score of point 2
is considerably larger than that of the other two points but becomes quite small at the 1-week
time point and beyond.
Point 4 in Figure 3.3 A is a point of additional interest in that it is characterized by a
similar release time as point 3 but with an initial drug concentration that is ten-fold smaller.
As shown in Table 3.2, this point still allows significant exposure of the endothelial surface to
unacceptably high concentrations despite the low level of initial stent loading. This observation
underscores the generally poor drug delivery strategies associated with the intermediate release
(FO) region.
The results thus far have focused on quantitative assessments averaged over the entire stent.
In order to gain additional physical insight into the optimization results, we now turn our
attention to a more local level and consider the drug concentration distributions around the
stent struts. Fig. 3.4 depicts the normalized concentration distributions around the stent strut
furthest downstream (third strut) at the 1-hour, 2-week, and 4-week time points and for the
three representative design points 1, 2, and 3 representative respectively of quasi-bolus release,
zero-order release, and first-order release as was defined above.
The quasi-bolus drug release kinetics (left column in Fig. 3.4 B) lead to the release of all
of the drug within the first few hours after implantation. Accordingly, the highest drug concen-
trations are attained at the 1-hour time point with very high local concentrations (exceeding
100 times the toxic threshold) in the media near the stent strut and unacceptably high con-
centrations in the subendothelial space (SES). At this time point, drug concentrations are at
efficacious levels over practically the entire media. The next two time points illustrate how
the magnitude of drug concentration decays over the following four weeks. At the four-week
time point, concentrations in the media in between the stent struts and closest to the stent
surface have lost their efficacy. Because the characteristic time for drug release in this case
is considerably shorter than all of the time scales characterizing drug transport and reaction
(convection, diffusion, as well as drug binding and unbinding), the quasi-bolus release strategy
can be thought of as a transport-limited scenario.
For the first-order drug release kinetics (middle column), large parts of the media are
exposed to efficacious concentration levels at the 1-hour time point. This is also true for the
SES. In the downstream zone close to the strut, the concentration levels reach ten-fold those of
the efficacious threshold. Two weeks later, the concentration levels are elevated in the media
and are efficacious over the entire width. Although the overall concentration in the SES has
dropped, the concentration close to the strut is considerably higher than the concentration that
would inhibit EC proliferation and this remains the case even at four weeks. In the media,
the concentration has decreased and in the areas in between the stent struts has attained
sub-efficacious levels.
For the zero-order drug release kinetics (right column), the concentrations do not attain
the efficacious threshold within the first hour anywhere in the domain. After two weeks, the
concentration levels in most of the media are efficacious, except for the zones in between struts
close to the lumenal surface. The steady release over the next two weeks leads to a very similar
concentration distribution at the end of the simulation. Since all time scales of the transport
and reaction problem in the arterial wall are significantly faster than the release time scale in
this case, we have reached a quasi-steady state of the transport in the arterial wall and hence a
release-limited scenario.
The above simulations were performed for the baseline case where the endothelium was
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Figure 3.4: Release kinetics and resulting normalized concentration distributions for repesentative
designs of the quasi-bolus (point 1), first-order (point 3), and zero-order (point 2) regions. A: Release
profiles as quantified by the time evolution of the remaining mass percentage (RMC) of drug in the
polymer coating. B: Contour plots of the normalized concentration distribution at 1 hour (first row),
2 weeks (second row) and 4 weeks (third row) post stent implantation. The different release kinetics
require adjustment of the color scale in some of the panels. The maximum value of the color scale
for the normalized concentration is indicated by the word “max”. The highest concentration values
encountered close to the stent strut surface are colored in black. With endothelium only present at the
downstream side of the strut, an asymmetric flow is induced around the strut causing an asymmetry
in the concentration distribution. A green contour line marks the threshold between efficacious and
non-efficacious drug concentration in the media: the depicted media at 2 weeks of quasi-bolus and
first-order release kinetics are entirely exposed to efficacious concentration, while drug concentration
in the depicted media at 1 hour of zero-order release kinetics has not yet reached efficacious levels.
Magenta countour lines in the media and vertical arrows at the endothelium indicate cont = c/ctox − 1.
The black horizontal arrow in the very first tile points in the direction of flow in the lumen.
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assumed to be completely denuded in the stented portion of the vessel but intact otherwise. In
order to investigate the sensitivity of our optimization results to this assumption, we performed
simulations where the endothelium was also denuded both upstream and downstream of the
stent. As depicted in Fig. 3.5 A, the resulting contour plot of the optimization in this case is very
similar to that of the baseline case (Figure 3.3 A) with two optimal valleys separated by a non-
optimal mountain. The contour line tracing a value of the cost function of 1 is shown for the
baseline case for comparison. For the present simulation the contour of JETH = 1 approximately
follows the border of the black regions. The quasi-bolus valley is almost unaltered with only
its western border shifted slightly to faster release times. The chasm of the zero-order release
is wider and more elongated compared to the baseline surface. Hypothetically, even initial
concentration values of up to 100 µgcm−2 can now lead to feasible designs; however, that would
require a release time of ≈ 30 years! Qualitatively, the upper bound formed by endothelial
toxicity has shifted to higher concentration values in the range of first and zero-order release.
This becomes evident quantitatively when we compare the score of the global optimum point
(point 5 in Table 3.2) of this optimization to the zero-order release optimum of the baseline
optimization (point 2). For a similar release time of approximately 13 months, the initial
concentration can be raised 5-fold, increasing the efficacy of the design by almost 40% and
entirely avoiding toxic concentration levels at the endothelial surface.
The contour plot in Fig. 3.5 B shows how the optimization results are affected when drug is
initially loaded only in the part of the stent polymer coating that is embedded into the arterial
wall. Again, the white contour line traces JETH = 1 for the baseline otpimization (Fig. 3.3)
whereas for the present simulation the contour of JETH = 1 approximately follows the border of
the black regions. It is important to note that the representation of the region with a release
time tE of months and years (ZO region) of the present simulation is less accurate since only few
designs have been evaluated in that region (indicated by gray dots) during the optimization.
The most obvious difference compared to panel A and to the baseline simulation is that the
bound to the west of the quasi-bolus region is no longer present. The release time can thus
be decreased without causing adverse concentration at the endothelium. The global optimum
(point 7) can be found in this valley. The differences between this optimum and the optimum
of the baseline optimization (point 1) are insignificant.
Figures 3.5 C and D compare the temporal evolution of the endothelial toxicity score and
the medial inefficacy score for points 5, 6 and 7. The detailed breakdown of the averaged scores
can be found in Table 3.2. The global optimum of the simulation with completely denuded
endothelium (point 5) shows zero toxicity at the lumenal surface at all times. The endothelial
toxicity of the quasi-bolus optima in both cases in Figure 3.5 (points 6 and 7) evolves identically,
shooting up to maximum toxicity within seconds after implantation and then decreasing to
zero after 6 hours. Fig. 3.5 C illustrates that the inefficacy of the zero-order optimum of the
denuded endothelium optimization case (point 5) decreases rapidly in the first week and then
more slowly thereafter until the end of the simulation. Both quasi-bolus optima decrease nearly
immediately to near zero inefficacy. At longer times, the inefficacy score of point 6 rises slowly,
whereas that of point 7 remains small for the entire simulation period.
3.3.2 Sirolimus delivery optimization
The above presentation of the results focused on paclitaxel as the eluted drug. When we
change the drug on the stent to sirolimus, we also need to shift the range of the design space
significantly because of sirolimus’ different therapeutic window. Fig. 3.6 A depicts the results
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Figure 3.5: Filled contour plot of the cost function over the design space of initial concentration in the
stent polymer c0 and release time tE for a paclitaxel-eluting stent with A: endothelium denuded both
upstream and downstream of the stent and B: drug initially only loaded in the polymer part embedded in
the arterial wall. The scale for the cost function representation is truncated at a maximum of 1; all values
larger than 1 are colored black. The white contour line traces JETH = 1 for the baseline otpimization
(Fig. 3.3). The horizontal axis on top of the plots marks the time points of 1 (h)our, 1 (d)ay, 1 (w)eek,
1 (m)onth and 1 (y)ear. C and D: Time evolution of the endothelial toxicity (Te) and medial inefficacy
( Im) scores for the representative design points 5 - 7 shown in panels A and B and summarized in Table
3.2. In panel C, points 6 and 7 overlap.
of the baseline optimization (denuded endothelium in the stented portion but intact otherwise)
for sirolimus. The results offer a very different picture from the case of paclitaxel: there is
only a single, narrow, band of optimal release starting at a characteristic release time of ≈ 9
weeks with an initial concentration of ≈ 1.8 · 104 µgcm−2 (point 2) and ending at the global
optimum point (point 1) with a release time of ≈ 2.5 years and an initial concentration of
≈ 2.8 · 105 µgcm−2. The detailed scores shown in the accompanying table reveal that within
this optimal band, the designs gain in efficacy at the expense of increasing toxicity in the media.
The optimal band in Fig. 3.6 A is bounded on one side by the region of unacceptably
high drug toxicity both in the media and at the lumenal surface (delineated respectively by
the yellow and red contour lines which nearly overlap), and on the other side by the zone of
unacceptably low drug efficacy in the media (delineated by the green contour line).
Fig. 3.6 B depicts the contour plot of the optimization when the endothelium is also
denuded upstream and downstream of the stent. The results demonstrate that the effect of
additional endothelial denudation is minimal. Differences between the two cases can only
be found in small details: the optimum value shifts to a lower concentration at an increased
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4 1.2 · 105 2.6 · 10−18 0.19 0.18 0 0.025
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Figure 3.6: Sirolimus optimization. A: Filled contour plot of the cost function over the design space of
initial concentration in the stent polymer c0 and release time tE under baseline conditions. The scale for
the cost function representation is truncated at a maximum of 1; all values larger than 1 are colored
black. The green contour line traces Im = 1, the yellow contour line Tm = 1, and the red contour line
T e = 1. B: Similar simulation but with the endothelium also denuded upstream and downstream of
the stent. C: Sirolimus simulation using the therapeutic window previously used for paclitaxel. The
white contour traces JETH = 1 of the default paclitaxel optimization (Fig. 3.3) for comparison. The white
dashed vertical lines separate the three regions of quasi-bolus, first-order and zero-order release kinetics.
The dashed magenta line marks the time scale for drug unbinding. The horizontal axis on top of the
plots marks the time points of 1 (h)our, 1 (d)ay, 1 (w)eek, 1 (m)onth and 1 (y)ear. Detailed scores of
the representative design points 1 - 5 are summarized in the table.
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release rate (point 4 in the table of Fig. 3.6), but the medial toxicity and efficacy scores are
not much different from the equivalent point 3 of the baseline optimization run. Moreover, the
toxicity and efficacy contour bounds follow largely the same behavior in both cases.
Figure 3.6 C depicts what the optimization would yield had we assumed sirolimus to have
the same efficacy and toxicity thresholds (and hence the same therapeutic window) as pacli-
taxel. This efficacy threshold would only be about a factor of five higher than the minimum
effective concentration observed in experiments. It is important to point out the different axes
of this plot relative to those in Figure 3.3 A. The contour plot is somewhat similar to the
paclitaxel baseline case, but it exhibits only a single optimal region in the zero-order kinetics
valley. Notably, the yellow and red contour lines respectively marking a value of 1 for the
medial and endothelial toxicity score shift towards lower concentrations; the yellow contour
shifting significantly by almost an entire order of magnitude. Moreover, the inefficacy border in
the southeast zone disappears. The breakdown of the score of the global optimum (point 5) is
very similar to that of the optimum of the baseline sirolimus optimization, the only difference
being that instead of a small medial toxicity score, this point has a very small SES toxicity score.
Figure 3.7 Left depicts the sirolimus concentration distribution in the arterial wall at one
week post implantation for the optimal drug delivery strategy under baseline conditions (point
3 in Fig. 3.6 A). This time point corresponds to the highest toxicity levels in the arterial
wall. Drug concentration is highest near the stent struts, surpassing the 1% toxicity threshold
as indicated by the magenta contour line. Almost the entire remaining therapeutic domain
has attained efficacious drug concentration levels, as can be seen by the green contour line
engulfing most of the medial domain. Figure 3.7 Right shows the concentration distribution of
the optimum at the one-week time point assuming the wider therapeutic window corresponding
to paclitaxel. In this case, the highest concentration close to the struts does not surpass the
maximum toxic concentration. The green contour line confirms that concentrations are effective
in the entire medial domain. The distribution is, however, less homogeneous than the one on
the left.
0 0.5 1 1.5 2 2.5
Figure 3.7: Normalized concentration distribution for optimal release from a sirolimus-eluting stent
at one week post implantation. Left: Narrow therapeutic window; Right: wide therapeutic window
corresponding to the toxicity and efficacy thresholds of paclitaxel. The green contour line traces the
threshold between efficacious and non-efficacious drug concentration in the media, while the magenta
contour (close to the struts) denotes concentrations 1% higher than ctox. The arrow points in the
direction of lumenal flow.
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3.4 Discussion
In this chapter, we used the surrogate management framework to optimize drug delivery
from paclitaxel- and sirolimus-eluting stents. The design parameters in the optimization were
the drug release rate and the initial drug concentration loaded onto the stent. The results
revealed dramatically different results for the two drugs, primarily attributable to their different
therapeutic windows, i.e. their efficacy and toxicity thresholds as well as differences in reaction
kinetics. We now wish to summarize our findings and to gain insight into the physical basis
of the optimization results. Given the assumptions that we have made and the degree of
simplification in our numerical model of drug transport, we will refrain from denoting one
particular combination of design parameters as the optimum and rather focus on a broader
description of regions in the design space identified in the optimization.
3.4.1 Paclitaxel-eluting stents require quasi-bolus or zero-order drug release
kinetics to avoid adverse concentration levels at the endothelium
Optimization of paclitaxel-eluting stents (P-DES) led to a design space that is divided into four
zones. The first zone is characterized by initial drug concentrations higher than 10 µgcm−2.
This zone has no acceptable designs regardless of drug release kinetics. The sub-10 µgcm−2
area contains the remaining three zones of which only the designs with a quasi-bolus or zero-
order release kinetics lead to acceptable designs, while any designs with first-order release
kinetics result in undesirable conditions in the arterial wall.
Detailed inspection of the simulation results reveals that what primarily limits the efficacy of
a particular P-DES design is the excessive supply of drug to the SES, leading to concentrations
that are expected to inhibit EC proliferation. In the computations, we assumed drug concentra-
tion in the SES to be determined by convection and diffusion only; this is expected to lead to
lower drug concentrations in the SES than would be the case had we also taken into account
drug reaction in the SES. In principle, the reaction model that we used to describe drug-tissue
interaction in the media can be extended to the SES.
The baseline simulations assumed that the endothelium was denuded in the stented seg-
ment of the artery but intact both upstream and downstream of the stent. Our simulations
demonstrated that the optimization results are not very sensitive to the extent of endothelial de-
nudation around the stent. Removing the endothelium merely reduced the size of the mountain
of endothelial toxicity and shifted its southern rim to higher concentrations while not affecting
the 10 µgcm−2 demarcation described above. Given that typical P-DES in clinical use sit on
top of this mountain and beyond the 10 µgcm−2 limit, our results shed insight into one aspect
of the multi-factorial reasons for the sometimes poor re-endothelialization of P-DES [19, 50].
Especially notable is the observation of focal cell necrosis close to stent struts associated with
high-load P-DES, which is not surprising in light of the present results [49, 152].
Based on the present findings, we propose a number of recommendations for improved
drug delivery strategies from P-DES. The first recommendation would be to lower the initial
drug load by an order of magnitude and to shift the designs to slower release kinetics on the
order of several months or even a year. The combination of the wide therapeutic window of
paclitaxel and its long retention properties ensures sufficient efficacy in the media while the
slow release of the drug precludes adverse concentrations at the endothelial surface.
The long retention capabilities of paclitaxel also open up a second possible strategy: quick
unloading of the drug within hours thereby flushing the entire wall with paclitaxel and then
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letting arterial wall drug kinetics do the rest. This strategy is largely similar to the idea of a
drug-eluting balloon. If administered at the right concentration and in the right time frame,
the binding process takes up as much drug as is required to provide effective drug concentra-
tion levels in the entire therapeutic domain for weeks. The initial short concentration spike
should pose no significant problems from the standpoint of re-endothelialization because the
endothelium in the vicinity of the stent struts is severely denuded during the first few days, and
the extent of re-endothelialization in the first few days is quite limited in any case. Though
promising, the outcomes associated with this strategy are expected to be quite sensitive to
changes in the convective field within the arterial wall; therefore, a more accurate assessment
of this field is probably needed before implementation of such a strategy.
A third possibility to address the difficulties associated with paclitaxel is to position the
drug onto the stent in such a manner that it is as far away from the endothelial surface as
possible. The optimization performed with our model where only the abluminal half of the
coating contained drug showed, however, that it is not sufficient to only coat the abluminal
side (as is done for example on the BioMatrix® stent by Biosensors). More elaborate designs,
like drug-filled stent designs where the drug reservoir is inside of the stent body and the drug
is eluted directly into the arterial wall via small holes (currently developed by Medtronic) or
stents where small drug patches are applied only to the very abluminal surface of the stent body
(like for example the JACTAX HD stent by Boston Scientific) appear to be more promising.
3.4.2 Sirolimus-eluting stents require zero-order release kinetics due to
sirolimus’ weak retention capabilities
Aside from the differences in their biological mode of action [112], the most significant dif-
ference between sirolimus and paclitaxel is the factor of 20 that separates their time scales of
unbinding. Despite sirolimus’ very high lipophilicity (approximately three times higher than
paclitaxel), its weak retention capability requires constant supply of fresh drug from the stent
and renders the design of a sirolimus-eluting stent (S-DES) with quasi-bolus release kinetics
unfeasible. This sirolimus-specific feature has been reported in the literature [66]. The recent
redesign of the zotarolimus-eluting Endeavour Resolute (Medtronic) stent (zotarolimus is a
derivative of sirolimus) is another example highlighting this requirement: the release time was
increased from 2 weeks in the initial design to 4 months due to the poor restenosis outcome of
the original design [68, 90].
Time scale restriction aside, it should be noted that the kinetic properties of sirolimus make
it a desirable drug for the design of DES: the high lipophilicity renders transport process in
the arterial wall largely independent of changes in the convective field and thus predictable
and robust. Furthermore, initial sirolimus concentration in the stent polymer can be used to
tune the concentration profile to the requirements in the arterial wall, whether the therapeutic
window is wide or narrow. Additionally, cytotoxicity is less of an issue for this drug due to
its cytostatic mode of action. On the other hand, the lipophilicity of sirolimus also leads to
more pronounced concentration peaks close to the stent struts which might compromise tissue
integrity and explain the increased rate of stent strut malapposition observed with S-DES [108].
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3.4.3 Low-dose P-DES and S-DES with zero-order release kinetics lead to a
similar shape of the cost function
Comparing the contour plots of the cost function for paclitaxel and sirolimus with a narrow
therapeutic window, we can identify large similarities between the two drugs in the zero-order
release kinetics region. In this region the release from the stent coating is quasi-steady and the
concentration on the stent surface remains nearly constant over the entire period considered.
The time scales of transport and reaction in the arterial wall are all significantly faster than
the release time scale and we can thus assume that a quasi-steady state is established in the
arterial wall. For the case of constant surface concentration or equivalent constant surface flux,
strongly lipophilic drugs (like paclitaxel and sirolimus) have very similar transport dynamics
in the arterial wall that can be categorized depending on whether or not the applied surface
concentration/flux exceeds a well defined threshold [179].
In the case of above-threshold drug supply, drug concentration in the arterial wall exceeds the
binding capacity of the arterial wall and drug transport is increased since significant amounts
of drug are now in the mobile unbound state. In the case of sub-threshold drug supply, drug
concentration in the arterial wall is below the binding capacity of the arterial wall, and drug
transport is considerably decreased since the drug is now mostly in the bound and thus immobile
state. For paclitaxel and sirolimus this threshold is on the same order of magnitude as their
respective binding capacities. The cost function enforces that drug concentration throughout
the arterial wall remains below the toxic concentration threshold, which in the case of P-DES
and the S-DES optimization with the same therapeutic window is below the respective binding
capacities. Thus, by design of our cost function, the optimal slow-release P-DES and low-dose
S-DES both fall into the sub-threshold category, hence explaining the similarity of the resulting
cost function surfaces in the region of zero-order release kinetics. The optimized high-dose
S-DES falls in the above-threshold category.
3.4.4 The cost function responds to drug kinetics in the arterial wall
The shapes of the landscape of the cost function for both paclitaxel and sirolimus are a mere
reflection of the drug-related processes in the artery, confirming that the initial goal of creating
a cost function that scores designs rather than forcing designs in a distinct direction could be
achieved. At the same time, it leaves the designer with a necessary degree of liberty allowing
him to weigh the severity of inefficacious designs against designs that surpass preset concen-
tration thresholds in a physically meaningful way. The very conservative approach of choosing
very strict penalties at the toxic limit has identified stent designs of high efficacy throughout the
period of the first four weeks after stent implantation, almost entirely avoiding any exposure of
the endothelium to adverse and the media to toxic concentrations. Finally, comparing the con-
centration distributions of optimal S-DES for the two different therapeutic windows, we were
able to show that it is possible to control the degree of concentration distribution homogeneity
in the arterial wall without including a direct measure of homogeneity in the cost function.
3.4.5 Paclitaxel vs. sirolimus: a settled debate?
About a decade ago the FDA approved the first two DES: one eluting sirolimus (Cypher stent
by Cordis) and the other eluting paclitaxel (Taxus stent by Boston Scientific). When we look at
the current generation of DES that are either commercially available or at the clinical research
stage, the initial 50:50 split has shifted significantly in favor of sirolimus and its derivatives
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to the point where P-DES appear almost “exotic” [61, 62]. This trend appears to be driven
by clinical evidence which often ranks first- and second-generation S-DES ahead of their P-
DES counterparts [1, 20, 151, 168, 174]. Another explanation may be the aforementioned
robustness of sirolimus alluded to above.
However, our results also offer a different perspective on the sub-optimal performance of P-
DES: the applied concentrations and associated release kinetics in first-generation P-DES might
just have been unsuited for the kinetics of paclitaxel. Other numerical studies (see Chapter 2
or [124]) and several experimental studies [49, 50, 102, 152] point in a similar direction. The
recent success of paclitaxel-coated balloons [6, 37, 66, 158] indicates a level of incompletely
tapped potential of paclitaxel.
Late stent thrombosis remains the biggest risk in the clinical use of DES. The occurrence
of this viscious complication is strongly correlated with delayed endothelial healing [19, 53,
69, 74]. The cost function developed in the present study operates on the premise that drug
concentrations between efficacious and toxic levels would lead to favorable stent outcomes.
What is not accounted for in this model is a dependence of the efficacy and/or toxicity on the
amount of time that the tissue has been exposed to a certain concentration, i.e. the cumulative
dose. While both paclitaxel and sirolimus show dose-dependent behavior [7, 57, 87, 94, 142,
165], it is not clear how cumulative dose affects delayed endothelial coverage. If cumulative
drug dose plays an important role in delaying arterial re-endothelialization, then sirolimus
would be less flexible in its application than paclitaxel.
CHAPTER 4
Optimizing the Strut Design of
Paclitaxel- and Sirolimus-Eluting
Stents
4.1 Introduction
Drug-eluting stents (DES) have revolutionized the treatment of occlusive coronary disease. By
coating existing bare-metal stents (BMS) with an anti-proliferative drug that is released in a
controlled manner into the arterial wall, the occurrence of in-stent restenosis has been reduced
from ≈ 30% to less than 5%. Shortly after the introduction of first generation DES, major safety
concerns were raised: early data [173] suggested that the overall rate of late stent thrombosis
(LST) of DES was significantly increased compared to BMS. Although these concerns have been
ameliorated for second generation DES [157], the long-term safety of DES (especially after
cessation of anti-thrombotic treatment [26, 145]) remains a controversial and timely topic in
the design of DES [83].
LST is an incompletely understood complication that is associated with a particularly high
mortality rate when it occurs. Currently, a low incidence rate of LST is assured with post-surgical
anti-coagulation medication. The ideal duration of this treatment is currently unknown and
is a controversial topic [34, 67, 88, 143, 167, 184, 194]. It appears, however, that LST is
strongly related to poor and delayed recovery of the endothelial cell layer damaged by DES
implantation [53, 54, 69]. Delayed endothelial healing is a more acute problem for DES
than BMS and is thought to be related to the effect of the anti-proliferative drug, traditionally
sirolimus (or one of its derivatives) or paclitaxel, on endothelial cell wound healing. As we
showed in Chapter 3, drug release kinetics of DES can lead to drug concentration levels at the
endothelial surface that would inhibit the proliferation of endothelial cells and thus interfere
with stent strut re-endothelialization. However, drug release kinetics cannot entirely explain
poor endothelialization of DES that can be observed up to 5 years after surgery [151], long after
all of the drug has been eluted from the stent. Therefore, there is a need to better understand
factors that influence re-endothelialization following DES deployment.
Implantation of a stent (BMS or DES) in an artery perturbs the arterial flow field around the
stent struts and downstream of the stent [18, 31, 44, 149, 163]. Endothelial cells are known to
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exquisitely respond to hemodynamic forces [32, 33, 42] which can even affect wound healing
[64]. Changes in the local flow field at the site of stent implantation have also been associated
with the incidence of in-stent restenosis and stent thrombosis [96].
In a review of first generation DES, Pendyala et al. conclude that “the optimal DES should
have minimal impact on endothelial cell structural and functional recovery along with maximal
inhibitory effect on SMC proliferation and migration” [144]. Considering the multiplicity of
physical phenomena involved, devising an optimal DES becomes quite a challenge. An added
source of complexity is that the fluid dynamics in the lumen and the drug transport in the
arterial wall are coupled [11, 127, 128, 162, 183]. Accounting for all contributing phenomena
leads to complex computational models (see Chapter 2, [24, 51, 139]) that are expensive to
evaluate.
Studies that have performed optimization of stent design have often focused on minimizing
blood flow disturbance in the arterial lumen [9, 70, 71, 171], but also stresses in the stent
itself [196] or stresses in the arterial wall [178]. Pant and collaborators conducted the most
comprehensive optimization to date by including multiple objectives and multiple physical
phenomena [140, 141]. More specifically, they incorporated six performance measures includ-
ing fluid dynamic stent performance metrics based on time-dependent momentum transport
and drug-related metrics based on steady drug transport. Other studies optimized geometric
features of stents including stent strut width [140, 171], stent strut height [171], the number
of consecutive stent segments [70, 71], and the shape of stent strut connectors [141] with
either circular or rectangular stent struts. The time-dependent character of drug transport and
its effect on optimal strut shapes as well as optimal properties of polymeric stent coatings for
the two different drugs have not been included in these studies.
A second issue stemming from the complexity of the computational model is that classical
optimization methods are rendered unfeasible by the very long computational time necessary
to explore a multi-dimensional parameter space. A very common optimization framework used
with this type of expensive computational models is the surrogate management framework
(SMF) [23]. This method has previously been applied to the optimization of aerospace [118,
119] and bioengineering [120, 198] problems. In all of these studies, a Cartesian lattice is used
to discretize the design space, i.e. the parameter space that is explored by the optimization.
Belitz and Bewley [16, 17] demonstrated that the use of other lattices with a denser and more
regular discretization of the design space can lead to significantly improved performance of
these algorithms in finding an optimal design.
The primary purpose of the present chapter is to determine optimal stent strut designs for
DES eluting paclitaxel or sirolimus. The design objective is to maximize drug efficacy in the
arterial wall while avoiding adverse concentrations and simultaneously minimally disturbing
the flow field in the lumen. Optimal designs are identified by a novel SMF optimization
algorithm [16, 17] that uses a lattice with optimal discretization properties to discretize the
design space of the parameters that define the stent strut design. The strut shape can be
varied continuously from circular to rectangular. Cost function scores are determined from the
drug concentration distribution and lumenal flow field obtained by the numerical simulation
of the computational model of drug transport in stented arteries described in Chapter 2. A
sensitivity analysis on the cost function reveals that the optimal properties of single-layered
polymer coatings of DES which were previously determined (see Chapter 3) can be re-used in
the context of the present strut design optimization. Our results demonstrate that optimal strut
designs need to be tailored to the drug transport in the arterial wall.
The analysis of the cost function also motivates a second set of optimization runs which
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aim at identifying optimal properties of two-layered polymer coatings where an additional thin
top-coat encases a thicker polymeric layer. The thick layer contains either of the two drugs
paclitaxel or sirolimus while the thin top-coat is void of drug. This investigation complements
our previous investigation of optimal one-layered polymer coating properties (see Chapter
3). In addition to the initial concentration and diffusion coefficient of the drug in the thick
polymeric layer, we optimize the thickness of this layer and the permeability of the additional
top-coat. The results of this study demonstrate that an optimal polymer coating of paclitaxel-
eluting stents can be relatively thin and does not require a top-coat while an optimal coating
for sirolimus-eluting stents needs to be thick with an added top-coat.
4.2 Materials and methods
4.2.1 Computational model
We will begin by briefly recalling the most important features of the computational model used
to carry out the numerical simulations. A detailed discussion of this model can be found in
Chapter 2. We consider a 2D axisymmetric straight arterial segment of radius rl = 1.5 mm
within which a model drug-eluting stent (DES) with three struts spaced at intervals of 0.7 mm
is deployed (Fig. 3.1 A). We define the strut shape using the so-called “Superformula” [63]:
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The six parameters of the Superformula
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allow the generation of a large
diversity of shapes. Fixing ms = 4 and setting n1 = n2 = n3 = n restricts the set of attainable
shapes to variations ranging from diamonds (n = 1, Fig. 4.1 A) to rectangles (n 1, Fig. 4.1
C). The parameters as and bs set the semi-strut height as and width bs, respectively. Setting
n= 2 we recover the familiar equation describing an ellipse (Fig. 4.1 B). A 10 µm-thick polymer
coating containing the drug is applied to the stent strut reflecting typical dimensions of second
generation DES [164]. We apply the transport model of Chapter 2 to the elution of the two
commonly used hydrophobic drugs paclitaxel and sirolimus.
We use two different configurations of the computational model for the simulations. The first
configuration considers an endothelium that is completely denuded within the stented portion
of the vessel but intact otherwise (configuration E1 in Fig. 3.1 A). The second configuration
considers endothelium that is denuded not only in the stented zone but also upstream and
downstream of the stent for a distance half the length of the inter-strut spacing and intact
otherwise (configuration E2 in Fig. 3.1 B). The two different assumptions result in a change
in the convective field in the arterial wall around the upstream and downstream strut due to
as
bs
as
bs
as
bs
Figure 4.1: Different shapes generated with the Superformula. A: diamond; B: ellipse; C: rectangle.
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the shielding function of the endothelium (see Chapter 2 Fig. 2.6). We define the therapeutic
domain as the volume of the arterial wall containing the stent and extending by 2/3 of the stent
length both upstream and downstream of the stent.
In the literature, the drug concentration that is initially loaded onto a DES is typically pre-
sented in terms of drug mass per unit stent strut surface area [152]. However, the physically
relevant quantity is the drug concentration in the polymer coating. In Chapter 3, the thickness
and shape of the polymer coating were constant, so we could simply convert the drug concen-
tration to drug mass per unit strut surface area. In the present chapter, the shape and thickness
of the polymer coating are variable, so we will express drug load in terms of concentrations,
since the conversion to drug mass per unit strut surface area depends on the coating thickness.
4.2.2 Cost function
In this chapter, we propose the following total cost function to measure the quality of a stent
design:
J
 
x i

= JETH
 
x i

+wFDIJFDI
 
x i

, (4.2)
where JETH (defined and discussed in Chapter 3) is the drug-related cost function related to
drug efficacy, toxicity, and homogeneity; JFDI is the flow-related cost function which will be
defined below; and wFDI is a weight factor that establishes the relative weight of the flow-
related cost function relative to the drug-related cost function. We will refer to a stent design
as the set of d design variables (e.g. semi-strut height as, semi-strut width bs, and strut shape
exponent n) x (i) =
 
x1 x2 . . . xd
T (i) that determine a particular stent strut shape. As detailed
in Chapter 3, minimizing JETH aims to provide a therapeutically efficacious but sub-toxic drug
concentration in the media, minimal drug concentration at the lumenal surface, and maximal
homogeneity of the drug concentration in the media. To this function we now add JFDI whose
minimization is intended to minimize the extent of lumenal flow disturbance induced by the
stent [31, 149]. This is motivated by studies that have established that flow perturbations in
the form of low shear stress or recirculating flow zones can greatly hinder the healing of a
damaged endothelium [33, 64].
The drug-related cost function JETH was defined in Chapter 3 as:
JETH (x ) = Im+
1
3

T l+ T ses+ Tm

+Hm . (4.3)
and is thus the sum of three scores: the inefficacy score Im , the arithmetic average of the
three toxicity scores T l, T ses and Tm, and the homogeneity score Hm. Each score is spatially
averaged in the therapeutic domain and temporally averaged over a period beginning with
stent deployment and ending after four weeks ( tend) of drug elution.
The score JFDI portion of the cost function measures the flow disturbance in the lumen
induced by the presence of a stent and is given as follows:
JFDI (x ) =min (FDI, 1) (4.4)
where the Flow Disturbance Index (FDI) is defined as:
FDI=
1
Sw
∫
Sw
τ−τ0τ0
dS , (4.5)
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similar to [70, 71]. It evaluates the deviation of the local wall shear stress (WSS) τ from the
unperturbed WSS τ0 that would exist in the vessel in the absence of the stent and averages this
quantity over the surface Sw. In the present study, the surface Sw spans the area of the lumenal
surface of the arterial wall that begins at the upstream end of the therapeutic domain and
ends at the downstream end of the computational domain. Even though our model stent only
consists of three consecutive struts, the work of Seo et al. [163] showed that three consecutive
struts are sufficient to approximate the degree of flow disturbance.
We assume blood to be a Newtonian fluid with density ρ = 1060 kgm−3 and dynamic
viscosity µb = 3.5 · 10−3 Pa s. This assumption is reasonable given the shear rate values under
consideration for the flow conditions of interest (lumenal Reynolds number Rel = 400). For
fully developed flow through a circular cross-section vessel pipe with radius rl:
τ0 =
2µ2bRel
r2l ρ
. (4.6)
The present work focuses on steady flow. However, were we to consider time-dependent
flow, then the WSS τ in Eq. (4.5) would be replaced by its time-average over a pulsatile cycle.
For the extreme case of purely oscillatory flow with a zero mean, τ= 0, yielding an FDI value
of 1. Because purely oscillatory flow leads to vascular inflammation and dysfunction, we will
consider this condition as the worst possible flow condition and consequently limit the FDI at
an upper value of 1 as indicated in Eq. (4.5).
Optimization in the present chapter is performed using the aggregate cost function J defined
in Eq. (4.2). This requires a choice of the weight factor wFDI. Without experimental evidence
of the relative importance of an optimal drug concentration distribution in the arterial wall (as
defined above) vs. having a stent design that minimally disturbs the flow field, the choice of
wFDI is arbitrary. We use a baseline value of wFDI = 0.5 in the majority of the optimization runs
but also briefly probe the effect of this parameter on the results.
A common approach to avoid using arbitrary weight factors in the cost function of multi-
objective optimization problems is to refrain from forming an aggregate cost function (sometimes
referred to as a utility function [153]) and instead searching for the pareto optimal design of
the different objectives [56, 140, 153]. A design is pareto optimal when a small deviation in
any of the design variables leads to an improvement in one of the objectives only at the expense
of another objective. Pareto optimal designs are thus typically non-unique, and identifying
them is an involved and computationally expensive process. On the other hand, the use of
an aggregate cost function as we have done here (J (Eq. (4.2))) allows us to create a fully
automated and efficient algorithm that, based on the a priori choices made by the designer,
yields a unique optimal design.
4.2.3 Optimization method
In this chapter, the goal is to identify the design which yields the lowest possible score of the
cost function J (Eq. (4.2)). Solving such an optimization problem is often associated with
gradient-based methods that estimate gradients of the cost function with respect to the design
variables in order to determine the direction of decreasing cost function. These methods are
known to have excellent convergence properties and can assure convergence to a minimum;
however, this class of methods requires the cost function to be continuously differentiable and
the gradient to be easy to obtain [153]. Furthermore, gradient methods can only search for
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a local minimum and will miss the global minimum that cannot be reached by a continuously
descending path from the initial guess.
In the present study, the cost function value is estimated using the computational model de-
scribed in Chapter 2. The model is implemented in the commercial multi-physics finite element
solver COMSOL and can require several hours of computation time for one evaluation. We have
thus no prior knowledge of the shape or differentiability of the cost function hypersurface in
the design space. Considering the computational cost, the use of gradient-based optimization
methods is intractable. We thus rely on the derivative-free optimization method described
below.
Basic concept of the optimization method
We use an optimization algorithm based on the Surrogate Management Framework (SMF) [23]
to minimize the cost function J (Eq. (4.2)). Following evaluation of an initial set of designs,
SMF algorithms use a succession of search and poll steps to identify the optimal design of
the cost function (Fig. 4.2). In the search step a Kriging model [97, 122] interpolating the
cost function (called the surrogate) is used to inexpensively scan the space of possible designs
(called design space) for prospective optimum points. The Kriging model is an interpolation
(and extrapolation) function based on previously evaluated designs which estimates the value
of the cost function and the uncertainty of the prediction for new designs of the design space
(Fig. 4.3). The predicted value and its uncertainty are combined to calculate the probability
that a new design would improve by a defined margin the cost function value of the best design
that has been identified to this point. Maximizing this probability of improvement is used to
identify new prospective optimal designs.
The cost function of the determined prospective optimal design is then evaluated using the
direct numerical simulation of the computational model. If this computed cost function score
J is smaller than the value of J of the current optimal design, then the new design and the
value of the cost function J are added to the Kriging model to generate a new interpolation
surrogate and the search step is repeated. Otherwise, a poll step is initiated which numerically
computes the value of J for new designs with design variables closer to the current optimal
design. Failure to identify a new optimum in the poll step results in a refinement of the grid on
which new designs are looked for in the design space. All newly evaluated designs and their
respective computed value of the cost function are again added to the Kriging model and a new
search step is initiated.
The following two key novelties have been implemented in the present SMF algorithm lead-
ing to improved performance of the optimization procedure: 1) The arrangement of different
designs is on a grid with a higher number of directly neighboring designs than in the case of
the typically used Cartesian grid [70, 118–120, 198]. 2) The factor by which the grid is refined
after a failed poll step is reduced compared to other algorithms so that the number of designs
that can be investigated in each poll step increases without having to pick designs that are very
close to the current optimal design (see Fig. 4.4 and the discussion below for details).
In the following section we will discuss the SMF algorithm in more depth. We will outline
the derivation of Kriging, detail some of the particularities of our method, and highlight the ex-
tensions made to the code (generously supplied by our UCSD collaborators Belitz and Bewley).
A detailed description including studies investigating the performance of the method can be
found in [16] and [17].
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Figure 4.2: Flow diagram of the optimization algorithm and its coupling to the computational model.
Detailed description of the optimization method
Definitions: Before we begin the more detailed description of the optimization method, we
need to define a few terms that will be useful throughout the remainder of this section:
• design variable x i: property of a stent which is to be optimized, e.g. stent semi-strut height
as, stent semi-strut width bs, or strut shape exponent n.
• design range: For each design variable a range of interest is specified in which the op-
timization shall be performed. The range is bounded by “soft” constraints which can
be overcome by the optimization algorithm in certain cases. For some design variables,
“hard” constraints can be defined reflecting physical considerations that are not consid-
ered by the computational model and thus should not be overcome by the algorithm. See
the section Implementing constraints as well as encountering infeasible designs and failed
function evaluations below for more details.
• design x (i) =
 
x1 x2 . . . xd
T (i): vector of d design variables defining a particular stent
design.
• design (hyper-)space D= Rd : space of all possible designs. Each design variable forms an
axis of the design space. All designs are located on a grid that discretizes the design space
with a grid size G(k) (minimum distance between two design variables). To avoid any bias
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Figure 4.3: One-dimensional example of a Kriging interpolation hypersurface (red) of the true cost
function hypersurface (black) based on 10 evaluated points P (green) with uncertainty s (blue) over
the design space x . The design space x and the cost function values form the cost function hyper-space.
The true cost function minimum (green cross) could almost perfectly be identified by the Kriging model
(predicted minimum marked by red circle) with only 10 points.
or distortion of the optimization procedure related to different dimensions or units of the
design variables, the d design variables are mapped onto the unit hyper-cube D∗ = [0,1]d
based on the range of the soft constraints [56, 153]. Our initial grid is discretized by 6
grid points per design variable [16] and thus the initial grid size G(0) = 1/5.
• cost function (hyper-)surface J (x )⊂O: true surface of the cost function.
• cost function (hyper-)space O= Rd+1: space in which the hypersurface of the cost function
J lies.
• surrogate (hyper-)surface Jˆ (x ) ⊂ O: estimated surface of the cost function surface ob-
tained via interpolation and extrapolation of a Kriging model.
• current optimum design (COD) xCOD: design that yields the lowest cost function JCOD
value among all evaluated designs up to the current iteration.
• search direction: vector connecting the xCOD and a design x (∗),i that is designated for
evaluation in the current iteration.
• indices i, j: i, j ∈ (0,1,2, . . .), x (i), x ( j) denote different designs.
• index k: k ∈ (0,1,2, . . .), G(k) is the grid size after k grid refinements.
Generating a surrogate surface via Kriging: Kriging [97, 122] is the essential tool used in the
search step of the SMF algorithm to generate an estimated cost function surface that reflects the
trends of previously evaluated designs. We will thus outline the major steps in the derivation
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Figure 4.4: Polling the design space. A: Two consecutive factor of 4 grid refinements and factor of 2
shell of prospective polling designs refinements of the LT-MADS algorithm on a 2-dimensional Cartesian
lattice; B: Two consecutive factor of 2 mesh refinements of the λ-MADS algorithm on a hexagonal lattice
A2 with a shell of prospective polling designs at a distance of 1, 2 and 3 grid points for the initial grid
(k = 0) and after k = 1 and k = 2 consecutive grid refinements, respectively. Search directions (in blue)
of a minimal positive basis connect the current optimum design (in green) with the selected poll designs
(red). Current shell of prospective polling designs is marked in red, previous shell of prospective polling
designs is marked in orange.
of this method. The interested reader is advised to consult Jones et al. [86] or Forrester et al.
[56] for an excellent review of the method.
The fundamental assumption of Kriging is that the cost function value J (i) of a design x (i) is
the observation of a normally distributed random process with mean µ and standard deviation
σ. Furthermore, we are going to assume that the random processes of two different designs
x (i) and x ( j) are correlated by the expression:
φ

x (i), x ( j)

= exp
 
−
d∑
l=1
θl
x (i)l − x( j)l pl
!
i j
. (4.7)
The two parameters θl and pl , which are the most notable difference between this correlation
and the standard Gaussian distribution formula, serve as tuning parameters of the Kriging
model. These parameters are tuned during the derivation of the Kriging model such that the
shape of the surrogate surface has the highest probability of correctly mimicking the trends
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of previously evaluated designs. A low value of θl leads to a wider shape of the Gaussian
bell function indicating less variation of the surrogate surface along the design variable x l . pl
ranges from 0 to 2 whereby values in the lower range indicate a rather discontinuous shape
and pl = 2 characterizes a smooth shape. To save time in the optimization, we will omit the
optimization of the exponents pl and simply fix a value of pl = 2 [56].
Based on neval previously-evaluated designs X =

x (1) x (2) . . . x (neval)
T
with cost function
values J =

J

x (1)

J

x (2)

. . . J

x (neval)

, the Kriging model estimates the cost function
value of a new and unknown design x (∗) as:
Jˆ

x (∗)

= µˆ+ ψˆT Ψˆ−1  J − 1µˆ (4.8)
where
Ψˆ=

φˆ

x (i), x ( j)

i j
with i, j = 1, . . . ,neval (4.9)
is the correlation matrix of all previously evaluated designs,
ψˆ
T =

φˆ

x (1), x (∗)
T
. . . φˆ

x (neval),x
(∗)
(4.10)
is the correlation vector of the previously evaluated designs with the unknown design, and 1 is
an neval× 1 vector of ones. φˆ is a similar correlation expression to that in Eq. (4.7) except that
the tuning parameters θl and pl are replaced by their optimal values θˆl and pˆl . To obtain the
optimal parameters θˆl and µˆ (remember we do not optimize for pˆl ), we start by expressing the
likelihood of observing J given the parameters µ and σ:
L =

2piσ2
−neval/2 |Ψ|−1/2 exp− 1
2σ2
 
J − 1µT Ψ−1  J − 1µ . (4.11)
Maximizing this likelihood with respect to σ and µ yields the optimal values
µˆ=
1TΨ−1J
1TΨ−11 , (4.12)
σˆ2 =
1
neval
 
J − 1µT Ψ−1  J − 1µ . (4.13)
Plugging these values back into Eq. (4.11) and optimizing the likelihood function numerically
with Brent’s method (a modified bisection method) [25] yields the optimal parameters θˆl .
We have obtained the model parameters that are most likely to yield the observed cost
function values J of our designs. Given this model, we now wish to obtain the most likely
prediction of a cost function value Jˆ for a new design x (∗). We thus add the predicted objective
value Jˆ to obtain J˜ =
 
J Jˆ
T together with the new design to the rest of the designs which
yields an additional correlation vector ψˆ (Eq. (4.10)) and the augmented correlation matrix
Ψ˜=

Ψˆ ψˆ
ψˆ
T
1

. (4.14)
Plugging Ψ˜, ψˆ, θˆ , pˆ, µˆ and σˆ into Eq. (4.11) and maximizing the resulting expression with
respect to Jˆ finally gives Eq. (4.8). This value is has an associated uncertainty that can be
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derived as the mean squared error of a Gaussian process [155]:
sˆ2

x (∗)

= σˆ2
1− ψˆT Ψˆ−1ψˆ+

1− 1T Ψˆ−1ψˆ
2
1T Ψˆ−11
 . (4.15)
In our implementation we omit the last term of this equation which is very small and prone to
cause numerical issues.
Inititalizing the optimization algorithm: In the initial step of a SMF algorithm, a sample of
10d designs is distributed over the design space which serves as the basis of the first Kriging
model. We use the latin hypercube sampling algorithm presented in [56] to assure a uniform
distribution of these points throughout the design space.
The global search step: The purpose of the search step is to explore the entire design space
for prospective new designs that minimize the cost function and then evaluate these prospective
designs with the expensive computational model to obtain the true cost function value. We saw
above that a Kriging model inexpensively yields a prediction of the cost function value Jˆ

x (∗)

as well as the associated uncertainty sˆ2

x (∗)

for unevaluated designs based on previously
evaluated designs. The uncertainty is maximal in between and zero at already evaluated
designs (Fig. 4.3). Instead of searching the surrogate surface directly for minima, Jones et
al. [86] recommend the following strategy: given a target TG = JCOD − α

Jmax− JCOD for
improvement over the COD (JCOD), we can evaluate the likelihood that a certain design x (∗)
improves the COD by at least this value. Minimizing the expression [86]:
Jˆ

x (∗)
− TG
sˆ

x (∗)
 (4.16)
(which is equivalent to maximizing the likelihood of improvement) with a conjugate gradient
method will then reveal a prospective design x (∗) that has a high likelihood of having a lower
cost function value than the COD. The choice of α controls whether this search in the design
space will be more exploratory (meaning scanning the entire design space) or local (looking
in the vicinity of the COD). As the density of evaluated designs around the COD increases, the
uncertainty about this region decreases. Eventually the uncertainty sˆ

x (∗)

of designs close to
the COD approaches 0 and the ratio in Equation (4.16) becomes very large, driving the search
step towards unexplored regions of the design space away from the COD.
The convergence rate of this method is highly sensitive to the choice of the control parameter
α which sets the target value of improvement for the search. The optimal choice of this value is
not only tied to the optimization problem at hand but might also change during the course of
the optimization. While in the beginning of the optimization larger (and thus more exploratory
values) are desirable, a smaller value of α might be necessary to speed up the convergence
to the optimum once the design space has been scanned sufficiently. To solve this issue, we
investigate 10 values of α spanning the range from 0 to 3 in every search step as suggested by
Jones et al. [86] to ensure that at every iteration candidate designs emerge that are close to the
optimum as well as in less explored regions of the design space. To maximize the performance
of this method, the search and evaluation of the different candidate designs is performed in
parallel and as soon as one of these evaluations yields a lower cost function, the search step is
deemed successful and a new search step is initiated with the newly evaluated points added to
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the Kriging model. The search step is repeated until no new point can be identified in which
case a poll step is initiated around the COD.
The local poll step: The poll step of the SMF algorithm investigates the vicinity of the COD
for designs that yield lower cost function values than the COD. This assures convergence of
the algorithm to a design for which gradients of the cost function with respect to the design
variables vanish [95]. We use a novel Mesh-Adaptive Direct Search (MADS) algorithm, dubbed
λ-MADS [16], in the poll step. To explain the concept of this MADS algorithm, it is helpful to
remain in a two-dimensional example as depicted in Fig. 4.4 B, with the understanding that all
of the following can be extended to higher dimensions. After a failed search step, we are now
looking at the COD (the green point) on our initial grid (discretizing the design space) with
grid spacing G(0).
Starting from the COD, a set of d + 1 = 3 search directions is chosen on the grid which
positively spans the design space, meaning that any grid point of the design space is expressible
as a linear combination of these search directions with only positive coefficients. The first of
these search directions (the seed search direction) is chosen at random while the remaining two
search directions are the solutions of the Thomson problem [177] which seeks the equilibrium
solution of equally charged particles distributed on a (hyper-)sphere. The length of these
search directions is exactly one grid size. The designs that are at the tip of these search
directions (marked with red points) will then be polled, meaning their cost function values will
be evaluated using our computational model. All prospective designs that could be polled lie on
the hexagon around the COD marked in red; we call this set of designs the shell of prospective
polling designs (henceforth referred to simply as shell). If any of these polled designs yields
a cost function value that is lower than the cost function value of the COD, the poll step is
deemed successful, otherwise it is deemed to have failed. Independent of the outcome, the
evaluated designs and their respective cost function values are added to the Kriging model and
a new search step is initiated (we call this updating the Kriging model).
If the poll step fails, then we will also reduce the grid size by a factor of 2 (the number of
grid refinements is thus k = 1) and the shell will be moved to a distance of k+1= 2 grid points.
This means for the first grid refinement that the shell will remain at the same distance, however,
with an increased number of prospective polling designs. Again a set of search directions is
determined (with a random seed search direction) and the selected designs polled. To avoid
selecting the same poll designs as in the previous iteration, these designs will be assigned
a smaller charge, thus diverting the equilibrium search of the Thompson algorithm to other
designs. If the poll step fails again, the grid is again refined by a factor of 2 (k = 2) and the
width of the new shell is moved to a distance of 3 grid points, which corresponds to 3/4 of the
width of the previous shell (marked in orange).
If, on the other hand, the poll step is successful, then the grid size remains constant and the
seed search direction will be the same as the previously successful search direction. After two
successful poll steps, the grid is coarsened by a factor of 2 (meaning that k is reduced by one)
and the distance of the shell adjusted accordingly.
Separating refinement of the grid from the refinement of the shell is the key advantage
of MADS algorithms compared to other direct search algorithms since in every iteration the
number of search directions increases. Eventually, the search directions become dense in the
design space, a property of these algorithms which can assure convergence to a local optimum
[2]. A key novelty of λ-MADS compared to other MADS algorithms like LT-MADS [10] is that
these refinements are slowed down (see Fig. 4.4 A for a two-dimensional example). Typically
a factor of 2 refinement is chosen for the shell and a factor of 4 for the mesh. The advantage
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of slowing down the refinement is that the number of search directions is increased without
drastically reducing the size of the shell at the same time.
Laminated lattices at the heart of the optimization algorithm: The second novelty of the
SMF algorithm used in this study, which was introduced by Belitz and Bewley [16, 17], was
to break with the paradigm of using a Cartesian lattice to discretize the design space and
use more uniform and densely packed lattices instead (meaning every grid point has a larger
number of directly neighboring grid points). For every dimension d a lattice can be found that
maximizes these two properties, the so called laminated lattices λd : this is in two dimensions
the hexagonal lattice A2, in three dimensions the face-centered-cubic lattice A3 and in four
dimensions the checkerboard lattice D4. An overview of the theory behind these lattices can be
found in [16, 17]. Belitz and Bewley [16, 17] were able to show that using laminated lattices
significantly improves the performance of SMF algorithms. If we compare the initial grids in Fig.
4.4, we see that the Cartesian lattice has only 4 direct neighbors while the hexagonal lattice
has 6 and the d + 1 search directions are perfectly isotropic compared to the search directions
of the LT-MADS algorithm. These benefits account in part for the improved performance of the
current SMF algorithm.
Implementing constraints as well as encountering unfeasible designs and failed function eval-
uations: The searching procedure of the search step is restricted to a set of constraints on
the design space that are defined a priori. The constrained search is realized by penalizing
search results that violate these constraints by a dynamically adjusted weighting factor. We
call these constraints soft constraints, since the search can still converge on a design outside
of the borders of these constraints if the prospect of finding improved designs is so high that
it surpasses those of the designs that lie inside the constraints. Moreover, the poll step is an
unconstrained optimization algorithm per se and can explore the design space far beyond the
soft constraints. The advantage of having soft constraints is that it gives the designer some
flexibility regarding the definition of the design space. The designer might, for example, have
envisioned a certain range of a design variable to be explored during the optimization, which
is not based on any physical constraints. If, however, the optimization algorithm discovers
that significantly superior designs can be found outside of this range, the algorithm has the
possibility to explore them.
Other design constraints might have physical bases that are not considered by the compu-
tational model and are thus undesired by the designer. If the search or poll step encounters
a design that goes beyond these hard constraints, the cost function is not evaluated and the
design is imputed with a value that corresponds to
J

x (i)

= Jimp,hard

x (i)

= Jˆ

x (i)

+ 2sˆ2

x (i)

. (4.17)
This strategy of assigning a value is inspired by Forrester et al. [56] who suggest imputing the
values of designs that lead to failed function evaluation by their predicted value Jˆ
 
x i

plus a
penalty corresponding to the square of the uncertainty at the design x i:
J

x (i)

= Jimp,fail

x (i)

= Jˆ

x (i)

+ sˆ2

x (i)

. (4.18)
This method ensures that the algorithm is diverted from the design without exceedingly distort-
ing the surrounding interpolation model. We adopted the same strategy in our algorithm when
a cost function evaluation failed.
Quality management of the Kriging model: As the optimization algorithm progresses, the
design space becomes more and more explored and the underlying mesh gets increasingly
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refined. After a number of mesh refinements the density of polling points increases significantly
and design clusters are formed. This causes the correlation matrix, required in the process of
generating the Kriging model, to become ill-conditioned which results in an inaccurate Kriging
model [23, 56]. One way to address this issue is to add a small constant to the leading diagonal
of the correlation matrix and generate a Kriging model with regression [23, 56]. Although the
Kriging model obtained is no longer an exact interpolation of the data points, the quality of the
Kriging model is not compromised.
We have developed an alternative approach to tackle this issue by filtering the data points
used to create the Kriging predictor and hence thinning the clusters in the design space re-
sponsible for the ill-conditioned matrix. First we determine the average minimum Euclidean
distance of our data points, which serves as an upper bound ffilt,max of the filtering process,
and the minimum Euclidean distance of our data points, which marks the lower bound ffilt,min.
Starting from the current optimum design (COD), we now filter (remove) any points within
the hyper-sphere of radius ffilt,min/2 that have a higher cost function value than the COD. This pro-
cedure is then repeated for the point with the lowest cost function value among the remaining
points and so on. Once all points have been filtered with the lowest filtering scale ffilt = ffilt,min,
we attempt again to create the Kriging model. If the process fails again, then the filtering scale
is increased by a factor of 2 and the filtering procedure repeated until the maximum filtering
scale ffilt,max is reached at which point the set of data points has been sufficiently thinned to
allow the Kriging model to be computed.
This method has two key benefits: the Kriging model will still pass through the evaluated
data points and since the minimum points in every filtered cluster are preserved, the search
method will not be inclined to revisit the filtered regions. Moreover, even if we have removed
some (less crucial) information from the Kriging model, we can leverage the filtered points to
test the quality of the Kriging model during the current optimization.
Since we know the true cost function values of filtered points x filt, we can calculate a
correlation coefficient r2cor between the predicted values Jˆ
 
x filt

and the true function values
J
 
x filt

[56]
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A high correlation coefficient indicates that the current Kriging model is capable of appropriately
mimicking the trends of the cost function while a low value would indicate that either the
Kriging model is missing important features of the cost function or that the cost function is
very irregular. Beyond serving as a simple indicator of the quality of the Kriging model, this
information could also be implemented as part of the termination strategy of the optimization.
Terminating the optimization algorithm: The optimization is terminated when we consider
the design space exhaustively explored. In our definition, this point is reached when the
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following three criteria are met:
1. The mesh of the poll step was 10-fold refined.
2. At least as many search directions were polled on this finest mesh as there are direct
neighbors to the COD.
3. 5 consecutive search steps failed following these poll steps.
4.2.4 Sensitivity estimation of the cost function to design variables and model
parameters
Taking the physiological parameters of our computational model (Chapter 2) and the calibration
parameters of the cost function as given, we are left with 10 parameters in our computational
model that need specification (Table 4.1). The first group contains the geometric design
variables that appear in the Superformula (Eq. (4.1)): the stent semi-strut height as, the stent
semi-strut width bs, and the strut shape exponent n. The indicated design range of as and
bs reflects the typical dimensions of modern stents (low end) up to the thicker struts of first
generation DES [60]. The shape exponent covers the range of round (n = 2) to chamfered
rectangular (n= 6) struts. These design ranges also indicate the bounds of the soft constraints
used for the search step of the SMF algorithm. Values in parentheses mark hard constraints.
The meaning of the sensitivity range will become evident in a moment.
The second group contains design variables that define the drug delivery strategy of the
polymer coating (without specifying the exact type of release): the effective diffusion coefficient
Dc which controls the release rate from the polymer coating, the drug concentration c0 which
is initially loaded in the polymer coating, the thickness of the polymer coating Lc, and the
permeability Pc of a possible top-coat that encases the polymer. The highest value in these
ranges (Dc = 1 · 10−13 m2 s−1) is indicative of a rapid release of the drug (quasi-bolus release
kinetics) and the lowest (Dc = 1 · 10−18 m2 s−1) of concentration-independent long-term release
(zero-order release kinetics). Whenever there are two rows of values for a design variable, the
upper row of values corresponds to the range that we used for the optimization of paclitaxel-
eluting stents (P-DES) while the lower row contains the range for the optimization of sirolimus-
eluting stents (S-DES). We chose different ranges for paclitaxel and sirolimus based on our
experiences in Chapter 3. The ranges of c0 are also influenced by the results of Chapter 3; they
do, however, contain the order of magnitude which can be found for typical P-DES and S-DES
(≈ 100 molm−3). The design range of Lc reflects the dimensions of typical DES. The upper
end of the range of top-coat permeabilities (Pc = 1 ms−1) is in principle identical to a situation
without any top-coat, while the low end (Pc = 1 · 10−10 ms−1) represents a very resistant barrier
to the elution of drug from the underlying polymer coating.
The third and final group contains parameters of the computational model that express
assumptions we made in the computational model setup rather than actual variables of the stent
design. The strut embedment pst determines how far the struts of our model stent penetrate the
arterial wall. This parameter represents the outcome of the implantation process rather than an
actual variable that can be controlled. For all simulations, we assume the hypothetical situation
where the stent is exactly half embedded into the arterial wall. The time parameter tend controls
the time period covered by the simulation and set as the target time for the evaluation of the
cost function. We chose tend = 4 weeks based on typical DES release times and motivated by
the pathobiology following stent implantation [3, 94, 121, 150]. Finally, the parameter tpdf
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Table 4.1: Model parameters and design variables of the computational model with respective design
and sensitivity ranges
Symbol Description
Sensitivity range Design range
Unit
min max min max
geometrical design variables
as semi-strut height 25 75 25 (12.5) 75 µm
bs semi-strut width 25 75 25 (12.5) 75 µm
n strut shape exponent 1.5 6 2 (1.5) 6 −
design variables of two-layered polymer coatings
c0 initial concentration
0.1 100 0.1 100
molm−3
100 1 · 105 100 1 · 105
Dc diffusion coefficient 1 · 10−18 1 · 10−15 1 · 10
−18 1 · 10−13
m2 s−1
1 · 10−17 1 · 10−14
Lc polymer coating thickness 10 50 10 30 µm
Pc top-coat permeability
1 · 10−10 1 1 · 10−10 1
ms−1
1 · 10−10 1 1 · 10−10 1 · 10−6
parameters of the computational model
pst strut embedment 20% 80% 50% −
tend simulation time 1 6 4 weeks
tpdf therapeutic domain size 50% 100% 100% −
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defines the percentage of the radial width of the arterial wall that is considered to be part of
the therapeutic domain in which the cost function is evaluated. In all simulations we set the
therapeutic domain to span 100% of the arterial wall.
Estimated mean and standard deviation of elementary effects
The elementary effect e(
j)
i of a design variable x i at a design x
( j) on the cost function J is
defined as [129]:
ei

x ( j)

= e(
j)
i =
1
∆

J
 
x1, . . . , x i +∆, . . . , xd
T ( j)− J  x1, . . . , x i , . . . , xdT ( j) (4.20)
where ∆= 1/(m−1) is the mesh size of the mapped design space (D∗, where all design variables
x i are scaled to the interval [0,1]) discretized by m mesh points per dimension (m= 10 in our
case). An elementary effect is thus an evaluation of the gradient of the cost function J with
respect to the design variable x i at a design x ( j). If we distribute a number of nelem (nelem = 5
in our case) designs throughout the design space D∗ (following the randomized statistical
process described in [129]) and evaluate their elementary effects e(
j)
i at these designs, then
the estimated mean value and standard deviation of the elementary effects e(
j)
i of each design
variable x i gives an estimate of the importance of the design variable x i for the cost function J :
a large estimated mean (absolute value > 1) indicates that the cost function J is sensitive to
variations of the design variable x i (i.e. on average the non-dimensional gradients throughout
the design space are large) and a large standard deviation (absolute value > 1) implies that
the design variable x i is involved in interactions with other variables (i.e. the non-dimensional
gradients vary a lot throughout the design space).
4.3 Results
4.3.1 Sensitivity estimation of the cost function
We will first apply the sensitivity estimation method to estimate the importance of the design
variables and model parameters shown in Table 4.1 for the flow-related (JFDI, Eq. (4.4)) and
the drug-related parts of the cost function (JETH, Eq. (4.3)). This approach has previously been
suggested in [56]. Although the parameters pst, tend and tpdff (Table 4.1) of the computational
model are not strictly speaking design variables, we will treat them as such for the first part of
this section and will simply refer to the ensemble of design variables and computational model
parameters as parameters.
We will consider four different cases in this analysis: two cases with paclitaxel as the
eluted drug, once without a top-coat being applied to the polymer coating and once with
a top-coat; and two cases with sirolimus again with and without a top-coat. All four cases
consider an endothelium that is completely denuded within the stented portion of the vessel
but intact otherwise (configuration E1 in Fig. 3.1 A). We will then discuss the importance
of the parameters for the total cost function J (Eq. (4.2)). Afterwards we will be ready to
determine the optimization runs considered in this chapter. The design range we investigated
in the following analysis is indicated in the column “sensitivity range” of Table 4.1.
Since the estimated mean and standard deviation of the elementary effects of each parame-
ter as depicted in Figs. 4.5 and 4.6 are based on a single random distribution of a small number
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(5) of designs, the values are not fully converged and only the order of magnitude of these two
quantities will be of interest.
Sensitivity estimation of the flow-related part of the cost function JFDI
Fig. 4.5 depicts the estimated mean values and standard deviations of the elementary effects
of each parameter on JFDI. Only parameters that determine the geometry of the stent strut (as,
bs, n and Lc) or its embedment in the arterial wall (pst) are important for JFDI. For the other
parameters, the estimated mean and standard deviation of their respective elementary effects
is zero and thus JFDI is neither sensitive to these parameters nor are these parameters involved
in interactions with other parameters. Therefore, these parameters are not shown in Fig. 4.5.
JFDI is most sensitive to the strut embedment pst since out of all considered parameters, the
estimated mean value of the elementary effects of pst is the largest. The strut embedment pst is
involved in interactions with other parameters since the standard deviation of the elementary
effects of pst is also the largest one. This is not unexpected since the embedment controls the
degree to which the entire stent structure is exposed to lumenal flow. The shape exponent n of
the struts has a more significant effect on JFDI than the semi-strut height as and the polymer
coating thickness Lc. The flow disturbance caused by the stent is least sensitive to the semi-strut
width bs. The overall small magnitudes of the estimated mean values and standard deviations
indicate that changes of the parameters in the considered ranges only lead to mild variations
of JFDI.
Sensitivity estimation for the drug-related part of the cost function JETH
Fig. 4.6 depicts the distribution of the estimated mean values and standard deviations of the
elementary effects of the investigated parameters on JETH. In this figure, estimated means and
standard deviations of the elementary effects of some of the parameters are not shown because
their absolute values are negligibly small, indicating lack of sensitivity of the cost function to
those parameters. The four panels correspond to the four different model setups discussed
above: P-DES without (Fig. 4.6 A) and with (Fig. 4.6 B) a top-coat and S-DES without (Fig.
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Figure 4.5: Sensitivity estimation of JFDI. Distribution of the estimated mean values and standard
deviations of the elementary effects of each parameter (see Table 4.1) on JFDI (Eq. 4.4). Parameters
with an estimated mean and standard deviation of elementary effects of zero are not shown.
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Figure 4.6: Sensitivity estimation of JETH. Distribution of the estimated mean values and standard
deviations of the elementary effects of each parameter (see Table 4.1) on JETH (Eq. 4.3) for: A: P-DES
without a top-coat, B: P-DES with a top-coat, C: S-DES without a top-coat, and D: S-DES with a top-coat.
Parameters with an estimated mean and standard deviation of elementary effects of absolute value
smaller than 1 are not shown.
4.6 C) and with (Fig. 4.6 D) a top-coat. For both DES drugs studied and regardless of whether
or not a top-coat is applied (i.e. all four panels), the mean and standard deviation of the
elementary effects of the initial concentration c0 and the effective diffusivity in the polymer
coating Dc have the largest absolute values. This indicates that these parameters have the
strongest effect on JETH and that they exhibit the highest level of interaction with other design
variables. For the case of S-DES without a top-coat (Fig. 4.6 C), The diffusivity Dc plays a
smaller role relative to the initial concentration c0 than in the other three cases. Interestingly,
the thickness of the polymer coating Lc plays a role in the cost function of P-DES (Fig. 4.6 B)
but not S-DES (Fig. 4.6 D). The permeability of the top-coat Pc is the third most important
parameter for S-DES (Fig. 4.6 D) but is a much less significant parameter for P-DES (Fig. 4.6
B). The means and standard deviations of the elementary effects of the remaining parameters
shown in Fig. 4.6 cluster closer to zero; however, since their absolute values are larger than 1,
they do have an effect on JETH.
The stent strut geometric parameters as, bs and n only play an important role in the design
of P-DES and not S-DES (Fig. 4.6). The strut width bs is the most dominant parameter amongst
these if no top-coat is applied to the paclitaxel polymer coating (Fig. 4.6 A), while the strut
shape exponent n is the only variable that influences the drug-related part of the cost function
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for P-DES with a top-coat (Fig. 4.6 B).
Another interesting observation is that the extent of strut embedment pst can have a sig-
nificant effect on JETH but only for the case of P-DES with a top-coat (Fig. 4.6 B). The results
also show that the simulation time tend has a strong effect on JETH only for DES with a top-coat
(Figs. 4.6 B and D). As long as the radial thickness of the therapeutic domain (controlled by
tpdf) is chosen to be larger than half of the arterial wall thickness, this thickness does not have
a significant effect on JETH.
The last two observations concerning the simulation time tend and the thickness of the
therapeutic domain (controlled by tpdf) have a rather simple explanation: the highest con-
centrations in the arterial wall during a simulation are encountered close to the stent struts
and the endothelial surface and without a top-coat the highest concentrations typically occur
within the first week of drug elution. A top-coat can significantly delay the incidence of highest
concentration, causing drug concentration to reach efficacious levels very late. Therefore, the
drug-related score of the cost function JETH becomes sensitive to variations of tend beyond one
week in the case of DES with a top-coat. Since the range investigated for tpdf yields therapeutic
domains that always include the highest computed concentrations, JETH is not affected by a
variation of tpdf over the range studied.
Sensitivity estimation of the total cost function J
We obtain the estimated mean value of the elementary effects of a parameter with respect
to the total cost function J by adding the estimated mean value of the elementary effects of
that parameter on JETH to the product of the estimated mean value of the elementary effects
of that parameter on JFDI and the FDI weight factor wFDI. This summation does not hold
for the standard deviation of elementary effects but it still gives a good estimate. Since the
estimated sensitivity of JFDI to geometric parameters (Fig. 4.5) is about ten times smaller than
the sensitivity of JETH to these parameters (Fig. 4.6), only when the FDI weight factor wFDI is
larger than 10 does JFDI play a significant role in the variation of the total cost function J . In
such a case, the geometric parameters strut height as, width bs, and shape exponent n to which
JFDI is sensitive will induce variations in J comparable to the variations induced through JETH
by the parameters of the polymer coating drug delivery strategy, i.e. the initial concentration
c0 and the effective diffusion coefficient Dc. This implies that a value of wFDI of order 1 or
below will not significantly affect optimization of the total cost function J . In this case, we
can separate the optimization of the drug delivery parameters from the optimization of the
geometric parameters, since the impact of the geometric parameters on the optimum of the
cost function J is negligible in comparison to the effect of the parameters that govern the drug
delivery strategy.
4.3.2 Optimization results
We have performed two groups of simulation runs. The first group aims to determine optimal
stent strut geometries, whereas the second group focuses on two-layered polymer coatings and
aims to optimize the design of the stent coating. Both groups of optimization are investigated
for stents eluting either paclitaxel or sirolimus.
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Group 1: Optimization of stent strut design
In this group of simulations, the goal is to determine optimal strut geometries for stents eluting
either paclitaxel or sirolimus. The three design variables used in the optimization are the
semi-strut height as, the semi-strut width bs, and the strut shape exponent n. Drug release is
assumed to occur at the optimal slow-release values identified in Chapter 3, where drug release
becomes concentration-independent and thus follows zero-order release kinetics (implying a low
effective diffusivity Dc in the polymeric coating).
We carried out six optimization runs. Two runs, one with paclitaxel at low initial loading
(henceforth referred to as low-dose P-DES) and one with sirolimus at a high initial loading
concentration (high-dose S-DES), assumed a model configuration where the endothelium is
denuded within the stented portion of the vessel and also upstream and downstream of the
stent (configuration E2 in Fig. 3.1 B). Two runs, again one for low-dose P-DES and one
for high-dose S-DES, were performed assuming that the endothelium is denuded within the
stented portion of the vessel but intact otherwise (configuration E1 in Fig. 3.1 A). The fifth
optimization run in this group was with low-dose S-DES with the goal of gaining insight into
the extent to which the optimization results depend on the type of drug used or the initial
loading concentration; this run was performed assuming the therapeutic window of paclitaxel
and with endothelial model configuration E1. Finally, the sixth optimization run explored the
consequences on the optimal design of choosing a large value for the FDI weight factor wFDI.
In this simulation, we set wFDI = 10 (all other optimization runs in this group were performed
with wFDI = 0.5) and used low-dose P-DES in model configuration E1. In all optimization runs
of this first group, the thickness of the polymer coating was set to Lc = 10 µm. An overview of
the six Group 1 optimization runs is provided in Table 4.2.
Table 4.2: Group 1 optimization runs: strut design optimization with semi-strut height as, semi-strut
width bs, and strut shape exponent n as the design variables
# Figurea Drug Dose Release c0 Dc ceff ctox Config.
b wFDI
c
(molm−3) (m2 s−1) (molm−3) (molm−3)
1 4.8 A Pd low ZOf 2.0 2.6·10−18 1·10−5 1·10−2 E2 0.5
2 4.9 A P low ZO 2.0 2.6·10−18 1·10−5 1·10−2 E1 0.5
3 4.10 P low ZO 2.0 2.6·10−18 1·10−5 1·10−2 E1 10
4 4.12 A Se high ZO 2.8·105 1.0·10−18 0.29 0.73 E2 0.5
5 4.13 S high ZO 2.8·105 1.0·10−18 0.29 0.73 E1 0.5
6 4.14 S low ZO 2.4 1.2·10−18 1·10−5 1·10−2 E1 0.5
a figure depicting optimal strut design
b model configuration of the endothelium as depicted in Fig. 3.1
c FDI weight factor
d P: paclitaxel
e S: sirolimus
f zero-order release kinetics, i.e. concentration-independent long-term release
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Strut design optimization of paclitaxel-eluting stents
Optimization case 1: As indicated in Table 4.2, the first optimization is for a low-dose P-DES in
configuration E2. In all of the simulations, we do not know the true shape of the cost function
at every point in the design space. Rather, we can only rely on presenting designs that have
actually been calculated during the optimization runs. Extracting detailed information from
an interpolated representation of the three-dimensional hypersurface of the cost function that
results from the optimization is challenging and can be deceiving, especially since the interpo-
lation is only as good as the underlying calculated designs. Therefore, to better understand and
more clearly present the results of the optimization, we use the following multi-step approach,
which is explained with the help of the optimization results in Fig. 4.7 A for optimization
case 1:
1. We selected sample sets of designs (among all simulated designs) for which the cost
function was evaluated with two design variables kept approximately constant (within
the constraints of the simulated designs) and the third one varied along its design range.
For instance, in Fig. 4.7 A, the semi-strut width (bs = 68± 1.1 µm) and the strut shape
exponent (n = 5.1± 0.63) are fixed while the semi-strut height as is varied in the range
as = [14,75]µm.
2. Starting with the design for which the varied design variable is lowest, we compared
the magnitudes of the contributing scores of the total cost function of two designs in
increasing order of the varied design variable. In Fig. 4.7 A, the two scores that contribute
to the value of the overall cost function are the inefficacy score in the media Im (black)
and the flow disturbance score JFDI (white).
3. From the comparison in the previous step, we estimated the trend of the contributing
scores, i.e. whether these scores increased or decreased with an increase in the design
variable. In Fig. 4.7 A, the inefficacy score Im and JFDI both increase with increasing
semi-strut height as.
4. We repeated steps 1-3 for different parts of the design space. If we observed the same
estimated trend for each of these samples, then we considered the trend as global, i.e.
valid for the entire design space. Fig. 4.7 A depicts a representative sample of the
estimated global trend and can thus be understood as a discrete line cut through the
three-dimensional cost function hypersurface along the semi-strut height as.
Fig. 4.7 B shows the evolution of the inefficacy score Im (black) and the flow disturbance
score JFDI (white) with increasing semi-strut width bs. All values are normalized by their
respective maximum score encountered among the depicted designs (marked by an ×). For a
fixed strut height (as = 45± 27 µm, Fig. 4.7 B) the inefficacy score Im decreases significantly
with increasing bs while JFDI remains virtually constant in a range of bs = [27,94]µm.
Fig. 4.7 illustrates the following two global trends that can be observed for the cost function
of the P-DES strut design optimization with an endothelial model configuration that assumes
the endothelium denuded within the stented portion of the vessel and also upstream and
downstream of the stent (configuration E2): 1) Thinner struts (smaller as) lead to decreased
inefficacy scores Im (and hence to more efficacious stent designs) as well as to lower JFDI (thus
less flow disturbance). 2) Wider struts (larger bs) improve (i.e. reduce) the inefficacy score Im.
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Figure 4.7: Optimization case 1: estimated global trends of the cost function of the P-DES (configuration
E2) strut design optimization for a variation of semi-strut height as and semi-strut width bs. Change
in the inefficacy score Im (black bars) and flow disturbance score JFDI (white bars) for increasing A:
semi-strut height and B: semi-strut width. The scores are normalized by the maximum score among the
presented designs which is marked by an ×.
Thus, a smaller semi-strut height as has a desirable effect on both the drug- and flow-related
contributions to the cost function.
Fig. 4.8 A depicts the optimal strut shape that results from the optimization of P-DES in
configuration E2. The optimal strut design has a small semi-strut height as = 12.5 µm, a large
semi-strut width bs = 92.2 µm and a large shape exponent n = 5.8. Fig. 4.8 B and C depict
two sub-optimal strut designs. The struts in both these cases have virtually identical semi-strut
height and width with the major difference between them being their strut shape exponent n:
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# J Im Tm T e JFDI
A 0.206 0.132 0 0 0.148
B 0.348 0.226 0 0 0.245
C 0.350 0.251 0 0 0.199
Figure 4.8: Optimization case 1: optimal P-DES strut designs compared to sub-optimal strut designs
similar to commercial strut designs for wFDI = 0.5 and configuration E2. A: Optimal strut design, B: strut
design for high n, C: strut design for low n. The table provides the total score J and the contributing
scores Im, Tm, T e, and JFDI for each strut design.
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the strut in Fig. 4.8 B has an exponent at the upper end of the considered range (n= 6) which
results in a rectangular shape, whereas the strut in Fig. 4.8 C has a small exponent (n = 2.1)
resulting in an ellipsoidal shape. On the other hand, the optimal strut design is very elongated
and extremely thin (as = 12.5 µm is the hard constraint of the specified design range) compared
to typical strut designs of current DES, which resemble those shown in Fig. 4.8 B and C.
The table in Fig. 4.8 shows that both toxicity scores (Tm, T e) of the optimal strut design
are zero, and the inefficacy score is Im = 0.13. With a JFDI of 0.15, the total cost function
value sums up (wFDI = 0.5) to J = 0.2. The strut design of Fig. 4.8 B yields an increase in the
total cost function score of 69% compared to the optimum. 66% of this change is due to an
increased inefficacy score Im = 0.23 and 34% due to an increased JFDI = 0.25. The strut design
of Fig. 4.8 C results in an increase of 70% of the total cost function score relative to the optimal
strut design. 82% of this increase can be attributed to Im = 0.25 and only 17% to an increase
of JFDI = 0.2. The toxicity scores remain 0 for both sub-optimal strut designs, similar to the
optimal strut design.
The near three-fold size of the semi-strut minor axis as and the drastically reduced size
of the semi-major axis bs of both sub-optimal strut designs compared to the optimal strut
design account to a large degree for the increased JFDI and inefficacy Im scores. When we
compare the scores of the two sub-optimal strut designs directly to one another, we can see
that the high exponent n leads to an improved efficacy of the drug in the arterial wall which
compensates for the increased flow disturbance score JFDI (at a wFDI = 0.5) resulting from the
high n. Consequently, the total score of the strut design with the higher shape exponent (Fig.
4.8 B) is slightly better than that of the low n design (Fig. 4.8 C).
Similarly to the procedure described above to estimate the global trends of the cost function
for the semi-strut height as and width bs, we have investigated the trend for the strut shape
exponent n. The three strut designs presented in Fig. 4.8 are a representative sample of the
results used to deduce the estimated global trend of the cost function of a P-DES (configuration
E2) optimization for the strut shape exponent n. The results indicate that for otherwise identical
strut geometry parameters, a larger n decreases the inefficacy score Im and increases JFDI.
Contrary to strut height, the strut shape exponent n drives the drug-related inefficacy score
Im and the flow disturbance score JFDI in opposite directions. For the case of wFDI = 0.5
considered thus far, the effect of n on Im outweighs its effect on JFDI for most of the design
range until a balance is reached between the two, which determines the optimal shape exponent
n.
The flat and elongated strut with a high shape exponent n of the optimal strut design (Fig.
4.8 A) is the result of all three estimated global trends. The small height leads to a low inefficacy
score Im and JFDI. Although the wide strut and the high shape exponent n increase the flow
disturbance score JFDI, this increase is overwhelmed by the additional reduction in the inefficacy
score Im at high n.
Optimization case 2: The results shown above were for a low-dose P-DES in configuration E2
where the endothelium is denuded within the stented portion of the vessel and also upstream
and downstream of the stent but intact otherwise (case 1 in Table 4.2). We now consider a
low-dose P-DES in configuration E1 where the endothelium is assumed to be denuded only
within the stented portion of the vessel (case 2 in Table 4.2). Fig. 4.9 A shows the final optimal
result of the strut design optimization in this case. The optimal strut design has a large strut
shape exponent of n= 5 and is almost 3 times wider than high (as = 27.6 µm and bs = 75.9 µm).
The sub-optimal strut design shown in Fig. 4.9 B has an almost identical semi-strut width bs
(difference of 2%) and a 17% smaller semi-strut height as with a basically identical strut shape
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A 0.19 0.080 0 0 0.23
B 0.66 0.079 0 0.73 0.20
Figure 4.9: Optimization case 2: optimal P-DES strut design compared to sub-optimal strut design with
smaller as for wFDI = 0.5 and configuration E1. A: Optimal strut design, B: strut design for smaller as.
The table provides the total score J and the contributing scores Im, Tm, T e, and JFDI for each strut design.
exponent n compared to the optimal strut design.
The table in Fig. 4.9 shows that the two scores that are responsible for the total score
J = 0.19 of the optimal design are the inefficacy score Im = 0.08 and the flow disturbance score
JFDI = 0.23. Both toxicity scores are zero. The cost function score of the sub-optimal strut design
is increased by 240% (J = 0.66), almost entirely due to the appearance of endothelial toxicity
measured by T e = 0.73. These results suggest that a minimal change in the strut height has a
significant effect on the toxicity performance of the strut design and may point to limitations
in the robustness of our modeling.
The increase in the endothelial toxicity when endothelium is present immediately upstream
and downstream of the stent stems from the altered convective field within the arterial wall
which leads to drug transport from the struts towards the lumenal surface. The added en-
dothelial toxicity in the presence of endothelium represents the only difference between the
optimization with and without endothelium for P-DES. Otherwise, the same three global trends
are observed: 1) thinner struts lead to decreased inefficacy and flow disturbance scores Im and
JFDI; 2) wider struts improve the inefficacy score Im; and 3) larger n decreases the inefficacy
score Im and increases JFDI.
Optimization case 3: Figure 4.10 depicts the optimal low-dose P-DES strut design that results
from an optimization with a FDI weight factor of wFDI = 10 and in configuration E1 (case 3 in
Table 4.2). In this case, the optimal strut shape is ellipsoidal with n = 2.1 and an aspect ratio
b/a ≈ 2 with a small semi-strut width of bs = 24.5 µm. The inefficacy score is Im = 0.31 and the
endothelial toxicity score is T e = 1.1. Compared to the optimal strut design obtained for a FDI
weight factor wFDI = 0.5 (Figs. 4.9 A), these values are very high, in particular the endothelial
toxicity T e which was zero in the previous case. For the present optimum with wFDI = 10, the
high values of Im and T e are balanced by lowering JFDI to 0.1. The optimal strut design for
wFDI = 0.5 had JFDI = 0.23 (see Fig. 4.9 A).
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Figure 4.10: Optimization case 3: optimal P-DES strut design for wFDI = 10 and configuration E1. The
table provides the total score J and the contributing scores Im, Tm, T e, and JFDI.
Stent strut design optimization of sirolimus-eluting stents
Optimization case 4: Fig. 4.11 depicts the change in the inefficacy score Im (black) and the flow
disturbance score JFDI (white) for increasing semi-strut height as (Fig. 4.11 A) and semi-strut
width bs (Fig. 4.11 B) for a high-dose S-DES and configuration E2 (case 4 in Table 4.2). Fig.
4.11 A demonstrates how increasing the semi-strut height as from 25 µm to 72 µm with the
other design variables held constant in a narrow band (semi-strut width (bs = 39± 3.2 µm)
and shape exponent n = 2.2± 0.17) decreases the inefficacy score Im by 32%. Over the same
range, the flow disturbance score JFDI increases by 146%. This behavior is observed for other
pairs of bs and n throughout the design space (data not shown).
Fig. 4.11 B shows that Im and JFDI both decrease moderately (by approximately 20%) when
the semi-strut width bs varies from bs = 27 µm to bs = 82 µm. In Fig. 4.11 B n was fixed at
approximately 2.2 and as at 50± 18 µm. A decrease in the inefficacy score Im for increasing bs
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Figure 4.11: Optimization case 4: estimated global trends of the cost function of the high-dose S-
DES (configuration E2) strut design optimization for a variation of semi-strut height as and semi-strut
width bs. Change in the inefficacy score Im (white bars) and flow disturbance score JFDI (black bars)
for increasing A: semi-strut height as and B: semi-strut width bs. The scores are normalized by the
maximum score among the presented designs which is marked by a ×.
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is observed for all other combinations of as and n (data not shown). This is not the case for
JFDI where the variation with bs depends on the values of as and n (data not shown).
Thus, two global trends for high-dose S-DES strut design optimization in configuration E2
are: 1) thinner struts (smaller as) lead to increased inefficacy scores Im and to lower flow
disturbance scores JFDI and 2) wider struts (larger bs) weakly improve (reduce) the inefficacy
score Im.
The effects of as on the drug-related objectives outweigh its effect on the flow-related
objective when wFDI = 0.5 for most of the design range until a balance is reached between the
two objectives, which determines the optimal semi-strut height as. Interestingly, the effect of
as on the drug-related objective for a S-DES is opposite to that seen previously for P-DES.
The optimal strut design of a high-dose S-DES in configuration E2 where the endothelium
is denuded within the stented portion of the vessel and also upstream and downstream of
the stent (case 4 in Table 4.2) is depicted in Fig. 4.12 A. The optimal strut design has equal
semi-strut height as and semi-strut width bs of approximately 72 µm and a small strut shape
exponent of n = 1.6. The sub-optimal strut design (Fig. 4.12 B) has equal semi-strut height
and width as = bs = 75 µm and a strut shape exponent of n= 1.9. The second sub-optimal strut
design (Fig. 4.12 C) has a semi-strut height as = 74 µm, a semi-strut height bs = 72 µm, and a
strut shape exponent of n= 5.9. The shapes of these two struts correspond to typical DES strut
shapes, their strut sizes are comparable to first generation DES.
The table in Fig. 4.12 shows that the two scores contributing to the total cost function
score of J = 0.30 of the optimal strut design are the inefficacy score Im = 0.14 and the flow
disturbance score JFDI = 0.33. Holding strut dimensions approximately constant, we can
observe how slightly increasing the strut shape exponent n to form a more circular strut shape
only marginally increases (by 4%) the total cost function score J . This increase is due to an
increase of JFDI. If we increase the exponent further to n = 5.9, the total score J of the strut
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A 0.30 0.14 0 0 0.33
B 0.31 0.14 0 0 0.34
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Figure 4.12: Optimization case 4: optimal high-dose S-DES strut design compared to sub-optimal strut
designs similar to commercial strut designs for wFDI = 0.5 and configuration E2. A: Optimal strut design,
B: strut design for high n, C: strut design for low n. The table provides the total score J and the
contributing scores Im, Tm, T e, and JFDI for each strut design.
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design increases dramatically by 130% which can almost entirely be attributed to an increase
in the medial toxicity Tm. Generally speaking, for an otherwise identical strut design of a
high-dose S-DES in configuration E2, a smaller shape exponent n decreases both the toxicity
score Tm and the flow disturbance score JFDI without significantly affecting the inefficacy score
Im.
Optimization case 5: Figure 4.13 illustrates the optimal strut design for a high-dose S-DES
with endothelium denuded only in the stented region, i.e. configuration E1 (case 5 in Table
4.2). The optimal strut has an aspect ratio b/a = 1.2 and a semi-strut width of bs = 47.5 µm.
The strut shape exponent is at the lowest limit of the design range we allowed (hard constraint
of the design range) with n = 1.5. The table in Fig. 4.13 shows that this strut design yields
a low inefficacy score of Im = 0.12 with a minimal medial toxicity score of Tm = 0.02 and a
JFDI = 0.2.
Comparison of this optimal strut design with the optimal strut design for a similar stent but
with endothelial configuration E2 (Fig. 4.12 A) reveals that the strut shape is not significantly
altered, i.e. the shape exponent n is very similar in both cases. The aspect ratio, however,
of the optimal strut design for the E1 configuration is about 20% higher and the semi-strut
width bs is reduced by 33% compared to the optimal strut design for the E2 configuration. Due
to the reduced transport in the arterial wall, which results from the shielding function of the
endothelium upstream and downstream of the stent, a smaller strut size in the E1 configuration
(as and bs, Fig. 4.13) achieves a similar inefficacy score Im to that in the E2 configuration.
Optimization case 6: The S-DES simulations considered so far focused on high-dose S-DES;
therefore, the binding sites in the arterial wall were predominantly occupied. Given the wide
therapeutic window of sirolimus, we were also interested in investigating how the optimal strut
design needs to be adjusted to be suitable for S-DES with a low initial concentration loaded
onto the polymer coating. In this case, the effective and toxic concentration thresholds of the
cost function are reduced to the values of the therapeutic window of paclitaxel.
Fig. 4.14 shows the optimal strut design for a low-dose S-DES with an E1 configuration
(case 6 in Table 4.2). The optimization results in a highly elongated and rectangular strut with
a semi-strut width of bs = 126 µm, a semi-strut height of as = 37 µm and a strut shape exponent
of n = 4.8. This design achieves an extremely low inefficacy score of Im = 0.067 and a flow
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Figure 4.13: Optimization case 5: optimal high-dose S-DES strut design for wFDI = 0.5 and configuration
E1. The table provides the total score of the cost function J and its contributing scores Im, Tm, T e, and
JFDI.
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Figure 4.14: Optimization case 6: optimal low-dose S-DES strut design for wFDI = 0.5 and configuration
E1. The table provides the total cost function score J and its contributing scores Im, Tm, T e, and JFDI.
disturbance score of JFDI = 0.27, adding up to a total cost function value of J = 0.2. This strut
design has an even larger semi-strut width bs than the optimal P-DES (Fig. 4.9 A) but has
otherwise similar strut design variables (as and n).
Group 2: Optimization of two-layered polymer coatings
The second group of optimization runs aims to determine optimal properties of two-layered
polymer coatings for both P-DES and S-DES. The four most significant design variables for
a DES with a top-coat (as revealed by the sensitivity estimation study) are the initial drug
concentration c0, the effective drug diffusion coefficient in the polymer coating Dc, the thickness
of the polymer coating Lc, and the permeability of the top-coat Pc that encases the first polymeric
layer. These parameters define the key properties of the stent polymer coating and are thus
the design variables of the optimization problem. The thicker polymer coating layer encasing
the stent strut contains either of the two drugs paclitaxel or sirolimus, while the thin top-coat
encasing the thick polymer coating is assumed to be initially devoid of drug. We investigated
the differences of an optimal coating design for the two different drugs paclitaxel and sirolimus
with stents having circular struts of radius 50 µm and for the case of configuration E1 where the
endothelium is denuded only in the stented zone. The specifications for the two optimization
runs are summarized in Table 4.3.
The results of the two optimization runs are depicted in Fig. 4.15. The optimal polymer
Table 4.3: Group 2 optimization runs: two-layered polymer coating optimization
Figurea Drug ceff ctox Config.
b wFDI
c
4.15 A Paclitaxel 1 · 10−5 1 · 10−2 E1 0.5
4.15 B Sirolimus 0.29 0.73 E1 0.5
a figure depicting optimal polymer coating properties
b model configuration of the endothelium as depicted in Fig.
3.1
c FDI weight factor
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Optimal P−DES design Optimal S−DES designA B
#
Polymer coating properties Scores
Dc (m2 s−1) c0 (molm−3) Lc (µm) Pc (ms−1) J Im Tm T e JFDI
A 2.6·10−14 3 5.8 7.7 0.18 0.029 0 0.025 0.26
B 2.5·10−18 1.1·105 28 3.5·10−7 0.25 0.089 0 0 0.32
Figure 4.15: Optimal two-layered polymer coating properties for wFDI = 0.5 and configuration E1. A:
P-DES, B: S-DES. The table provides the optimal polymer coating properties comprised of effective drug
diffusivity Dc, initial drug concentration c0, polymer thickness Lc, and top-coat permeability Pc as well as
the associated total cost function score J and its contributing scores Im, Tm, T e, and JFDI. Visualization
of the parameters c0, Lc and Pc is achieved as follows: the magnitude of c0 is depicted using grey levels
with white indicating a very low concentration and dark grey a very high concentration; the coating
thickness is drawn on top of the circular strut (relative to the strut radius of 50 µm); the permeability of
the top-coat Pc is visualized by the thickness of the outer contour of the strut geometry with a thin line
indicating a high permeability and a thick line representing a low permeability.
coating of a P-DES (Fig. 4.15 A) has a thickness of Lc = 5.8 µm and is initially loaded with
paclitaxel at a concentration of only c0 = 3 molm−3. Optimal drug release from the polymer
coating occurs with an effective diffusivity Dc = 2.6 · 10−14 m2 s−1, and the top-coat has a high
permeability of Pc = 7.7 ms−1. A P-DES with these coating properties exhibits an inefficacy
score of Im = 0.03, a low endothelial toxicity score of T e = 0.025, and a flow disturbance score
of JFDI = 0.26, yielding an overall cost function value of J = 0.18.
In contrast, an optimal S-DES polymer coating (Fig. 4.15 B) has very different properties.
More specifically, the optimal coating thickness is Lc = 28 µm that is initially loaded with a
sirolimus concentration of c0 = 1.1 · 105 molm−3. Optimal drug release requires an effective
drug diffusivity of Dc = 2.5 · 10−18 m2 s−1, and the top-coat needs to have a low permeability
of Pc = 3.5 · 10−7 ms−1. This combination of polymer coating properties leads to an inefficacy
score of Im = 0.09, a zero medial toxicity score Tm, and a flow disturbance score of JFDI = 0.32,
yielding a total cost function value of J = 0.25.
4.4 Discussion
The derivative-free optimization framework we have developed in this chapter has been applied
for the identification of unique optimal strut designs for paclitaxel- and sirolimus-eluting stents
with zero-order release kinetics. The optimal P-DES strut (Fig. 4.8 A) is very thin and elongated
and has a cross-section that is rather rectangular. The general design features of the optimal
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low-dose S-DES (Fig. 4.14) are comparable to the P-DES design. The optimal high-dose S-DES
stent strut design (Fig. 4.12 A), however, is very different from the two previous strut designs.
The strut is almost diamond-shaped with equal length and height.
4.4.1 Optimal DES strut designs are tailored to optimized transport dynamics
in the arterial wall
With the exception of the semi-strut width bs, we can explain the optimal values of the design
variables of P-DES and high-dose S-DES strut designs based on the global trends of the con-
tributing scores of the cost function (Table 4.4). For P-DES (Fig. 4.8 A), the optimal semi-strut
height as is at the low end of the design range and the strut shape exponent n at the high end
of the design range. For high-dose S-DES (Fig. 4.12 A), the value of the optimal semi-strut
height as is at the upper end of the design range and the strut shape exponent n at the low
end. When the drug-related and flow-related objectives have opposing trends with respect to
a change in the design variable (e.g. semi-strut height as for high-dose S-DES), the optimal
value is derived from the balance between the contributing scores which depends on the choice
of the flow disturbance weight factor wFDI. When the drug-related and flow-related objectives
follow the same trend with a change in the design variable (e.g. semi-strut height as for P-DES),
the optimal value of the design variable is expectedly at the extreme of the permitted design
range. In that case, the gradient of the cost function J with respect to the design variable x i
has the same sign over the entire design space. Consequently, the optimum of the cost function
J is located on one of the borders of the design space.
Changing the semi-strut width bs has a weak effect on JFDI due to the very low sensitivity
of JFDI to bs (Fig. 4.5). The small optimal bs seen with the P-DES optimization with wFDI = 10
indicates that JFDI increases with increasing bs. This positive gradient of JFDI with respect to bs
is indicated in Table 4.4 with a + sign. The weak dependence of JFDI on a change in bs for both
P-DES and high-dose S-DES explains the large semi-strut width bs of the optimal strut designs.
Since the optimal semi-strut height as of P-DES is very small, the optimal semi-strut width bs
can be very large, even outside of the typical design range, without excessively increasing JFDI.
The optimal semi-strut height as of high-dose S-DES is larger than that of optimal P-DES; thus,
the optimal semi-strut width bs needs to be smaller in order to reduce JFDI, but bs in that case
remains near the upper end of the typical design range.
Two key elements are necessary to understand the difference in the global trends of the
cost function between P-DES and high-dose S-DES strut design optimizations (and thus to
understand why the strut designs of P-DES (Fig. 4.8 A) and low-dose S-DES (Fig. 4.14) are so
similar). First, in the cases considered, the drug is assumed to be released from the stent over
a time period that is significantly longer than any of the time scales governing the processes
involved in drug transport (convection, diffusion, binding and unbinding). For this slow release,
the concentration in the polymer coating remains nearly constant (equal to the initial value
c0) during the period of four weeks considered in our simulations, and this concentration sets
the drug concentration level in the arterial wall. After an initial transient phase, a quasi-steady
state of drug transport in the arterial wall is attained (see Chapter 3). The process dominating
drug transport in the transient phase and in the subsequent quasi-steady regime depends on
the occupancy of drug binding sites in the media [179] (see also Chapter 2).
The transport processes of convection and diffusion only govern free (mobile), unbound
drug concentration in the arterial wall. This can be seen, for example, in Equation (A.9)
in Appendix A which was derived under the simplifying condition of constant equilibrium
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Table 4.4: Summary of estimated global trends of the cost function of paclitaxel- and high-dose sirolimus
eluting stent strut design optimizations with a FDI weight wFDI = 0.5. The upper row corresponds to
P-DES and the lower row to S-DES.
x i J Im Tm JFDI
as
+ + 0 +
+/− − 0 +
bs
+/− − 0 +
+/− − 0 +
n
+/− − 0 +
+ 0 + +
+: the contributing score (Im, Tm or JFDI) or the cost function J (assuming wFDI = 0.5) increases with increasing design
variable x i (i.e. the estimated gradient of the score with respect to a change of the design variable is positive in the
estimation of global trends)
0: the contributing score (Im, Tm or JFDI) or the cost function J (assuming wFDI = 0.5) does not change significantly with
increasing design variable x i (i.e. the estimated gradient of the score with respect to a change of the design variable is
negligible in the estimation of global trends)
−: the contributing score (Im, Tm or JFDI) or the cost function J (assuming wFDI = 0.5) decreases with increasing design
variable x i (i.e. the estimated gradient of the score with respect to a change of the design variable is negative in the
estimation of global trends)
+/−: the behavior of the cost function J (assuming wFDI = 0.5) depends on the range of the design variable x i . The optimal
design variable x i corresponds to the value at which the variation of Im (with respect to x i) balances the variation of JFDI
(with respect to x i).
between the bound drug concentration b and the free drug concentration c, a situation that
arises if the time scales of drug binding and unbinding are very fast compared to the time scales
of convection and diffusion. The concentration equilibrium between the two drug states is
expressed by the total binding coefficient κ. The inverse of κ only multiplies the convective
and diffusive term of Eq. (A.9), so if κ is large, then drug transport is reduced while if κ ≈ 1,
then transport (of the free drug) is unhindered. In the present case, this κ depends on the free
concentration: if the binding sites are saturated, then any drug concentration exceeding the
maximum binding site density in the arterial wall is governed by convection and diffusion and
κ would be small, and convection and diffusion become the two dominant processes of drug
transport. If, on the other hand, the binding sites are not saturated, then κ would be large, and
the fast binding process becomes the dominant drug transport process and significantly (by an
order of magnitude) slows down convection and diffusion.
Consequently, the optimum high-dose S-DES, for which the cost function dictates concen-
trations of the order of the binding site density and beyond, is in the convection- and diffusion-
dominated regime. Conversely, the optimum P-DES and the low-dose S-DES, for which the
cost function dictates concentrations that are at least an order of magnitude lower than the
drug binding site density (see Chapter 2), is in the binding-dominated regime with reduced
convection and diffusion.
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The second key element to understand in considering differences between P-DES and high-
dose S-DES strut design optimization is that optimal strut design is determined by the balance
of scores that contribute to the overall cost function. In most of the simulations, the only scores
relevant to the optimization are the inefficacy score Im and the flow disturbance score JFDI.
The one exception is the case of high-dose S-DES with configuration E1 (Fig. 4.13) where the
medial toxicity score Tm remains in the formulation; however, this score typically is an order
of magnitude lower than Im and JFDI and thus has a limited effect on the optimization results.
The two optimal designs, the elongated rectangular strut (Figs. 4.8 A, 4.9 A and 4.14) and
the diamond-shaped strut (Figs. 4.12 A and 4.13), identified by the optimization algorithm
constitute a compromise between a fluid mechanically streamlined design and an efficient
design from the perspective of optimized drug transport in the arterial wall. In this regard, we
identify two regimes:
• Binding-dominated regime: When the binding sites are not saturated, convection and
diffusion are significantly slowed down by the binding and unbinding dynamics. The
only effective solution to rapidly achieve maximum efficacy in the arterial wall during the
transient phase is to maximize the width of the strut, which in turn requires minimizing
the strut height to obtain a streamlined design. The lower bound of this minimization is,
in our case, either given by our choice of the design range or the occurrence of endothelial
toxicity. In the case where endothelium is present immediately upstream and downstream
of the stent (configuration E1), this endothelial toxicity occurs as a result of the convection
field around the first and last struts. However, even if the endothelium is denuded
upstream and downstream of the stent (configuration E2), endothelial toxicity would
increase dramatically if the strut height were so small that the strut would sit in the
subendothelial space and thus elute massively into this layer.
• Convection- and diffusion-dominated regime: When the binding sites are saturated, con-
vection and diffusion are not slowed down, and a small strut size is sufficient to rapidly
achieve high drug efficacy. The diamond strut shape enhances convection around the
stent struts relative to a more rectangular strut thereby reducing concentration peaks
close to the stent struts which would otherwise risk to become toxic. A flat strut design
(high shape exponent n or a large aspect ratio bs/as) similar to the one obtained for the
binding dominated regime risks toxic concentrations in zones close to the strut where
convection is small (shielding effect). The optimal S-DES strut with configuration E1
(Fig. 4.13), thus, has a slightly higher aspect ratio compared to the optimal strut with
configuration E2 (Fig. 4.12 A) in order to direct convection from the central stent region
to the zones where convection is shielded by the endothelium.
4.4.2 Optimal two-layered DES polymer coatings are tailored to the eluted drug
The optimization of the drug delivery strategy for single-layered P-DES and S-DES coatings,
described in Chapter 3, revealed an essential difference between optimal release kinetics of
P-DES and S-DES. The high retention capabilities of paclitaxel in the media, resulting from
the significantly slower unbinding kinetics (see Chapter 2), enable an optimal strategy where
all drug stored in the polymer coating is quickly released into the arterial wall and then the
drug dynamics ensure a satisfactory concentration distribution within the therapeutic window
for the remainder of the intended period of therapy (typically several weeks). Even though
exposure of the arterial wall to adverse concentrations (toxic concentrations in the media and
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unacceptably high concentrations at the endothelium) cannot be prevented with this strategy,
the exposure times are very short. This strategy is impossible to achieve with sirolimus because
of the significantly shorter retention time of sirolimus in the arterial wall resulting from the
faster unbinding time scale. Thus, only very slow release kinetics at relatively high initial
concentrations c0 can assure sufficient concentration levels throughout the period of the therapy.
The results presented in this chapter for optimal two-layered polymer coatings are in line
with and complement the results described above. For P-DES releasing a low initial drug load
quickly, a setup unhindered by a top-coat is the best solution (Fig. 4.15 A). Also, only a
relatively small amount of drug is necessary to achieve the efficacy goals of the cost function,
and the consequently low resulting coating thickness further serves to reduce flow disturbance.
This optimal design is consistent with recent trends towards thinner coatings on P-DES [60].
The optimal design of S-DES polymer coatings (Fig. 4.15 B) is opposite to that of P-DES.
High drug loads in this case need to be stored in a thick coating and released at a very slow
rate that is additionally controlled by a top-coat with low permeability. Addition of a top-coat
to extend drug release time is a common feature in the design of S-DES in order to extend their
efficacy in inhibiting smooth muscle cell proliferation [3, 90]. It also appears to be beneficial
for stent re-endothelialization [57].
4.4.3 Challenges of the FDI weight factor
Although we haven chosen a FDI weight factor that heavily favors the drug-related objectives
of the cost function (wFDI = 0.5) in the majority of the simulations considered in this chapter,
we were able to identify optimal strut shapes that depended on fluid dynamic considerations.
The highly elongated shapes of the optimal designs we obtained for P-DES and low-dose S-
DES are probably extreme cases that are very difficult to implement in clinical practice due to
considerable challenges associated with the delivery via a balloon of a stent with struts that
have such high aspect ratios.
Taking the approach of optimizing the drug delivery strategy by focusing on the drug-related
goals and only then optimizing strut geometry to achieve the fluid dynamic objectives may not
necessarily be the most effective way to address this issue. In the one simulation in which
we chose wFDI = 10 we managed to obtain a fluid dynamically-shaped strut, but reducing JFDI
by about 1/3 came at the cost of almost tripling the inefficacy score (see Figs. 4.8 and 4.10).
Future experimental studies will be essential for defining the relative importance of drug- and
flow-related contributions to the cost function and hence for the most appropriate value of the
flow disturbance weight factor wFDI.
Another direction that merits future exploration is the optimization of DES that have dif-
ferent shapes on their luminal and abluminal sides. The fluid dynamic objective would be
emphasized in the optimization of the lumenal side of the stent strut, while the drug-related ob-
jectives would be most important in the optimization of the abluminal side of the stent geometry.
It is recognized, of course, that stent struts that have different luminal and abluminal shapes
might pose an additional manufacturing challenge. In the current study, the stent struts were
considered to be symmetric about both their major and minor axes; however, this constraint
can be readily relaxed by making the parameter ms (which controls the number of symmetry
axes of the shape) in the Superformula (Eq. (4.1)) an additional design variable.
Finally, we need to emphasize that the current study did not take into account the me-
chanical stresses that a stent needs to withstand to open an obstructed artery or the stresses
induced by the stent in the arterial wall. While the lowest values set for the design range of
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the semi-strut height and width were inspired by the lowest profile stent designs found in the
literature [164], the optimal results of the low-dose DES confirmed that these constraints do
not ensure reasonable designs from a solid mechanical point of view. It might thus be advisable
to extend the computational model via constitutive laws that describe the structural mechanics
of the stent and the biomechanics of the arterial wall and add adequate scores to the cost
function. However, as the number of objectives increases, an aggregate cost function approach
becomes less meaningful since it is very dependent on the choice of weighting factors among
the different objectives. Seeking pareto optimal solutions, which are the optimal designs for
which a change in any of the design variables decreases the score of one objective only at the
expense of another, might constitute a promising future approach in DES design optimization
[56, 141, 153].

CHAPTER 5
Conclusions
In the introductory chapter to this dissertation we raised four questions for which we can now
propose some answers with the material presented in the three chapters.
What is an optimal stent? An optimal stent re-establishes blood flow in a previously ob-
structed artery and assures this state permanently. Assuming that the implantation of a stent
has successfully re-opened the target vessel, the two major events that can potentially re-
occlude the blood vessel are in-stent restenosis and stent thrombosis. Prevention of these two
complications may be accomplished, on the one hand, by controlling proliferation and migra-
tion of smooth muscle cells (SMCs) and, on the other hand, by assuring a fast recovery of the
endothelium. We formulated our objective for ideal drug-eluting stents (DES) on this premise:
1. An ideal delivery of the anti-proliferative drug from the DES polymer coating leads a) to
therapeutic levels of drug concentration in the arterial media, limiting SMC proliferation
during the process of re-endothelialization and b) to minimal drug concentration at the
endothelial surface.
2. An ideal geometric design of the DES minimally disturbs the arterial flow field.
The strategy we developed to identify DES designs which comply with these two require-
ments used a physiologically based computational model (Chapter 2) coupled to an efficient
derivative-free optimization method via our cost function (Chapters 3 and 4). This strategy
proved successful in determining robust optimal DES design ranges (small changes in any of
the design variables did not yield a large change in performance) in a computationally efficient
manner.
What design elements are crucial for obtaining an optimal stent? The screening study per-
formed in Chapter 4 showed that the most crucial design variables are the drug diffusion
coefficient in the stent polymer coating Dc and the initial concentration of drug loaded in the
polymer c0, which determine the drug delivery strategy of the DES design. Next in importance
are the permeability of an optional top-coat encasing the polymeric coating on the DES Pc and
the thickness of the polymer coating Lc. Together they determine how the drug will be eluted
from the DES. Based on our cost function, the drug delivery strategy is the most crucial design
element of DES, while geometric variables of the strut shape are secondary to optimal designs
and can be used to refine the performance of DES.
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What should these design elements be like for an optimal stent? What is the role of the drug
choice? As we showed, these two questions are strongly coupled. Optimal designs depend
on the drug kinetics in the arterial wall, which in turn depend on the drug delivery from the
DES polymer coating. On the one hand, the therapeutic window of the drug sets the order
of magnitude of the drug concentration that should be loaded onto the stent initially. The
specific drug kinetics determine the rate at which the drug should be released. On the other
hand, the initial drug concentration and the release rate determine the prevalent drug transport
phenomena: if the drug delivery strategy results in the drug binding sites in the arterial wall
being predominantly occupied, then convection and diffusion dominate. Otherwise, binding
and unbinding dominate.
For optimal performance, the strut shape should be tuned to the dominant transport process.
If convection and diffusion are dominant, then a small strut still yields sufficient drug efficacy
throughout the arterial media, and the strut shape is adjusted to yield isotropic drug transport.
If drug binding and unbinding are dominant, only very wide struts can assure efficacious drug
concentrations reaching the inter-strut domains of the media, while the strut height should be
minimal to obtain a more fluid-dynamically streamlined strut.
The narrow therapeutic window of paclitaxel requires very low drug concentrations in the
polymer coating, thus yielding a low-dose design. These optimal drug concentrations are orders
of magnitude lower than typical concentrations found on today’s DES. The long retention of
paclitaxel in the media enables two types of efficient DES designs, with either fast (hours) or
slow (months) release of the drug. Sirolimus has a wide therapeutic window. Consequently,
we found low-dose and high-dose optimal stent designs. The short retention of sirolimus in the
media, however, requires a very slow release of the drug (years).
The strong coupling between physiological transport in the arterial wall and DES design
demands versatile computational models that simultaneously consider all contributing drug
transport phenomena that dominate at each relevant time scale. However, accurate modeling
of the binding and unbinding process significantly increases computational cost. This coupling
makes the model sensitive to the non-dimensional quantities that define the ratio between
transport processes. Specifically, the parameter values of the model need to be sufficiently
accurate to recover the dominant transport processes in the physiological situation. The rele-
vant non-dimensional quantities are the two Damköhler numbers, which compare binding to
convection and binding to diffusion, respectively. As discussed in Chapter 2, a time-dependent,
spatially averaged Damköhler number (rather than a constant value) is required to accurately
describe the varying importance of binding during the period of drug elution.
5.1 Future work
In the course of this dissertation a versatile framework for DES optimization was developed.
Application of this framework to idealized configurations of arteries stented with a DES yielded
some general guidelines for future DES design, especially concerning strategies for the effective
elution of the anti-proliferative drug from the stent. Despite these very useful results, many
improvements can be envisaged in future models. Limitations of the current model are that the
model geometry is 2D axisymmetric, the considered stent is idealized as a series of rings, and
the model is limited to a straight vessel segment. It will be important to eventually perform
the simulations on more realistic three-dimensional geometries where the detailed structure
of the stent design is taken into account. Such simulations, however, are expected to be much
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more expensive computationally and will thus require additional computing resources. Even in
the current context of two-dimensional simulations, the following three specific considerations
should be taken into account in future modeling efforts:
• additional physiological considerations: exploring model setups where the arterial wall is
in a diseased state or the stent is malapposed or poorly configured,
• expanding the cost function: adding other considerations to the cost function to account
for additional phenomena relevant for DES design (for example in-stent thrombosis),
• improved representation of the arterial wall: more accurate modeling of the structure of
the arterial wall paving the way for lesion-specific optimization.
The first of these pathways is a direct extension of this work that requires only minor modifica-
tions to the current computational model, while the other two directions are more challenging.
5.1.1 Additional physiological considerations
The parameter choice for the computational model as implemented throughout this dissertation
assumes a healthy arterial wall, i.e. the subendothelial space (SES) has a normal physiological
thickness and is free of SMCs [47, 59]. Arteries that require stenting are, of course, diseased
such that SMCs, foam cells, and other constituents of plaques are present in the SES. Athero-
matous arteries also exhibit a thickened intima with an occasionally damaged internal elastic
lamina (IEL). It is of interest to investigate how these various conditions affect the outcome
of the optimization. Conditions that reflect aspects of a diseased arterial wall can be readily
taken into account in the current computational model in several ways. For instance, drug
reaction as used in the media can be added to the SES to model the presence of SMCs in the
SES (maybe with a reduced maximum binding capacity bmax to account for a lower density of
SMCs than in the media). Because inclusion of drug reaction in the SES is expected to lead
to higher drug concentrations in the vicinity of the endothelium, design strategies focusing on
abluminal drug release merit further investigation. To investigate the effect of intimal thickness
on the optimization results, the parameter controlling the SES thickness Lses can be increased.
Finally, the Kedem-Katchalsky matching condition at the IEL can be replaced by a constant flux
condition to model a damaged IEL. We intend to investigate the effect of such diseased arterial
wall configurations on optimal release kinetics of paclitaxel- and sirolimus-eluting stents and
on optimal DES strut shapes in future simulations.
Chapter 4 did not include the strut shape optimization of fast-release paclitaxel-eluting
stents (P-DES). Figure 5.1 depicts preliminary results on the optimal strut shape and the
associated cost function scores for a P-DES with fast release kinetics. The computational model
setup of this case assumed the endothelium to be denuded only in the stented portion of
the vessel but intact otherwise. The optimal shape is elongated (bs = 82.5 µm) and very
thin (as = 12.5 µm) with a strut shape exponent of n = 2.6. The resulting partial scores are:
Im = 0.03, Tm = 0.01, T e = 0.06 and JFDI = 0.12. If we compare these results to the slow-release
P-DES strut design optimizations (Fig. 4.8 A and Fig. 4.9 A), we see immediately that the strut
shape is much more streamlined (yielding a reduced JFDI) and that this optimal strut height as
corresponds to the low strut height as that was obtained for the setup with entirely denuded
endothelium.
Since paclitaxel in this case is released within hours after stent implantation, the former
strut height as restriction, which prevented prolonged exposure of the endothelial surface to
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Figure 5.1: Optimal fast-release P-DES strut design for dc = 0.5 and a model configuration that assumes
the endothelium is denuded in the stented portion of the vessel but intact otherwise. The table provides
the associated total cost function score J and its contributing partial scores Im, Tm, T e, and JFDI.
adverse concentrations, is no longer the dominant effect. Similarly, the advantage of a high
strut shape exponent n on the inefficacy score obtained for slow-release DES is reduced and the
flow-related objective dominates the final outcome of the optimization. We note at this point
that these results are rather preliminary and require further analysis.
As mentioned in the discussion of Chapter 4, the idea of a DES with different shapes on the
luminal and abluminal sides merits further investigation. The idea is that the fluid-dynamical
considerations are the most relevant for the lumenal side of the stent strut, while drug-related
considerations are the most important on the abluminal side of the stent. The resulting strut
shape could potentially yield an overall optimal design that is superior to any of the designs
that we were able to identify in this dissertation. Such an optimization can be realized by
choosing a different set of design variables in (Eq. (4.1)). This increases, however, the number
of design variables and thus the run-time of the optimization.
Stent malapposition is a complication of stenting where some stent struts (typically at the
end of a stent) are either poorly embedded in the arterial wall or even protrude entirely into the
bloodstream [74, 93, 116]. Malapposition can arise either as an immediate result of the surgery
or develop over time [126], a process that is not well understood and that is more prevalent
with DES [36, 108]. This complication can be related to delayed endothelial recovery and late
stent thrombosis [35]. It is thus of interest to investigate how malapposed stent struts affect
the optimization of DES and if it might be possible to devise stent designs whose performance
is to some degree insensitive to malapposition.
Throughout this thesis we assumed an idealized strut embedment of 50% and the sensitivity
estimation of Chapter 4 showed (with the exception of P-DES with a top-coat, Fig. 4.5) no
significant effect of the strut embedment pst on the drug-related part of the cost function JETH
in the range of 20− 80% embedment. However, the flow-related part of the cost function JFDI
is more sensitive to strut embedment pst than to any other parameter considered. One manner
to further investigate this issue is to perform optimizations with a setup where the most distal
stent strut is completely exposed to the bloodstream whereas the remaining stent struts are
embedded normally.
Another useful configuration might be a setup where one strut is fully embedded, one is half
embedded, and the last strut is not embedded. The endothelium would have to be denuded in
this case to assure a homogeneous convection field in the arterial wall. Moreover, to investigate
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the effect of fluid mechanical interactions among the struts on the optimization, the order of
which struts are embedded and which are not needs to be varied. We performed preliminary
studies (results not shown) investigating the fluid mechanics of unembedded stent struts. The
results indicated that the flow disturbance index as defined in this dissertation (Eq. 4.5) might
not be a sufficient indicator to quantify the severity of the flow disturbance of unembedded
stent struts. Rather, the flow disturbance index should be extended to also account for the
length of the flow recirculation zone downstream of the stent.
Last, to complete the investigation of sirolimus-eluting stents (S-DES), it is necessary to
perform a drug release optimization where the therapeutic window of sirolimus spans the
maximum possible range (from the low efficacy concentration threshold of paclitaxel ceff =
1 · 10−5 molcm−3 to the high toxic concentration threshold of sirolimus ctox = 0.73 mol cm−3).
These results will clarify whether low-dose or high-dose S-DES yield an overall optimal drug
delivery strategy.
5.1.2 Expanding the cost function
The second direction proposed as a follow-up to this work consists of resolving specific short-
comings of the cost function and extending its objectives. When we look at the contour plots
of the cost function that are obtained for the drug release kinetics optimizations of Chapter 3,
we can see that the optimal designs are often very close to non-optimal regions of the design
space. We initially intended to alleviate this issue by introducing the homogeneity score Hm.
The contour plots also reveal that the non-optimal designs neighboring the optimal designs are
non-optimal because of their endothelial toxicity score T e. One problem is that the homogene-
ity score Hm only “buffers” the toxicity in the media and not at the endothelial surface. Thus,
we suggest that future efforts add a homogeneity score of the endothelium to the cost function.
An important motivation for this work is the unresolved problem of late stent thrombosis.
The cost function we have developed does not explicitly account for this issue. More specifically,
there is no score in the present cost function that measures the risk of thrombosis for a particular
stent design. Future models stand to benefit from adding such a term to the cost function. We
currently do not have a concrete idea for what this metric should look like; however, there are
at least two possibilities from which it could be derived. The first possibility is based on recent
work [135] that has shown that fluid mechanical shear stress gradients can induce thrombosis
independently of any biochemical considerations. Thus, a possible metric might be based on
the magnitude of wall shear stress gradients.
The second possibility is to use numerical models similar to those described by [52, 65, 113]
to simulate the formation and progression of thrombosis and to use these results to obtain a
thrombosis score that can be added to the cost function. The thrombosis simulation could at
first be performed independently from the drug transport simulation with subsequent coupling
to model active thrombus growth. It is of course expected that the coupling will significantly
increase simulation time.
A shortcoming of the stent strut shape optimization performed in Chapter 4 is that the size
(in particular the strut width) of optimal designs is not feasible for clinical practice. This is
due to the strong emphasis we have placed on optimizing drug transport from these struts. A
possibility to alleviate this problem, mentioned in the discussion of Chapter 4, is to account
for mechanical stresses in the stent as well as in the arterial wall in the cost function, which
would potentially drive the strut designs to smaller struts. Motivated by the fact that stent
struts should be small in order to minimize injury of the vessel wall at implantation [27, 48],
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we also suggest including the notion of stent porosity "stent [111] in future versions of the cost
function. This parameter measures the radially projected surface of the stent struts compared
to the total radially projected surface of a stent, i.e. for a stent with total length ls and a strut
diameter ds that is comprised of a series of ns rings the porosity is calculated as:
"stent = 1−
 
ns− 1 ds
ls
. (5.1)
5.1.3 Improved representation of the arterial wall
The two most restrictive simplifying assumptions of the computational model used in this
thesis are steady flow conditions and a 2D axisymmetric geometry. Arterial geometry is three-
dimensional and blood circulation is unsteady and both phenomena play an important role for
stent design [100, 189]. We thus recommend extending the current computational model to
3D and investigating the effect of unsteady flow on the optimization results.
Last but not least, we showed in this dissertation how important drug transport kinetics
are for the design of optimal DES and how crucial accurate modeling of the arterial wall is to
correctly predicting drug transport. The computational model used in this work accounted for
the media and the intima as two separate layers; however, the media itself has a layered sub-
structure [136, 199] which can impact the transport of the drug. We thus suggest investigating
yet more realistic models of the media [78, 103]. Given the difference of the arterial wall
composition in different parts of the blood circulation, a more accurate and modular model of
the arterial wall can pave the way for lesion-specific and location-specific DES optimization.
APPENDIX A
A.1 From the Brinkman equation to Darcy’s Law
Fluid flow in the porous layers of the arterial wall can be described by the standard Darcy-
Brinkman equation
∇p =− µp
PDRe0
u +
µ∗p
Re0
∆u . (A.1)
An order-of-magnitude analysis on the Brinkman equation reveals that the viscous term only
plays a significant role when L˜2 ∼ P˜D. Thus, the effect of the viscous term is limited to a
boundary layer which is an order of magnitude thinner than the endothelium. Consequently,
for both layers the governing equation is simplified to Darcy’s original formulation:
∇p =− µp
PDRe0
u . (A.2)
A.2 Derivation of the weighted concentration
The local average fluid concentration c¯α, j as required by the Kedem-Katchalsky matching bound-
ary conditions is calculated from the integral of the solution of the attributed differential equa-
tion for the concentration distribution in one dimension [106]:
c¯α, j =
cα, j−1ePe
∗
j − cα, j+1
ePe
∗
j − 1 −
cα, j−1− cα, j+1
Pe∗j
(A.3)
with
Pe∗j =
s j jv, j
Pj
. (A.4)
Given strictly radial transport from domain j−1 to j+1, this expression allows an approximate
evaluation of the average concentration in the respective “layer” j. When the exponential
function is expanded to third order, it becomes obvious that this expression reflects the weighted
average concentration of the layer:
c¯α, j =
1
2

cα, j−1+ cα, j+1

+
Pe∗j
12

cα, j−1− cα, j+1

. (A.5)
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A.3 Including reaction at the endothelial surface
Like smooth muscle cells, endothelial cells interact with the drugs eluted from the stent surface.
Thus, we wish to include this interaction in the boundary condition at the endothelium via
a concentration-dependent partition coefficient. The Kedem-Katchalsky equation is derived
assuming steady state conditions [106]. Assuming ∂ b
∂ t
= 0 for the reaction equation (Eq.
(2.10)) yields
b =
c
c+

fcbBp
−1 . (A.6)
Reintroducing this expression into the transport equation of the arterial wall (Eq. (2.7)) leads
to the concentration-dependent partition coefficient:
kp (c) =
1
B−1p + 2 fcbc+ Bp
 
fcbc
2 . (A.7)
Assuming an instantaneous reaction of the drug on the surface of ECs, the intrinsic fluid
concentration used in the Kedem-Katchalsky equation is now:
cα,e±1 =
ce±1
"e±1

kp
 
ce±1

+ 1
 . (A.8)
A.4 Governing equation for the equilibrium case
Assuming constant equilibrium between bound and free drug concentration (Eq. (2.9)), the
governing equation (Eq. (2.7)) reduces to:
∂ cT, j
∂ t
+
1
κ
∇Λ jPe0~ujcT, j − D j∇cT, j= 0 , (A.9)
where cT, j represents the total drug concentration, the sum of the free concentration c j and the
bound concentration b: cT, j = b+ c j = κc j.
A.5 Remaining drug-dependent parameters of the model
Except for the lag coefficient Λ j, we followed in our derivation of the remaining model param-
eters the description of [55]. The lag coefficient Λ j of the convective transport term which
results from averaging can be calculated as:
Λ j =
γ j
" j
. (A.10)
where γ j ≤ 1 is the hindrance coefficient (in layer j) accounting for the frictional loss occurring
during the transport of the drug through porous media. By means of fiber matrix theory, Curry
[39] initially derived an expression for the hindrance coefficient
γf, j = 1−

1−Φf, j
2
=

2−Φf, j

Φf, j , (A.11)
where the reduction coefficient is computed by
Φf, j = exp

−1− "f, j2r˜molr˜f + r˜
2
mol
r˜2f

. (A.12)
With a mean fiber radius of r˜f = 3.2 nm [55], the values for the SES and media can be calculated.
A.6. DIFFUSIVITY OF SIROLIMUS 99
A.6 Diffusivity of sirolimus
No experimental data on the diffusivity of sirolimus in blood or blood plasma is available to the
authors. Approximating sirolimus and paclitaxel as spheres, we estimate the average radius of
sirolimus rescaling the radius of paclitaxel as a function of the molecular weight:
r˜mol =

3M˜
4piρ˜NA
 1
3
, (A.13)
yielding
r˜SIRmol =

M˜SIR
M˜PAX
 1
3
r˜PAXmol = 1.23 · 10−9 m . (A.14)
This result, combined with the Stokes-Einstein equation and the free plasma diffusivity of
paclitaxel, then results in the adjusted diffusivity for sirolimus.

Bibliography
[1] Abizaid A (2007) Sirolimus-eluting coronary stents: a review. Vascular Health and Risk
Management 3(2):191–201
[2] Abramson MA, Audet C (2006) Convergence of mesh adaptive direct search to second-
order stationary points. SIAM Journal on Optimization 17(2):606–619
[3] Acharya G, Park K (2006) Mechanisms of controlled drug release from drug-eluting
stents. Advanced Drug Delivery Reviews 58(3):387–401
[4] Ai L, Vafai K (2006) A coupling model for macromolecule transport in a stenosed arterial
wall. International Journal of Heat and Mass Transfer 49(9-10):1568–1591
[5] AIAA (1998) AIAA Guide for the Verification and Validation of Computational Fluid
Dynamics Simulations. American Institute of Aeronautics & Astronautics
[6] Alfonso F, Pérez-Vizcayno MJ (2013) Drug-eluting balloons for restenosis after stent
implantation. The Lancet 381(9865):431–433
[7] Aragon J, Kar S, Tio F, Trauthen B, Parisky A, Watanabe C, Jamali A, Eigler N, Serruys
PW, Litvack F (2005) The effect of variable release kinetics on paclitaxel efficacy from a
drug eluting stent in a porcine model. EuroIntervention 1(2):228–235
[8] Asakura T, Karino T (1990) Flow patterns and spatial distribution of atherosclerotic
lesions in human coronary arteries. Circulation Research 66(4):1045–1066
[9] Atherton MA, Bates RA (2004) Robust optimization of cardiovascular stents: a compari-
son of methods. Engineering Optimization 36(2):207–217
[10] Audet C, Dennis Jr JE (2007) Mesh adaptive direct search algorithms for constrained
optimization. SIAM Journal on optimization 17(1):188–217
[11] Balakrishnan B, Tzafriri AR, Seifert P, Groothuis A, Rogers C, Edelman ER (2005) Strut
position, blood flow, and drug deposition - implications for single and overlapping drug-
eluting stents. Circulation 111(22):2958–2965
[12] Balakrishnan B, Dooley JF, Kopia G, Edelman ER (2007) Intravascular drug release ki-
netics dictate arterial drug deposition, retention, and distribution. Journal of Controlled
Release 123(2):100–108
[13] Barakat A, Lieu D (2003) Differential responsiveness of vascular endothelial cells to
different types of fluid mechanical shear stress. Cell Biochemistry and Biophysics
38(3):323–343
101
102 BIBLIOGRAPHY
[14] Barakat AI, Karino T, Colton CK (1997) Microcinematographic studies of flow patterns
in the excised rabbit aorta and its major branches. Biorheology 34(3):195–221
[15] Barakat AI, Leaver EV, Pappone PA, Davies PF (1999) A flow-activated chloride-selective
membrane current in vascular endothelial cells. Circulation Research 85(9):820–828
[16] Belitz P (2011) Applications on multi-dimensional sphere packings: Derivative-free
optimization. PhD thesis, University of California at San Diego
[17] Belitz P, Bewley T (2012) New horizons in sphere-packing theory, part II: lattice-based
derivative-free optimization via global surrogates. Journal of Global Optimization pp
1–31
[18] Berry JL, Santamarina A, Moore JE, Roychowdhury S, Routh WD (2000) Experimental
and computational flow evaluation of coronary stents. Annals of Biomedical Engineering
28(4):386–398
[19] van Beusekom HM, Saia F, Zindler JD, Lemos PA, Swager-ten Hoor SL, van Leeuwen
MA, de Feijter PJ, Serruys PW, van der Giessen WJ (2007) Drug-eluting stents show
delayed healing: paclitaxel more pronounced than sirolimus. European Heart Journal
28(8):974–979
[20] Birkmeier KA, Kastrati A, Byrne RA, Holle H, Schulz S, Tiroch K, Kufner S, Massberg
S, Laugwitz KL, Schömig A, Mehilli J (2011) Five-year clinical outcomes of sirolimus-
eluting versus paclitaxel-eluting stents in high-risk patients. Catheterization and Cardio-
vascular Interventions 77(4):494–501
[21] Bloom DA, Clayman RV, McDougal E (1999) Stents and related terms: a brief history.
Urology 54(4):767–771
[22] Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M,
Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title
LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GJ,
Weintraub WS (2007) Optimal medical therapy with or without PCI for stable coronary
disease. New England Journal of Medicine 356(15):1503–1516
[23] Booker AJ, Dennis JE, Frank PD, Serafini DB, Torczon V, Trosset MW (1999) A rigorous
framework for optimization of expensive functions by surrogates. Structural Optimiza-
tion 17(1):1–13
[24] Borghi A, Foa E, Balossino R, Migliavacca F, Dubini G (2008) Modelling drug elution
from stents: effects of reversible binding in the vascular wall and degradable polymeric
matrix. Computer Methods in Biomechanics and Biomedical Engineering 11(4):367–
377
[25] Brent RP (1972) Algorithms for minimization without derivatives. Prentice-Hall series
in automatic computation, Prentice-Hall
[26] Buchanan GL, Basavarajaiah S, Chieffo A (2012) Stent thrombosis: Incidence, predictors
and new technologies. Thrombosis 2012:1–12
BIBLIOGRAPHY 103
[27] Butany J, Carmichael K, Leong SW, Collins MJ (2005) Coronary artery stents: identifi-
cation and evaluation. Journal of Clinical Pathology 58(8):795–804
[28] Caro C (2009) Discovery of the role of wall shear in atherosclerosis. Arteriosclerosis,
Thrombosis, and Vascular Biology 29(2):158–161
[29] Caro CG, Fitz-Gerald JM, Schroter RC (1969) Arterial wall shear and distribution of
early atheroma in man. Nature 223(5211):1159–1161
[30] Caro CG, Fitz-Gerald JM, Schroter RC (1971) Atheroma and arterial wall shear. ob-
servation, correlation and proposal of a shear dependent mass transfer mechanism for
atherogenesis. Proceedings of the Royal Society of London Series B, Containing papers
of a Biological character Royal Society (Great Britain) 177(46):109–159
[31] Charonko J, Karri S, Schmieg J, Prabhu S, Vlachos P (2009) In vitro, time-resolved
PIV comparison of the effect of stent design on wall shear stress. Annals of Biomedical
Engineering 37(7):1310–1321
[32] Chien S (2007) Mechanotransduction and endothelial cell homeostasis: the wis-
dom of the cell. American Journal of Physiology - Heart and Circulatory Physiology
292(3):H1209–H1224
[33] Chiu JJ, Chien S (2011) Effects of disturbed flow on vascular endothelium: Pathophysi-
ological basis and clinical perspectives. Physiological Reviews 91(1):327–387
[34] Colombo A, Gerber RT (2008) Should dual antiplatelet therapy after drug-eluting stents
be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents
should not be continued for more than 1 year and preferably indefinitely. Circulation:
Cardiovascular Interventions 1(3):226–232
[35] Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier
B, Windecker S (2007) Incomplete stent apposition and very late stent thrombosis after
drug-eluting stent implantation. Circulation 115(18):2426–2434
[36] Cook S, Eshtehardi P, Kalesan B, Räber L, Wenaweser P, Togni M, Moschovitis A, Vogel R,
Seiler C, Eberli FR, Lüscher T, Meier B, Jüni P, Windecker S (2012) Impact of incomplete
stent apposition on long-term clinical outcome after drug-eluting stent implantation.
European Heart Journal 33(11):1334–1343
[37] Cortese B, Sgueglia GA, Granada JF (2013) Paclitaxel coated balloons, the time for
awareness has come. International Journal of Cardiology 164(1):1–2
[38] Creel CJ, Lovich MA, Edelman ER (2000) Arterial paclitaxel distribution and deposition.
Circulation Research 86(8):879–884
[39] Curry FRE (1984) Mechanics and thermodynamics of transcapillary exchange. In:
Renkin E, Michel C (eds) The Cardiovascular System. Microcirculation, no. 4 in Hand-
book of Physiology, American Physiological Society, pp 309–374
104 BIBLIOGRAPHY
[40] Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni
P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S,
Serruys PW (2007) Early and late coronary stent thrombosis of sirolimus-eluting and
paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional
cohort study. The Lancet 369(9562):667–678
[41] Davies PF (1995) Flow-mediated endothelial mechanotransduction. Physiological Re-
views 75(3):519–560
[42] Davies PF (2009) Hemodynamic shear stress and the endothelium in cardiovascular
pathophysiology. Nature Clinical Practice Cardiovascular Medicine 6(1):16–26
[43] Dewey J C F, Bussolari SR, Gimbrone J M A, Davies PF (1981) The dynamic response
of vascular endothelial cells to fluid shear stress. Journal of Biomechanical Engineering
103(3):177–185
[44] Duraiswamy N, Schoephoerster RT, Moreno MR, Moore JE (2007) Stented artery
flow patterns and their effects on the artery wall. Annual Review of Fluid Mechanics
39(1):357–382
[45] Eskin S, Ives C, McIntire L, Navarro L (1984) Response of cultured endothelial cells to
steady flow. Microvascular Research 28(1):87–94
[46] Ezzati M, Vander Hoorn S, Lawes CM, Leach R, James WPT, Lopez AD, Rodgers A,
Murray CJ (2005) Rethinking the “diseases of affluence” paradigm: global patterns of
nutritional risks in relation to economic development. PLoS Medicine 2(5):e133
[47] Falk E (2006) Pathogenesis of atherosclerosis. Journal of the American College of
Cardiology 47(8s1):C7–C12
[48] Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R (1999)
Pathology of acute and chronic coronary stenting in humans. Circulation 99(1):44–52
[49] Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J,
Virmani R (2001) Pathological analysis of local delivery of paclitaxel via a polymer-
coated stent. Circulation 104(4):473–479
[50] Farhan S, Hemetsberger R, Matiasek J, Strehblow C, Pavo N, Khorsand A, Petneházy O,
Petrási Z, Kaider A, Glogar D, Huber K, Gyöngyösi M (2009) Implantation of paclitaxel-
eluting stent impairs the vascular compliance of arteries in porcine coronary stenting
model. Atherosclerosis 202(1):144–151
[51] Feenstra PH, Taylor CA (2009) Drug transport in artery walls: A sequential
porohyperelastic-transport approach. Computer Methods in Biomechanics and Biomedi-
cal Engineering 12(3):263–276
[52] Filipovic N, Kojic M, Tsuda A (2008) Modelling thrombosis using dissipative particle
dynamics method. Philosophical Transactions of the Royal Society A: Mathematical,
Physical and Engineering Sciences 366(1879):3265–3279
BIBLIOGRAPHY 105
[53] Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani
R (2007) Pathological correlates of late drug-eluting stent thrombosis. Circulation
115(18):2435–2441
[54] Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R (2007) Vas-
cular responses to drug eluting stents: Importance of delayed healing. Arteriosclerosis,
Thrombosis, and Vascular Biology 27(7):1500–1510
[55] Formaggia L, Quarteroni A, Veneziani A (eds) (2009) Cardiovascular Mathematics.
Springer Milan
[56] Forrester AIJ, Sóbester A, Keane AJ (2008) Engineering design via surrogate modelling
a practical guide. J. Wiley
[57] Frey D, Billinger M, Meier P, Beslac O, Grossenbacher R, Hänni B, Hess OM (2008)
Endothelialization of sirolimus-eluting stents with slow and extended drug release in
the porcine overstretch model. The Journal of Invasive Cardiology 20(12):631–634
[58] Fry DL (1968) Acute vascular endothelial changes associated with increased blood ve-
locity gradients. Circulation Research 22(2):165–197
[59] Fukuda D, Aikawa M (2010) Intimal smooth muscle cells: The context-dependent origin.
Circulation 122(20):2005–2008
[60] Garg S, Serruys PW (2010) Coronary stents: Current status. Journal of the American
College of Cardiology 56(10, Supplement 1):S1–S42
[61] Garg S, Serruys PW (2010) Coronary stents: Looking forward. Journal of the American
College of Cardiology 56(10, Supplement 1):S43–S78
[62] Garg S, Magro M, Serruys P (2011) 6.627 – drug-eluting stents. In: Ducheyne P (ed)
Comprehensive Biomaterials, Elsevier, pp 427–448
[63] Gielis J (2003) A generic geometric transformation that unifies a wide range of natural
and abstract shapes. American Journal of Botany 90(3):333–338
[64] Gojova A, Barakat AI (2005) Vascular endothelial wound closure under shear stress: role
of membrane fluidity and flow-sensitive ion channels. Journal of Applied Physiology
98(6):2355–2362
[65] Goodman PD, Barlow ET, Crapo PM, Mohammad SF, Solen KA (2005) Computational
model of device-induced thrombosis and thromboembolism. Annals of Biomedical Engi-
neering 33(6):780–797
[66] Gray WA, Granada JF (2010) Drug-coated balloons for the prevention of vascular
restenosis. Circulation 121(24):2672–2680
[67] Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P,
Whitlow P (2007) Prevention of premature discontinuation of dual antiplatelet therapy
in patients with coronary artery stents. Circulation 115(6):813–818
106 BIBLIOGRAPHY
[68] Guagliumi G, Ikejima H, Sirbu V, Bezerra H, Musumeci G, Lortkipanidze N, Fiocca L,
Tahara S, Vassileva A, Matiashvili A, Valsecchi O, Costa M (2011) Impact of drug release
kinetics on vascular response to different zotarolimus-eluting stents implanted in pa-
tients with long coronary stenoses: The LongOCT study (optical coherence tomography
in long lesions). JACC: Cardiovascular Interventions 4(7):778–785
[69] Guagliumi G, Sirbu V, Musumeci G, Gerber R, Biondi-Zoccai G, Ikejima H, Ladich E,
Lortkipanidze N, Matiashvili A, Valsecchi O, Virmani R, Stone GW (2012) Examination
of the in vivo mechanisms of late drug-eluting stent thrombosis: Findings from optical
coherence tomography and intravascular ultrasound imaging. JACC: Cardiovascular
Interventions 5(1):12–20
[70] Gundert TJ, Marsden AL, Yang W, John F LaDisa J (2012) Optimization of cardiovascular
stent design using computational fluid dynamics. Journal of Biomechanical Engineering
134(1):011,002
[71] Gundert TJ, Marsden AL, Yang W, Marks DS, LaDisa J (2012) Identification of hemody-
namically optimal coronary stent designs based on vessel caliber. IEEE Transactions on
Biomedical Engineering 59(7):1992–2002
[72] Hahn C, Schwartz MA (2009) Mechanotransduction in vascular physiology and athero-
genesis. Nature Reviews Molecular Cell Biology 10(1):53–62
[73] Hara H, Nakamura M, Palmaz JC, Schwartz RS (2006) Role of stent design and coatings
on restenosis and thrombosis. Advanced Drug Delivery Reviews 58(3):377–386
[74] Hassan AK, Bergheanu SC, Stijnen T, van der Hoeven BL, Snoep JD, Plevier JW, Schalij
MJ, Wouter Jukema J (2010) Late stent malapposition risk is higher after drug-eluting
stent compared with bare-metal stent implantation and associates with late stent throm-
bosis. European Heart Journal 31(10):1172–1180
[75] Helmlinger G, Geiger RV, Schreck S, Nerem RM (1991) Effects of pulsatile flow on
cultured vascular endothelial cell morphology. Journal of Biomechanical Engineering
113(2):123–131
[76] Hilder T, Hill J (2008) Probability of encapsulation of paclitaxel and doxorubicin into
carbon nanotubes. Micro & Nano Letters 3(2):41–49
[77] Hindmarsh AC, Brown PN (2005) SUNDIALS: suite of nonlinear and Differen-
tial/Algebraic equation solvers
[78] Hollander Y, Durban D, Lu X, Kassab GS, Lanir Y (2011) Experimentally validated micro
structural 3D constitutive model of coronary arterial media. Journal of Biomechanical
Engineering 133(3):031,007
[79] Huang Y, Rumschitzki D, Chien S, Weinbaum S (1994) A fiber matrix model for the
growth of macromolecular leakage spots in the arterial intima. Journal of Biomechanical
Engineering 116(4):430–445
[80] Hwang CW, Edelman ER (2002) Arterial ultrastructure influences transport of locally
delivered drugs. Circulation Research 90(7):826–832
BIBLIOGRAPHY 107
[81] Hwang CW, Wu D, Edelman ER (2001) Physiological transport forces govern drug
distribution for stent-based delivery. Circulation 104(5):600–605
[82] Hwang CW, Wu D, Edelman ER (2003) Impact of transport and drug properties on the
local pharmacology of drug-eluting stents. Acute Cardiac Care 5(1):7–12
[83] Inoue K (2012) Pathological perspective of drug-eluting stent thrombosis. Thrombosis
2012:1–8
[84] Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK,
Virmani R (2006) Pathology of drug-eluting stents in humans: Delayed healing and late
thrombotic risk. Journal of the American College of Cardiology 48(1):193–202
[85] Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija
K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R (2008) Endothelial cell recovery
between comparator polymer-based drug-eluting stents. Journal of the American College
of Cardiology 52(5):333–342
[86] Jones DR (2001) A taxonomy of global optimization methods based on response surfaces.
Journal of Global Optimization 21(4):345–383
[87] Kamath KR, Barry JJ, Miller KM (2006) The taxus(TM) drug-eluting stent: A new
paradigm in controlled drug delivery. Advanced Drug Delivery Reviews 58(3):412–436
[88] Kandzari DE, Angiolillo DJ, Price MJ, Teirstein PS (2009) Identifying the “Optimal”
duration of dual antiplatelet therapy after drug-eluting stent revascularization. JACC:
Cardiovascular Interventions 2(12):1279–1285
[89] Karner G, Perktold K, Zehentner HP (2001) Computational modeling of macromolecule
transport in the arterial wall. Computer Methods in Biomechanics and Biomedical
Engineering 4(6):491–504
[90] Kaul U, Mansoor AH (2012) Choice of drug-eluting stent – evidence-based or empirical.
Journal of Indian College of Cardiology 2(1):22–28
[91] Kedem O, Katchalsky A (1958) Thermodynamic analysis of the permeability of biological
membranes to non-electrolytes. Biochimica et Biophysica Acta 27:229–246
[92] Khakpour M, Vafai K (2008) A comprehensive analytical solution of macromolecular
transport within an artery. International Journal of Heat and Mass Transfer 51(11-
12):2905–2913
[93] Kim BK, Hong MK, Shin DH, Kim JS, Ko YG, Choi D, Jang Y (2012) Relationship
between stent malapposition and incomplete neointimal coverage after drug-eluting
stent implantation. Journal of Interventional Cardiology 25(3):270–277
[94] Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, Sasseen B,
Adelman SJ, Falotico R, Wilensky RL (2002) Twenty-eight-day efficacy and phamacoki-
netics of the sirolimus-eluting stent. Coronary Artery Disease 13(3):183–188, PMID:
12131023
108 BIBLIOGRAPHY
[95] Kolda TG, Lewis RM, Torczon V (2003) Optimization by direct search: New perspectives
on some classical and modern methods. SIAM Review 45(3):385–482
[96] Koskinas KC, Chatzizisis YS, Antoniadis AP, Giannoglou GD (2012) Role of endothe-
lial shear stress in stent restenosis and thrombosis: Pathophysiologic mechanisms and
implications for clinical translation. Journal of the American College of Cardiology
59(15):1337–1349
[97] Krige D (1951) A statistical approach to some basic mine valuation problems on the
witwatersrand. Journal of the Chemical, Metallurgical and Mining Society of South
Africa 52(6):119–139
[98] Ku DN, Giddens DP, Zarins CK, Glagov S (1985) Pulsatile flow and atherosclerosis in
the human carotid bifurcation. positive correlation between plaque location and low
oscillating shear stress. Arteriosclerosis, Thrombosis, and Vascular Biology 5(3):293–
302
[99] LaDisa JF (2004) Stent design properties and deployment ratio influence indexes of wall
shear stress: a three-dimensional computational fluid dynamics investigation within a
normal artery. Journal of Applied Physiology 97(1):424–430
[100] LaDisa JF, Olson LE, Hettrick DA, Warltier DC, Kersten JR, Pagel PS (2005) Axial stent
strut angle influences wall shear stress after stent implantation: analysis using 3D compu-
tational fluid dynamics models of stent foreshortening. BioMedical Engineering OnLine
4:59
[101] Lally C, Kelly DJ, Prendergast PJ (2006) Stents. Wiley Encyclopedia of Biomedical
Engineering
[102] Lao LL, Venkatraman SS (2008) Adjustable paclitaxel release kinetics and its efficacy to
inhibit smooth muscle cells proliferation. Journal of Controlled Release 130(1):9–14
[103] Lee K, Saidel GM, Penn MS (2005) Macromolecular transport in the arterial wall: alter-
native models for estimating barriers. Annals of Biomedical Engineering 33(11):1491–
1503
[104] Lei L, Guo SR, Chen WL, Rong HJ, Lu F (2011) Stents as a platform for drug delivery.
Expert Opinion on Drug Delivery 8(6):813–831
[105] Levin AD, Vukmirovic N, Hwang CW, Edelman ER (2004) Specific binding to intra-
cellular proteins determines arterial transport properties for rapamycin and paclitaxel.
Proceedings of the National Academy of Sciences of the United States of America
101(25):9463–9467
[106] Levitt DG (1975) General continuum analysis of transport through pores: I. proof of
onsager’s reciprocity postulate for uniform pore. Biophysical Journal 15(6):533–551
[107] Li H, Zhang Lj, Chen Bh, Zhou X, Su K, Shi Wt, Wu Jz, Yu H, Wei L (2010) Inhibitory
effect of paclitaxel on endothelial cell adhesion and migration. Pharmacology 85(3):136–
145
BIBLIOGRAPHY 109
[108] Li S, Wang Y, Gai L, Yang T, Liu H, Wang Z, Bai Q, Xu X, Chen Y (2013) Evaluation
of neointimal coverage and apposition with various drug-eluting stents over 12 months
after implantation by optical coherence tomography. International Journal of Cardiology
162(3):166–171
[109] Libby P (2002) Inflammation in atherosclerosis. Nature 420(6917):868–874
[110] Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the
biology of atherosclerosis. Nature 473(7347):317–325
[111] Liou TM, Li YC (2008) Effects of stent porosity on hemodynamics in a sidewall aneurysm
model. Journal of Biomechanics 41(6):1174–1183
[112] Liuzzo JP, Ambrose JA, Coppola JT (2005) Sirolimus- and taxol-eluting stents differ to-
wards intimal hyperplasia and re-endothelialization. The Journal of Invasive Cardiology
17(9):497–502
[113] Longest PW, Kleinstreuer C (2003) Comparison of blood particle deposition models for
non-parallel flow domains. Journal of Biomechanics 36(3):421–430
[114] Lovich MA, Creel C, Hong K, Hwang CW, Edelman ER (2001) Carrier proteins determine
local pharmacokinetics and arterial distribution of paclitaxel. Journal of Pharmaceutical
Sciences 90(9):1324–1335
[115] Lum RM, Wiley LM, Barakat AI (2000) Influence of different forms of fluid shear stress
on vascular endothelial TGF-beta1 mRNA expression. International Journal of Molecular
Medicine 5(6):635–641
[116] Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R (2007)
Drug-eluting stent and coronary thrombosis: Biological mechanisms and clinical impli-
cations. Circulation 115(8):1051–1058
[117] Lusis AJ (2000) Atherosclerosis. Nature 407(6801):233–241
[118] Marsden AL, Wang M, Dennis JE, Moin P (2004) Optimal aeroacoustic shape design
using the surrogate management framework. Optimization and Engineering 5(2):235–
262
[119] Marsden AL, Wang M, Dennis JE, Moin P (2007) Trailing-edge noise reduction using
derivative-free optimization and large-eddy simulation. Journal of Fluid Mechanics
572:13
[120] Marsden AL, Feinstein JA, Taylor CA (2008) A computational framework for derivative-
free optimization of cardiovascular geometries. Computer Methods in Applied Mechanics
and Engineering 197(21-24):1890–1905
[121] Marx SO, Totary-Jain H, Marks AR (2011) Vascular smooth muscle cell proliferation in
restenosis. Circulation: Cardiovascular Interventions 4(1):104–111
[122] Matheron G (1963) Principles of geostatistics. Economic Geology 58(8):1246–1266
110 BIBLIOGRAPHY
[123] Matter CM, Rozenberg I, Jaschko A, Greutert H, Kurz DJ, Wnendt S, Kuttler B, Joch
H, Grünenfelder J, Zünd G, Tanner FC, Lüscher TF (2006) Effects of tacrolimus or
sirolimus on proliferation of vascular smooth muscle and endothelial cells. Journal of
Cardiovascular Pharmacology 48(6):286–292
[124] McGinty S, McKee S, Wadsworth RM, McCormick C (2011) Modelling drug-eluting
stents. Mathematical Medicine and Biology 28(1):1–29
[125] Migliavacca F, Gervaso F, Prosi M, Zunino P, Minisini S, Formaggia L, Dubini G (2007)
Expansion and drug elution model of a coronary stent. Computer Methods in Biome-
chanics and Biomedical Engineering 10(1):63–73
[126] Mintz GS (2007) What to do about late incomplete stent apposition? Circulation
115(18):2379–2381
[127] Mongrain R, Brunette J, Faik I, Bulman-Feleming N, Nguyen T (2005) Numerical model-
ing of coronary drug eluting stents. In: Suri J (ed) Plaque imaging : pixel to molecular
level, IOS Press, pp 443–458
[128] Mongrain R, Faik I, Leask RL, Rodes-Cabau J, Larose E, Bertrand OF (2007) Effects of
diffusion coefficients and struts apposition using numerical simulations for drug eluting
coronary stents. Journal of Biomechanical Engineering 129(5):733–742
[129] Morris MD (1991) Factorial sampling plans for preliminary computational experiments.
Technometrics 33(2):161–174
[130] Mueller RL, Sanborn TA (1995) The history of interventional cardiology: cardiac
catheterization, angioplasty, and related interventions. American Heart Journal
129(1):146–172
[131] Nakazawa G, Vorpahl M, Finn AV, Narula J, Virmani R (2009) One step forward and
two steps back with drug-eluting-stents: From preventing restenosis to causing late
thrombosis and nouveau atherosclerosis. JACC: Cardiovascular Imaging 2(5):625–628
[132] Nakazawa G, Nakano M, Otsuka F, Wilcox JN, Melder R, Pruitt S, Kolodgie FD, Virmani
R (2011) Evaluation of polymer-based comparator drug-eluting stents using a rabbit
model of iliac artery atherosclerosis / clinical perspective. Circulation: Cardiovascular
Interventions 4(1):38–46
[133] Nerem RM (1992) Vascular fluid mechanics, the arterial wall, and atherosclerosis. Jour-
nal of Biomechanical Engineering 114(3):274–282
[134] Nerem RM, Levesque MJ, Cornhill JF (1981) Vascular endothelial morphology as an
indicator of the pattern of blood flow. Journal of Biomechanical Engineering 103(3):172–
176
[135] Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, Carberry J, Fouras A,
Jackson SP (2009) A shear gradient-dependent platelet aggregation mechanism drives
thrombus formation. Nature Medicine 15(6):665–673
BIBLIOGRAPHY 111
[136] O’Connell MK, Murthy S, Phan S, Xu C, Buchanan J, Spilker R, Dalman RL, Zarins CK,
Denk W, Taylor CA (2008) The three-dimensional micro- and nanostructure of the aortic
medial lamellar unit measured using 3D confocal and electron microscopy imaging.
Matrix Biology 27(3):171–181
[137] Ormiston JA, Serruys PW (2009) Bioabsorbable coronary stents. Circulation: Cardiovas-
cular Interventions 2(3):255–260
[138] Pan CJ, Tang JJ, Weng YJ, Wang J, Huang N (2009) Preparation and in vitro release
profiles of drug-eluting controlled biodegradable polymer coating stents. Colloids and
Surfaces B: Biointerfaces 73(2):199–206
[139] Pant S, Bressloff NW, Forrester AIJ, Curzen N (2010) The influence of strut-connectors
in stented vessels: a comparison of pulsatile flow through five coronary stents. Annals
of Biomedical Engineering 38(5):1893–1907
[140] Pant S, Limbert G, Curzen N, Bressloff N (2011) Multiobjective design optimisation of
coronary stents. Biomaterials 32(31):7755–7773
[141] Pant S, Bressloff N, Limbert G (2012) Geometry parameterization and multidisciplinary
constrained optimization of coronary stents. Biomechanics and Modeling in Mechanobi-
ology 11(1):61–82
[142] Papafaklis MI, Chatzizisis YS, Naka KK, Giannoglou GD, Michalis LK (2012) Drug-eluting
stent restenosis: Effect of drug type, release kinetics, hemodynamics and coating strategy.
Pharmacology & Therapeutics 134(1):43–53
[143] Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee
SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ,
Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang
JS, Park HS, Lee K (2010) Duration of dual antiplatelet therapy after implantation of
drug-eluting stents. New England Journal of Medicine 362(15):1374–1382
[144] Pendyala LK, Yin X, Li J, Chen JP, Chronos N, Hou D (2009) The first-generation drug-
eluting stents and coronary endothelial dysfunction. JACC: Cardiovascular Interventions
2(12):1169–1177
[145] Petersen JL, Barron JJ, Hammill BG, Cziraky MJ, Anstrom KJ, Wahl PM, Eisenstein EL,
Krucoff MW, Califf RM, Schulman KA, Curtis LH (2010) Clopidogrel use and clinical
events after drug-eluting stent implantation: Findings from the HealthCore integrated
research database. American Heart Journal 159(3):462–470.e1
[146] Pontrelli G, de Monte F (2010) A multi-layer porous wall model for coronary drug-
eluting stents. International Journal of Heat and Mass Transfer 53(19-20):3629–3637
[147] Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR (1996) Rapamycin
inhibits vascular smooth muscle cell migration. Journal of Clinical Investigation
98(10):2277–2283
112 BIBLIOGRAPHY
[148] Prosi M, Zunino P, Perktold K, Quarteroni A (2005) Mathematical and numerical models
for transfer of low-density lipoproteins through the arterial walls: a new methodology
for the model set up with applications to the study of disturbed lumenal flow. Journal
of Biomechanics 38(4):903–917
[149] Quosdorf D, Brede M, Leder A, Lootz D, Martin H, Schmitz KP (2011) Micro-particle-
image-velocimetry zur bestimmung der geschwindigkeiten in einem koronargefäßmit
stent. tm - Technisches Messen 78(5):239–245
[150] R EE, Rogers C (1998) Pathobiologic responses to stenting. The American Journal of
Cardiology 81(7, Supplement 1):4E–6E
[151] Räber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S, Moschovitis
A, Vogel R, Kalesan B, Seiler C, Eberli F, Lüscher TF, Meier B, Jüni P, Windecker S (2011)
Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-
eluting and paclitaxel-eluting stents / clinical perspective. Circulation 123(24):2819–
2828
[152] Radeleff B, Lopez-Benitez R, Stampfl U, Stampfl S, Sommer C, Thierjung H, Berger I,
Kauffmann G, Richter GM (2010) Paclitaxel-induced arterial wall toxicity and inflam-
mation: Tissue uptake in various dose densities in a minipig model. Journal of Vascular
and Interventional Radiology 21(8):1262–1270
[153] Rao SS (2009) Engineering optimization: theory and praxis. Wiley
[154] Ruygrok PN, Serruys PW (1996) Intracoronary stenting: From concept to custom. Cir-
culation 94(5):882–890
[155] Sacks J, Welch WJ, Mitchell TJ, Wynn HP (1989) Design and analysis of computer
experiments. Statistical Science 4(4):409–423
[156] Sakai S, Mizuno K, Yokoyama S, Tanabe J, Shinada T, Seimiya K, Takano M, Ohba T,
Tomimura M, Uemura R, Imaizumi T (2003) Morphologic changes in infarct-related
plaque after coronary stent placement: A serial angioscopy study. Journal of the Ameri-
can College of Cardiology 42(9):1558–1565
[157] Sarno G, Lagerqvist B, Fröbert O, Nilsson J, Olivecrona G, Omerovic E, Saleh N, Venet-
zanos D, James S (2012) Lower risk of stent thrombosis and restenosis with unrestricted
use of ‘new-generation’ drug-eluting stents: a report from the nationwide swedish coro-
nary angiography and angioplasty registry (SCAAR). European Heart Journal 33(5):606
–613
[158] Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U (2006)
Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. New
England Journal of Medicine 355(20):2113–2124
[159] Schwartz CJ, Mitchell JR (1962) Observations on localization of arterial plaques. Circu-
lation Research 11:63–73
[160] Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Nerem RM (1991) The pathogenesis of
atherosclerosis: an overview. Clinical Cardiology 14(S1):1–16
BIBLIOGRAPHY 113
[161] Schwartz SM, deBlois D, O’Brien ERM (1995) The intima: Soil for atherosclerosis and
restenosis. Circulation Research 77(3):445–465
[162] Seo T, Barakat AI (2009) The assessment of the performance of drug-eluting stent using
computational fluid dynamics. Korea-Australia Rheology Journal 21(4):281–288
[163] Seo T, Schachter LG, Barakat AI (2005) Computational study of fluid mechanical distur-
bance induced by endovascular stents. Annals of Biomedical Engineering 33(4):444–456
[164] Serruys P (2002) Handbook of coronary stents, 4th edn. Taylor & Francis
[165] Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H, Smits P, McClean D,
Verheye S, Belardi J, Condado J, Pieper M, Gambone L, Bressers M, Symons J, Sousa E,
Litvack F (2005) The effect of variable dose and release kinetics on neointimal hyper-
plasia using a novel paclitaxel-eluting stent platform: The paclitaxel in-stent controlled
elution study (PISCES). Journal of the American College of Cardiology 46(2):253–260
[166] Sibson R (1981) A brief description of natural neighbor interpolation (chapter 2). In:
Barnett V (ed) Interpreting multivariate data, Wiley series in probability and mathemat-
ical statistics, Wiley, pp 21–36
[167] Singh T, Cuomo L, Cohen M, A Ahmad H, S Aronow W (2013) Use of antiplatelet
therapy after percutaneous coronary intervention with bare-metal stents and different
types of drug-eluting stents. Current Clinical Pharmacology 8(1):59–66
[168] Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, Mc-
Fadden E (2011) 2-year follow-up of a randomized controlled trial of everolimus- and
paclitaxel-eluting stents for coronary revascularization in daily practice. Journal of the
American College of Cardiology 58(1):11–18
[169] Spain DM (1966) Atherosclerosis. Scientific American 215(2):48–56
[170] Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW (2007) A pooled analysis of
data comparing sirolimus-eluting stents with bare-metal stents. New England Journal
of Medicine 356(10):989–997
[171] Srinivas K, Nakayama T, Ohta M, Obayashi S, Yamaguchi T (2008) Studies on design
optimization of coronary stents. Journal of Medical Devices 2(1):011,004
[172] Steigerwald K, Ballke S, Quee SC, Byrne RA, Vorpahl M, Vogeser M, Kolodgie F, Virmani
R, Joner M (2012) Vascular healing in drug-eluting stents: differential drug-associated
response of limus-eluting stents in a preclinical model of stent implantation. EuroInter-
vention 8(6):752–759
[173] Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Scham-
paert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB (2007)
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. New England
Journal of Medicine 356(10):998–1008
114 BIBLIOGRAPHY
[174] Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip
DE, Simonton CA, Sood P, Kereiakes DJ (2011) Randomized comparison of everolimus-
and paclitaxel-eluting stents2-year follow-up from the SPIRIT (clinical evaluation of the
XIENCE v everolimus eluting coronary stent system) IV trial. Journal of the American
College of Cardiology 58(1):19–25
[175] Tesfamariam B (2008) Drug release kinetics from stent device-based delivery systems.
Journal of Cardiovascular Pharmacology 51(2):118–125
[176] Thompson RC, Allam AH, Lombardi GP, Wann LS, Sutherland ML, Sutherland JD, Soli-
man MAT, Frohlich B, Mininberg DT, Monge JM, Vallodolid CM, Cox SL, Abd el Maksoud
G, Badr I, Miyamoto MI, el-Halim Nur el din A, Narula J, Finch CE, Thomas GS (2013)
Atherosclerosis across 4000 years of human history: the horus study of four ancient
populations. The Lancet 381(9873):1211–1222
[177] Thomson JJ (1904) On the structure of the atom: an investigation of the stability and
periods of oscillation of a number of corpuscles arranged at equal intervals around the
circumference of a circle; with application of the results to the theory of atomic structure.
Philosophical Magazine Series 6 7(39):237–265
[178] Timmins L, Moreno M, Meyer C, Criscione J, Rachev A, Moore JE (2007) Stented artery
biomechanics and device design optimization. Medical and Biological Engineering and
Computing 45(5):505–513
[179] Tzafriri AR, Levin AD, Edelman ER (2009) Diffusion-limited binding explains binary
dose response for local arterial and tumour drug delivery. Cell Proliferation 42(3):348–
363
[180] Tzafriri AR, Vukmirovic N, Kolachalama VB, Astafieva I, Edelman ER (2010) Lesion
complexity determines arterial drug distribution after local drug delivery. Journal of
Controlled Release 142(3):332–338
[181] Tzafriri AR, Groothuis A, Price GS, Edelman ER (2012) Stent elution rate deter-
mines drug deposition and receptor-mediated effects. Journal of Controlled Release
161(3):918–926
[182] Ueda Y, Nanto S, Komamura K, Kodama K (1994) Neointimal coverage of stents in
human coronary arteries observed by angioscopy. Journal of the American College of
Cardiology 23(2):341–346
[183] Vairo G, Cioffi M, Cottone R, Dubini G, Migliavacca F (2010) Drug release from coronary
eluting stents: A multidomain approach. Journal of Biomechanics 43(8):1580–1589
[184] Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo
F, Tebaldi M, Fucà G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C,
Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R (2012) Short- versus
long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized
multicenter trial. Circulation 125(16):2015–2026
[185] Venkatraman S, Boey F (2007) Release profiles in drug-eluting stents: Issues and uncer-
tainties. Journal of Controlled Release 120(3):149–160
BIBLIOGRAPHY 115
[186] Vergara C, Zunino P (2008) Multiscale boundary conditions for drug release from car-
diovascular stents. Multiscale Modeling & Simulation 7(2):565–588
[187] Wang XT, Venkatraman S, Boey F, Loo SC, Tan LP (2007) Effects of controlled-released
sirolimus from polymer matrices on human coronary artery smooth muscle cells. Journal
of Biomaterials Science, Polymer Edition 18(11):1401–1414
[188] Weinbaum S, Tzeghai G, Ganatos P, Pfeffer R, Chien S (1985) Effect of cell turnover and
leaky junctions on arterial macromolecular transport. American Journal of Physiology –
Heart and Circulatory Physiology 248(6):H945–H960
[189] Wentzel JJ, Whelan DM, Giessen WJvd, Beusekom HMMv, Andhyiswara I, Serruys PW,
Slager CJ, Krams R (2000) Coronary stent implantation changes 3-d vessel geometry
and 3-d shear stress distribution. Journal of Biomechanics 33(10):1287–1295
[190] Wessely R, Schomig A, Kastrati A (2006) Sirolimus and paclitaxel on polymer-based
drug-eluting stents: Similar but different. Journal of the American College of Cardiology
47(4):708–714
[191] Wessely R, Blaich B, Belaiba RS, Merl S, Görlach A, Kastrati A, Schömig A (2007)
Comparative characterization of cellular and molecular anti-restenotic profiles of pacli-
taxel and sirolimus. implications for local drug delivery. Thrombosis and Haemostasis
97(6):1003–1012
[192] Whitaker S (1986) Transient diffusion, adsorption and reaction in porous catalysts:
The reaction controlled, quasi-steady catalytic surface. Chemical Engineering Science
41(12):3015–3022
[193] Whitaker S (2010) The Method of Volume Averaging. Kluwer Academic Publishers
[194] Witzenbichler B (2012) Dual antiplatelet therapy after drug-eluting stent implantation.
Journal of the American College of Cardiology 60(15):1349–1351
[195] World Health Organisation (2008) WHO | the top 10 causes of death. http://who.
int/mediacentre/factsheets/fs310/en/ Accessed: 2013-04-06
[196] Wu W, Petrini L, Gastaldi D, Villa T, Vedani M, Lesma E, Previtali B, Migliavacca F (2010)
Finite element shape optimization for biodegradable magnesium alloy stents. Annals of
Biomedical Engineering 38(9):2829–2840
[197] Yang N, Vafai K (2006) Modeling of low-density lipoprotein (LDL) transport in the
artery–effects of hypertension. International Journal of Heat and Mass Transfer 49(5-
6):850–867
[198] Yang W, Feinstein JA, Marsden AL (2010) Constrained optimization of an idealized y-
shaped baffle for the fontan surgery at rest and exercise. Computer Methods in Applied
Mechanics and Engineering 199(33-36):2135–2149
[199] Zoumi A, Lu X, Kassab GS, Tromberg BJ (2004) Imaging coronary artery microstructure
using second-harmonic and two-photon fluorescence microscopy. Biophysical Journal
87(4):2778–2786
116 BIBLIOGRAPHY
[200] Zunino P (2004) Multidimensional pharmacokinetic models applied to the design of
drug-eluting stents. Cardiovascular Engineering 4(2):181–191
[201] Zunino P, D’Angelo C, Petrini L, Vergara C, Capelli C, Migliavacca F (2009) Numerical
simulation of drug eluting coronary stents: Mechanics, fluid dynamics and drug release.
Computer Methods in Applied Mechanics and Engineering 198(45-46):3633–3644
